NZ719163B2 - Co-crystals of (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as dna-pk inhibitors - Google Patents
Co-crystals of (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as dna-pk inhibitors Download PDFInfo
- Publication number
- NZ719163B2 NZ719163B2 NZ719163A NZ71916314A NZ719163B2 NZ 719163 B2 NZ719163 B2 NZ 719163B2 NZ 719163 A NZ719163 A NZ 719163A NZ 71916314 A NZ71916314 A NZ 71916314A NZ 719163 B2 NZ719163 B2 NZ 719163B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- cancer
- compound
- crystal
- methyl
- adipic acid
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title abstract description 58
- 239000003112 inhibitor Substances 0.000 title abstract description 38
- PEACIOGDEQRHFA-CQSZACIVSA-N N-methyl-8-[(2S)-1-[[6-(2-methylpyrimidin-5-yl)pyrimidin-4-yl]amino]propan-2-yl]quinoline-4-carboxamide Chemical compound C([C@@H](C)C1=C2N=CC=C(C2=CC=C1)C(=O)NC)NC(N=CN=1)=CC=1C1=CN=C(C)N=C1 PEACIOGDEQRHFA-CQSZACIVSA-N 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 455
- WNLRTRBMVRJNCN-UHFFFAOYSA-N Adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims abstract description 370
- 239000001361 adipic acid Substances 0.000 claims abstract description 185
- 235000011037 adipic acid Nutrition 0.000 claims abstract description 185
- 201000011510 cancer Diseases 0.000 claims abstract description 116
- -1 (S)-N-methyl(1-((2'- methyl-[4,5'-bipyrimidin]yl)amino)propanyl)quinolinecarboxamide Chemical compound 0.000 claims description 253
- 210000004027 cells Anatomy 0.000 claims description 105
- 206010028980 Neoplasm Diseases 0.000 claims description 76
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 48
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 45
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 43
- 229960005420 Etoposide Drugs 0.000 claims description 42
- 229960004679 Doxorubicin Drugs 0.000 claims description 38
- 239000008194 pharmaceutical composition Substances 0.000 claims description 33
- 239000003814 drug Substances 0.000 claims description 29
- 238000001959 radiotherapy Methods 0.000 claims description 28
- 239000002904 solvent Substances 0.000 claims description 24
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 22
- 201000005202 lung cancer Diseases 0.000 claims description 22
- 229960001561 Bleomycin Drugs 0.000 claims description 20
- 108010006654 Bleomycin Proteins 0.000 claims description 20
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 20
- 206010006187 Breast cancer Diseases 0.000 claims description 19
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims description 19
- 230000001225 therapeutic Effects 0.000 claims description 19
- AOJJSUZBOXZQNB-VTZDEGQISA-N EPIRUBICIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 17
- 229960001904 EPIRUBICIN Drugs 0.000 claims description 16
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims description 15
- 239000001257 hydrogen Substances 0.000 claims description 15
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 14
- 230000036210 malignancy Effects 0.000 claims description 13
- 210000004881 tumor cells Anatomy 0.000 claims description 13
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims description 12
- 238000002425 crystallisation Methods 0.000 claims description 12
- 230000005712 crystallization Effects 0.000 claims description 12
- 201000002528 pancreatic cancer Diseases 0.000 claims description 12
- 229960000975 Daunorubicin Drugs 0.000 claims description 11
- 206010024324 Leukaemias Diseases 0.000 claims description 11
- 201000009030 carcinoma Diseases 0.000 claims description 10
- 229910052805 deuterium Chemical group 0.000 claims description 10
- YZCKVEUIGOORGS-OUBTZVSYSA-N deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 10
- 239000003085 diluting agent Substances 0.000 claims description 10
- 230000002496 gastric Effects 0.000 claims description 9
- 206010060862 Prostate cancer Diseases 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 201000009251 multiple myeloma Diseases 0.000 claims description 8
- 206010025323 Lymphomas Diseases 0.000 claims description 7
- 239000000969 carrier Substances 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 7
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 7
- 239000007790 solid phase Substances 0.000 claims description 7
- 206010005003 Bladder cancer Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 206010029260 Neuroblastoma Diseases 0.000 claims description 6
- 206010041823 Squamous cell carcinoma Diseases 0.000 claims description 6
- 238000000227 grinding Methods 0.000 claims description 6
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 6
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 5
- 210000004392 Genitalia Anatomy 0.000 claims description 5
- 206010025650 Malignant melanoma Diseases 0.000 claims description 5
- 206010027476 Metastasis Diseases 0.000 claims description 5
- 208000000649 Small Cell Carcinoma Diseases 0.000 claims description 5
- 238000002512 chemotherapy Methods 0.000 claims description 5
- 201000011231 colorectal cancer Diseases 0.000 claims description 5
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 5
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 claims description 4
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 claims description 4
- 206010061289 Metastatic neoplasm Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- 201000006934 chronic myeloid leukemia Diseases 0.000 claims description 4
- 238000003181 co-melting Methods 0.000 claims description 4
- 230000001394 metastastic Effects 0.000 claims description 4
- 230000003389 potentiating Effects 0.000 claims description 4
- 206010003445 Ascites Diseases 0.000 claims description 3
- 210000003567 Ascitic Fluid Anatomy 0.000 claims description 3
- 210000000601 Blood Cells Anatomy 0.000 claims description 3
- 206010005949 Bone cancer Diseases 0.000 claims description 3
- 210000003169 Central Nervous System Anatomy 0.000 claims description 3
- 241000565118 Cordylophora caspia Species 0.000 claims description 3
- 208000006402 Ductal Carcinoma Diseases 0.000 claims description 3
- 206010063045 Effusion Diseases 0.000 claims description 3
- 208000007276 Esophageal Squamous Cell Carcinoma Diseases 0.000 claims description 3
- 208000005017 Glioblastoma Diseases 0.000 claims description 3
- 206010018338 Glioma Diseases 0.000 claims description 3
- 206010020243 Hodgkin's disease Diseases 0.000 claims description 3
- 208000007766 Kaposi Sarcoma Diseases 0.000 claims description 3
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 claims description 3
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 claims description 3
- 206010061309 Neoplasm progression Diseases 0.000 claims description 3
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 claims description 3
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 claims description 3
- 208000008798 Osteoma Diseases 0.000 claims description 3
- 206010025310 Other lymphomas Diseases 0.000 claims description 3
- 210000002394 Ovarian Follicle Anatomy 0.000 claims description 3
- 206010034299 Penile cancer Diseases 0.000 claims description 3
- 206010061529 Polyp Diseases 0.000 claims description 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 3
- 208000006265 Renal Cell Carcinoma Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 210000003491 Skin Anatomy 0.000 claims description 3
- 210000003932 Urinary Bladder Anatomy 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasm Diseases 0.000 claims description 3
- 210000003905 Vulva Anatomy 0.000 claims description 3
- 201000005510 acute lymphocytic leukemia Diseases 0.000 claims description 3
- 230000003140 astrocytic Effects 0.000 claims description 3
- 201000005216 brain cancer Diseases 0.000 claims description 3
- 230000004709 cell invasion Effects 0.000 claims description 3
- 201000008808 fibrosarcoma Diseases 0.000 claims description 3
- 201000010175 gallbladder cancer Diseases 0.000 claims description 3
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 200000000023 metastatic cancer Diseases 0.000 claims description 3
- 201000008968 osteosarcoma Diseases 0.000 claims description 3
- 201000000582 retinoblastoma Diseases 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 230000002992 thymic Effects 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 210000004404 Adrenal Cortex Anatomy 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 2
- 108009000344 Head and Neck Squamous Cell Carcinoma Proteins 0.000 claims description 2
- 208000006050 Hemangiopericytoma Diseases 0.000 claims description 2
- 210000002510 Keratinocytes Anatomy 0.000 claims description 2
- 210000004185 Liver Anatomy 0.000 claims description 2
- 208000007433 Lymphatic Metastasis Diseases 0.000 claims description 2
- 206010027406 Mesothelioma Diseases 0.000 claims description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 2
- 206010044412 Transitional cell carcinoma Diseases 0.000 claims description 2
- 206010046766 Uterine cancer Diseases 0.000 claims description 2
- 206010046885 Vaginal cancer Diseases 0.000 claims description 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 2
- 238000002665 ion therapy Methods 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 201000008026 nephroblastoma Diseases 0.000 claims description 2
- 229940035620 ACTH and synthetic analog preparations Drugs 0.000 claims 2
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 claims 2
- 201000006743 Hodgkin's lymphoma Diseases 0.000 claims 2
- 206010026673 Malignant pleural effusion Diseases 0.000 claims 2
- 206010057644 Testis cancer Diseases 0.000 claims 2
- 208000006786 Trophoblastic Neoplasm Diseases 0.000 claims 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 201000003120 testicular cancer Diseases 0.000 claims 2
- 208000003543 Lymphoma, T-Cell, Cutaneous Diseases 0.000 claims 1
- 210000002784 Stomach Anatomy 0.000 claims 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 1
- 238000001938 differential scanning calorimetry curve Methods 0.000 claims 1
- 230000002357 endometrial Effects 0.000 claims 1
- 230000001926 lymphatic Effects 0.000 claims 1
- 201000005962 mycosis fungoide Diseases 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 201000001539 ovarian carcinoma Diseases 0.000 claims 1
- 210000004872 soft tissue Anatomy 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 203
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract description 54
- 102000005768 DNA-Activated Protein Kinase Human genes 0.000 abstract description 37
- 108010006124 DNA-Activated Protein Kinase Proteins 0.000 abstract description 37
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 abstract description 36
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 abstract description 36
- VZCYOOQTPOCHFL-OWOJBTEDSA-N (E)-but-2-enedioate;hydron Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 abstract description 34
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract description 20
- 239000011976 maleic acid Substances 0.000 abstract description 19
- 239000005711 Benzoic acid Substances 0.000 abstract description 18
- 235000010233 benzoic acid Nutrition 0.000 abstract description 18
- 239000001384 succinic acid Substances 0.000 abstract description 18
- 239000001530 fumaric acid Substances 0.000 abstract description 17
- 239000003795 chemical substances by application Substances 0.000 description 57
- 239000007787 solid Substances 0.000 description 55
- DVQHYTBCTGYNNN-UHFFFAOYSA-N azane;cyclobutane-1,1-dicarboxylic acid;platinum Chemical compound N.N.[Pt].OC(=O)C1(C(O)=O)CCC1 DVQHYTBCTGYNNN-UHFFFAOYSA-N 0.000 description 50
- 229960004562 Carboplatin Drugs 0.000 description 48
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 41
- 229960001592 Paclitaxel Drugs 0.000 description 40
- 150000002500 ions Chemical class 0.000 description 40
- 229930003347 taxol Natural products 0.000 description 39
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 description 36
- 108009000071 Non-small cell lung cancer Proteins 0.000 description 36
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 36
- 229960004316 cisplatin Drugs 0.000 description 35
- 239000011780 sodium chloride Substances 0.000 description 35
- 235000002639 sodium chloride Nutrition 0.000 description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 34
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 33
- 230000000694 effects Effects 0.000 description 30
- 239000000243 solution Substances 0.000 description 30
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 28
- 238000002560 therapeutic procedure Methods 0.000 description 28
- 238000009474 hot melt extrusion Methods 0.000 description 26
- 150000003839 salts Chemical class 0.000 description 26
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 24
- 229960002949 Fluorouracil Drugs 0.000 description 24
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 23
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 22
- 239000011541 reaction mixture Substances 0.000 description 22
- 238000004458 analytical method Methods 0.000 description 21
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 20
- 239000000523 sample Substances 0.000 description 20
- 230000002829 reduced Effects 0.000 description 19
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 description 18
- 206010041067 Small cell lung cancer Diseases 0.000 description 18
- 238000007792 addition Methods 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 101700053624 PARP2 Proteins 0.000 description 17
- 239000002253 acid Substances 0.000 description 17
- 239000002552 dosage form Substances 0.000 description 17
- 239000000725 suspension Substances 0.000 description 17
- 206010000880 Acute myeloid leukaemia Diseases 0.000 description 16
- 239000000463 material Substances 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- 239000003981 vehicle Substances 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- 238000005160 1H NMR spectroscopy Methods 0.000 description 13
- 108009000276 Base Excision Repair Proteins 0.000 description 13
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 13
- BZLVMXJERCGZMT-UHFFFAOYSA-N MeOtBu Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 13
- 230000033590 base-excision repair Effects 0.000 description 13
- 238000004090 dissolution Methods 0.000 description 13
- 238000001228 spectrum Methods 0.000 description 13
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N DMSO-d6 Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 239000002246 antineoplastic agent Substances 0.000 description 12
- 238000004166 bioassay Methods 0.000 description 12
- 230000005496 eutectics Effects 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- KYARBIJYVGJZLB-UHFFFAOYSA-N 7-amino-4-hydroxy-2-naphthalenesulfonic acid Chemical compound OC1=CC(S(O)(=O)=O)=CC2=CC(N)=CC=C21 KYARBIJYVGJZLB-UHFFFAOYSA-N 0.000 description 11
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 11
- 235000019439 ethyl acetate Nutrition 0.000 description 11
- 238000001914 filtration Methods 0.000 description 11
- IUEWAGVJRJORLA-HZPDHXFCSA-N BMN-673 Chemical compound CN1N=CN=C1[C@H]1C(NNC(=O)C2=CC(F)=C3)=C2C3=N[C@@H]1C1=CC=C(F)C=C1 IUEWAGVJRJORLA-HZPDHXFCSA-N 0.000 description 10
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 10
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 10
- 239000002775 capsule Substances 0.000 description 10
- 229940079593 drugs Drugs 0.000 description 10
- 239000000706 filtrate Substances 0.000 description 10
- 229960005277 gemcitabine Drugs 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 230000000113 radiomimetic Effects 0.000 description 10
- 239000002002 slurry Substances 0.000 description 10
- 238000000371 solid-state nuclear magnetic resonance spectroscopy Methods 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- 210000001519 tissues Anatomy 0.000 description 10
- 230000033616 DNA repair Effects 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 108009000261 Non-homologous end joining Proteins 0.000 description 9
- 102100017733 PARP2 Human genes 0.000 description 9
- 230000037396 body weight Effects 0.000 description 9
- 238000002648 combination therapy Methods 0.000 description 9
- 238000010586 diagram Methods 0.000 description 9
- 238000000113 differential scanning calorimetry Methods 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 238000002844 melting Methods 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- 238000001757 thermogravimetry curve Methods 0.000 description 9
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 9
- 101700007241 APOC4 Proteins 0.000 description 8
- 108010022830 Cetuximab Proteins 0.000 description 8
- 101710038729 F2R Proteins 0.000 description 8
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Nitrumon Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 8
- 101700036247 PARP1 Proteins 0.000 description 8
- 102100014579 PARP1 Human genes 0.000 description 8
- 101700027237 PROA Proteins 0.000 description 8
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 8
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 8
- 230000003042 antagnostic Effects 0.000 description 8
- 101700004528 arp Proteins 0.000 description 8
- 229960005395 cetuximab Drugs 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 8
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 230000004614 tumor growth Effects 0.000 description 8
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 7
- 102100000648 ATM Human genes 0.000 description 7
- 108060006202 ATM Proteins 0.000 description 7
- 229960004397 Cyclophosphamide Drugs 0.000 description 7
- 231100000277 DNA damage Toxicity 0.000 description 7
- 229960004857 Mitomycin Drugs 0.000 description 7
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 7
- 101700061400 PRKDC Proteins 0.000 description 7
- 238000010928 TGA analysis Methods 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 7
- 230000001093 anti-cancer Effects 0.000 description 7
- 230000000340 anti-metabolite Effects 0.000 description 7
- 239000002256 antimetabolite Substances 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 230000003000 nontoxic Effects 0.000 description 7
- 231100000252 nontoxic Toxicity 0.000 description 7
- 238000010587 phase diagram Methods 0.000 description 7
- 230000000704 physical effect Effects 0.000 description 7
- 239000006187 pill Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 239000008247 solid mixture Substances 0.000 description 7
- 230000002195 synergetic Effects 0.000 description 7
- 238000002411 thermogravimetry Methods 0.000 description 7
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- 238000004922 13C solid-state nuclear magnetic resonance spectroscopy Methods 0.000 description 6
- 230000036912 Bioavailability Effects 0.000 description 6
- VSJKWCGYPAHWDS-FQEVSTJZSA-N Camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 6
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 6
- 229940121647 EGFR inhibitors Drugs 0.000 description 6
- UWKQSNNFCGGAFS-XIFFEERXSA-N Irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 6
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 102100003225 PRKDC Human genes 0.000 description 6
- CPTBDICYNRMXFX-UHFFFAOYSA-N Procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 6
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temodal Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 230000035514 bioavailability Effects 0.000 description 6
- 230000003115 biocidal Effects 0.000 description 6
- 239000012472 biological sample Substances 0.000 description 6
- 229960002092 busulfan Drugs 0.000 description 6
- 230000010261 cell growth Effects 0.000 description 6
- 230000000875 corresponding Effects 0.000 description 6
- 230000002708 enhancing Effects 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 239000002609 media Substances 0.000 description 6
- 229920000609 methyl cellulose Polymers 0.000 description 6
- 239000001923 methylcellulose Substances 0.000 description 6
- 230000000051 modifying Effects 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 description 5
- OMJKFYKNWZZKTK-UXBLZVDNSA-N (5E)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)N\N=C1\N=CN=C1C(N)=O OMJKFYKNWZZKTK-UXBLZVDNSA-N 0.000 description 5
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Belustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 5
- JCKYGMPEJWAADB-UHFFFAOYSA-N Chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 5
- 239000004971 Cross linker Substances 0.000 description 5
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 5
- AAKJLRGGTJKAMG-UHFFFAOYSA-N Erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 5
- 229960001433 Erlotinib Drugs 0.000 description 5
- 210000003236 Esophagogastric Junction Anatomy 0.000 description 5
- 229940090044 Injection Drugs 0.000 description 5
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 5
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 5
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N Melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 5
- 101700061424 POLB Proteins 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000002168 alkylating agent Substances 0.000 description 5
- 230000000259 anti-tumor Effects 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- 235000012970 cakes Nutrition 0.000 description 5
- 229960005243 carmustine Drugs 0.000 description 5
- 229960002436 cladribine Drugs 0.000 description 5
- 239000002270 dispersing agent Substances 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 102000017256 epidermal growth factor-activated receptor activity proteins Human genes 0.000 description 5
- 108040009258 epidermal growth factor-activated receptor activity proteins Proteins 0.000 description 5
- 238000001125 extrusion Methods 0.000 description 5
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- VSNHCAURESNICA-UHFFFAOYSA-N hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 230000000968 intestinal Effects 0.000 description 5
- 229960004768 irinotecan Drugs 0.000 description 5
- 239000000314 lubricant Substances 0.000 description 5
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 5
- 229960000485 methotrexate Drugs 0.000 description 5
- 230000000394 mitotic Effects 0.000 description 5
- 229960000624 procarbazine Drugs 0.000 description 5
- 239000007909 solid dosage form Substances 0.000 description 5
- 229960004964 temozolomide Drugs 0.000 description 5
- 229910052718 tin Inorganic materials 0.000 description 5
- ATJFFYVFTNAWJD-UHFFFAOYSA-N tin hydride Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 5
- 230000035899 viability Effects 0.000 description 5
- 239000001993 wax Substances 0.000 description 5
- CFCUWKMKBJTWLW-BGLFSJPPSA-N (2S,3S)-2-[(2S,4R,5R,6R)-4-[(2S,4R,5R,6R)-4-[(2S,4S,5R,6R)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-3-[(1S,3S,4R)-3,4-dihydroxy-1-methoxy-2-oxopentyl]-6-[(2S,4R,5S,6R)-4-[(2S,4R,5S,6R)-4,5-dih Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BGLFSJPPSA-N 0.000 description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 4
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical class CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 4
- 102100006824 ATR Human genes 0.000 description 4
- 108060000721 ATR Proteins 0.000 description 4
- 210000004369 Blood Anatomy 0.000 description 4
- 229960004630 Chlorambucil Drugs 0.000 description 4
- HAWPXGHAZFHHAD-UHFFFAOYSA-N Chlormethine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229940115080 Doxil Drugs 0.000 description 4
- 206010017758 Gastric cancer Diseases 0.000 description 4
- HOMGKSMUEGBAAB-UHFFFAOYSA-N Ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 4
- 239000005909 Kieselgur Substances 0.000 description 4
- 101700027219 LIG3 Proteins 0.000 description 4
- 102100003884 LRIG3 Human genes 0.000 description 4
- 101700041876 LRIG3 Proteins 0.000 description 4
- 210000004072 Lung Anatomy 0.000 description 4
- 229960004961 Mechlorethamine Drugs 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N N,N-Diethylethanamine Substances CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 4
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N Oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N Oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 229960003171 Plicamycin Drugs 0.000 description 4
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 4
- FKHIFSZMMVMEQY-UHFFFAOYSA-N Talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 description 4
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 4
- 229960005454 Thioguanine Drugs 0.000 description 4
- 102000005497 Thymidylate Synthase Human genes 0.000 description 4
- 108010067449 Thymidylate Synthase Proteins 0.000 description 4
- 229960004528 Vincristine Drugs 0.000 description 4
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000000996 additive Effects 0.000 description 4
- 230000000240 adjuvant Effects 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 235000010443 alginic acid Nutrition 0.000 description 4
- 229920000615 alginic acid Polymers 0.000 description 4
- RGHILYZRVFRRNK-UHFFFAOYSA-N anthracene-1,2-dione Chemical class C1=CC=C2C=C(C(C(=O)C=C3)=O)C3=CC2=C1 RGHILYZRVFRRNK-UHFFFAOYSA-N 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940045719 antineoplastic alkylating agents Nitrosoureas Drugs 0.000 description 4
- 235000020127 ayran Nutrition 0.000 description 4
- 229960002938 bexarotene Drugs 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- OKKJLVBELUTLKV-MZCSYVLQSA-N cd3od Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
- 230000022131 cell cycle Effects 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 229960003901 dacarbazine Drugs 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 229960000390 fludarabine Drugs 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 238000005755 formation reaction Methods 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 239000008079 hexane Substances 0.000 description 4
- 229960001330 hydroxycarbamide Drugs 0.000 description 4
- 229940027318 hydroxyurea Drugs 0.000 description 4
- 230000001965 increased Effects 0.000 description 4
- 239000003701 inert diluent Substances 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000000138 intercalating agent Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229960001924 melphalan Drugs 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 229960001428 mercaptopurine Drugs 0.000 description 4
- 239000000346 nonvolatile oil Substances 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 229960001756 oxaliplatin Drugs 0.000 description 4
- 201000008006 pharynx cancer Diseases 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 238000007747 plating Methods 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 230000002335 preservative Effects 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propanol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 201000011549 stomach cancer Diseases 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 230000004083 survival Effects 0.000 description 4
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 4
- 239000003039 volatile agent Substances 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- NRUKOCRGYNPUPR-QBPJDGROSA-N (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-thiophen-2-yl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 3
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-Methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
- 229940100198 ALKYLATING AGENTS Drugs 0.000 description 3
- 229940100197 ANTIMETABOLITES Drugs 0.000 description 3
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N Altretamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 3
- 229960002756 Azacitidine Drugs 0.000 description 3
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 3
- 229960004117 Capecitabine Drugs 0.000 description 3
- WDDPHFBMKLOVOX-AYQXTPAHSA-N Clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 description 3
- 229960000684 Cytarabine Drugs 0.000 description 3
- NOTIQUSPUUHHEH-UXOVVSIBSA-N Drostanolone propionate Chemical compound C([C@@H]1CC2)C(=O)[C@H](C)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)CC)[C@@]2(C)CC1 NOTIQUSPUUHHEH-UXOVVSIBSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 229910016860 FaSSIF Inorganic materials 0.000 description 3
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N Floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 3
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin hydrochloride Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 3
- 229960001101 Ifosfamide Drugs 0.000 description 3
- MDOJTZQKHMAPBK-UHFFFAOYSA-N Iniparib Chemical compound NC(=O)C1=CC=C(I)C([N+]([O-])=O)=C1 MDOJTZQKHMAPBK-UHFFFAOYSA-N 0.000 description 3
- 241000229754 Iva xanthiifolia Species 0.000 description 3
- 102100005410 LINE-1 retrotransposable element ORF2 protein Human genes 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- KKZJGLLVHKMTCM-UHFFFAOYSA-N Mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 3
- 229960001156 Mitoxantrone Drugs 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- 229950007221 Nedaplatin Drugs 0.000 description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 3
- 230000035536 Oral bioavailability Effects 0.000 description 3
- FPVKHBSQESCIEP-JQCXWYLXSA-N Pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 3
- 210000002307 Prostate Anatomy 0.000 description 3
- 102000001253 Protein Kinases Human genes 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 241000187747 Streptomyces Species 0.000 description 3
- FOCVUCIESVLUNU-UHFFFAOYSA-N ThioTEPA Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 3
- UCFGDBYHRUNTLO-QHCPKHFHSA-N Topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 3
- NMUSYJAQQFHJEW-KVTDHHQDSA-N U-18,496 Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 3
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N Valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 3
- 229960000473 altretamine Drugs 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 3
- 150000001541 aziridines Chemical class 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 239000006172 buffering agent Substances 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 230000001413 cellular Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 229960000928 clofarabine Drugs 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 238000010192 crystallographic characterization Methods 0.000 description 3
- 230000002354 daily Effects 0.000 description 3
- 230000003247 decreasing Effects 0.000 description 3
- 230000003111 delayed Effects 0.000 description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N deuterated chloroform Substances [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
- 229910001873 dinitrogen Inorganic materials 0.000 description 3
- 230000005670 electromagnetic radiation Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 201000004101 esophageal cancer Diseases 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 150000002334 glycols Chemical class 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 229960001691 leucovorin Drugs 0.000 description 3
- 229960002247 lomustine Drugs 0.000 description 3
- 230000003211 malignant Effects 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 230000011987 methylation Effects 0.000 description 3
- 238000007069 methylation reaction Methods 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 230000036220 oral bioavailability Effects 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 101710004466 rgy Proteins 0.000 description 3
- 101710030364 rgy1 Proteins 0.000 description 3
- 101710030359 rgy2 Proteins 0.000 description 3
- CKNPWBAXEKSCRG-UHFFFAOYSA-J satraplatin Chemical compound CC(=O)O[Pt-2]([NH3+])(Cl)(Cl)(OC(C)=O)[NH2+]C1CCCCC1 CKNPWBAXEKSCRG-UHFFFAOYSA-J 0.000 description 3
- 229960005399 satraplatin Drugs 0.000 description 3
- 238000009987 spinning Methods 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 238000001694 spray drying Methods 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229960000303 topotecan Drugs 0.000 description 3
- 150000004654 triazenes Chemical class 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- 229960000653 valrubicin Drugs 0.000 description 3
- JNAHVYVRKWKWKQ-CYBMUJFWSA-N veliparib Chemical compound N=1C2=CC=CC(C(N)=O)=C2NC=1[C@@]1(C)CCCN1 JNAHVYVRKWKWKQ-CYBMUJFWSA-N 0.000 description 3
- 229960002066 vinorelbine Drugs 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N (2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 2
- VWUXBMIQPBEWFH-WCCTWKNTSA-N (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 2
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-Bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
- BVDRUCCQKHGCRX-UHFFFAOYSA-N 2,3-dihydroxypropyl formate Chemical compound OCC(O)COC=O BVDRUCCQKHGCRX-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- HMABYWSNWIZPAG-UHFFFAOYSA-N 283173-50-2 Chemical compound C1=CC(CNC)=CC=C1C(N1)=C2CCNC(=O)C3=C2C1=CC(F)=C3 HMABYWSNWIZPAG-UHFFFAOYSA-N 0.000 description 2
- UZFPOOOQHWICKY-UHFFFAOYSA-N 3-[13-[1-[1-[8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21,24-dihydroporphyrin-2-yl]ethoxy]ethyl]-18-(2-carboxyethyl)-8-(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(C)C(C=C4N5)=N3)CCC(O)=O)=N2)C)=C(C)C(C(C)O)=C1C=C5C(C)=C4C(C)OC(C)C1=C(N2)C=C(N3)C(C)=C(C(O)C)C3=CC(C(C)=C3CCC(O)=O)=NC3=CC(C(CCC(O)=O)=C3C)=NC3=CC2=C1C UZFPOOOQHWICKY-UHFFFAOYSA-N 0.000 description 2
- VGPRNGGSKJHOFE-PBNXXWCMSA-N 4,6-dideuterio-2-methylpyrimidin-5-amine Chemical compound [2H]C1=NC(C)=NC([2H])=C1N VGPRNGGSKJHOFE-PBNXXWCMSA-N 0.000 description 2
- JRKLRIAIMIKGHT-UHFFFAOYSA-N 8-bromoquinoline-4-carbaldehyde Chemical compound C1=CN=C2C(Br)=CC=CC2=C1C=O JRKLRIAIMIKGHT-UHFFFAOYSA-N 0.000 description 2
- IKWTVSLWAPBBKU-UHFFFAOYSA-N A1010_SIAL Chemical compound O=[As]O[As]=O IKWTVSLWAPBBKU-UHFFFAOYSA-N 0.000 description 2
- 101710043194 APLN Proteins 0.000 description 2
- 101700004737 APTX Proteins 0.000 description 2
- 102100013042 APTX Human genes 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 2
- OFCNXPDARWKPPY-UHFFFAOYSA-N Allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 2
- YBBLVLTVTVSKRW-UHFFFAOYSA-N Anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 2
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 2
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 2
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 2
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 2
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N Benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 210000001124 Body Fluids Anatomy 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 210000000481 Breast Anatomy 0.000 description 2
- IVFYLRMMHVYGJH-PVPPCFLZSA-N Calusterone Chemical compound C1C[C@]2(C)[C@](O)(C)CC[C@H]2[C@@H]2[C@@H](C)CC3=CC(=O)CC[C@]3(C)[C@H]21 IVFYLRMMHVYGJH-PVPPCFLZSA-N 0.000 description 2
- 229950009823 Calusterone Drugs 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N Celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N DMA Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 102000020346 DNA glycosylase family Human genes 0.000 description 2
- 108020001738 DNA glycosylase family Proteins 0.000 description 2
- 229960000640 Dactinomycin Drugs 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- 229960000605 Dexrazoxane Drugs 0.000 description 2
- BMKDZUISNHGIBY-ZETCQYMHSA-N Dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 description 2
- 206010012818 Diffuse large B-cell lymphoma Diseases 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 102000008422 EC 2.7.1.78 Human genes 0.000 description 2
- 108010021757 EC 2.7.1.78 Proteins 0.000 description 2
- 102000010719 EC 4.2.99.18 Human genes 0.000 description 2
- 108010063362 EC 4.2.99.18 Proteins 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 210000003608 Feces Anatomy 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 229960000961 Floxuridine Drugs 0.000 description 2
- 229960002258 Fulvestrant Drugs 0.000 description 2
- 241000276438 Gadus morhua Species 0.000 description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N Gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229960002913 Goserelin Drugs 0.000 description 2
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 2
- 229960003690 Goserelin Acetate Drugs 0.000 description 2
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 2
- 102100013495 H2AX Human genes 0.000 description 2
- 101700085012 H2AX Proteins 0.000 description 2
- 240000006600 Humulus lupulus Species 0.000 description 2
- 235000008694 Humulus lupulus Nutrition 0.000 description 2
- 229960000908 Idarubicin Drugs 0.000 description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 2
- GOTYRUGSSMKFNF-UHFFFAOYSA-N Lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 2
- HPJKCIUCZWXJDR-UHFFFAOYSA-N Letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 2
- 229960004338 Leuprorelin Drugs 0.000 description 2
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levotetramisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 2
- 238000005004 MAS NMR spectroscopy Methods 0.000 description 2
- 102100008690 MBD4 Human genes 0.000 description 2
- 101700060039 MBD4 Proteins 0.000 description 2
- 229960004635 Mesna Drugs 0.000 description 2
- 229940101533 Mesnex Drugs 0.000 description 2
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 2
- 108020004999 Messenger RNA Proteins 0.000 description 2
- FUSUHKVFWTUUBE-UHFFFAOYSA-N Methyl vinyl ketone Chemical compound CC(=O)C=C FUSUHKVFWTUUBE-UHFFFAOYSA-N 0.000 description 2
- 229960000350 Mitotane Drugs 0.000 description 2
- 208000003003 Muscular Dystrophy, Congenital, Lmna-Related Diseases 0.000 description 2
- 101700052800 NEIL3 Proteins 0.000 description 2
- 102100018378 NEIL3 Human genes 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- IXOXBSCIXZEQEQ-UHTZMRCNSA-N Nelarabine Chemical compound C1=NC=2C(OC)=NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O IXOXBSCIXZEQEQ-UHTZMRCNSA-N 0.000 description 2
- 241001182492 Nes Species 0.000 description 2
- FAQDUNYVKQKNLD-UHFFFAOYSA-N Olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- 241000283898 Ovis Species 0.000 description 2
- 101700012117 POLG Proteins 0.000 description 2
- 229960002340 Pentostatin Drugs 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N Perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 108091000081 Phosphotransferases Proteins 0.000 description 2
- NJBFOOCLYDNZJN-UHFFFAOYSA-N Pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 102100016116 RAD50 Human genes 0.000 description 2
- 108060007644 RAD50 Proteins 0.000 description 2
- VHXNKPBCCMUMSW-FQEVSTJZSA-N Rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 description 2
- 229950009213 Rubitecan Drugs 0.000 description 2
- 101700072540 SMG1 Proteins 0.000 description 2
- 102100004167 SMG1 Human genes 0.000 description 2
- 210000000582 Semen Anatomy 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WINHZLLDWRZWRT-ATVHPVEESA-N Sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 102100019730 TP53 Human genes 0.000 description 2
- 101710026335 TP53 Proteins 0.000 description 2
- 108060008443 TPPP Proteins 0.000 description 2
- 229960001603 Tamoxifen Drugs 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 229940099419 Targretin Drugs 0.000 description 2
- 210000001138 Tears Anatomy 0.000 description 2
- 229960001278 Teniposide Drugs 0.000 description 2
- 229960005353 Testolactone Drugs 0.000 description 2
- 229960001196 Thiotepa Drugs 0.000 description 2
- 229940035295 Ting Drugs 0.000 description 2
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 2
- XFCLJVABOIYOMF-QPLCGJKRSA-N Toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- IDPUKCWIGUEADI-UHFFFAOYSA-N Uramustine Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 2
- 210000002700 Urine Anatomy 0.000 description 2
- 229960003048 Vinblastine Drugs 0.000 description 2
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- WAEXFXRVDQXREF-UHFFFAOYSA-N Vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 2
- 229940033942 Zoladex Drugs 0.000 description 2
- XRASPMIURGNCCH-UHFFFAOYSA-N Zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 2
- LIQODXNTTZAGID-OCBXBXKTSA-N [4-[(5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-8-oxo-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-9-yl]-2,6-dimethoxyphenyl] dihydrogen phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 description 2
- IKDXDQDKCZPQSZ-JHYYTBFNSA-N acetic acid;(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopro Chemical compound CC(O)=O.C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 IKDXDQDKCZPQSZ-JHYYTBFNSA-N 0.000 description 2
- 230000001154 acute Effects 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 229960001445 alitretinoin Drugs 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 229960003459 allopurinol Drugs 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 229960002932 anastrozole Drugs 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 229960002594 arsenic trioxide Drugs 0.000 description 2
- 238000000498 ball milling Methods 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 150000003857 carboxamides Chemical class 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 229960000590 celecoxib Drugs 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 230000035572 chemosensitivity Effects 0.000 description 2
- 230000000973 chemotherapeutic Effects 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 235000019516 cod Nutrition 0.000 description 2
- ZNEWHQLOPFWXOF-UHFFFAOYSA-N coenzyme M Chemical compound OS(=O)(=O)CCS ZNEWHQLOPFWXOF-UHFFFAOYSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 230000001351 cycling Effects 0.000 description 2
- 230000001472 cytotoxic Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 101700042245 ddx3 Proteins 0.000 description 2
- 230000001419 dependent Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 2
- 229940043264 dodecyl sulfate Drugs 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 229940017743 dromostanolone propionate Drugs 0.000 description 2
- 229950004683 drostanolone propionate Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 229960000752 etoposide phosphate Drugs 0.000 description 2
- 229960000255 exemestane Drugs 0.000 description 2
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 2
- 235000008191 folinic acid Nutrition 0.000 description 2
- 239000011672 folinic acid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229960002584 gefitinib Drugs 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000001738 genotoxic Effects 0.000 description 2
- 231100000024 genotoxic Toxicity 0.000 description 2
- 230000000762 glandular Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-M glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 230000001976 improved Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000000977 initiatory Effects 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 229940079866 intestinal antibiotics Drugs 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 238000010902 jet-milling Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 229960004942 lenalidomide Drugs 0.000 description 2
- 230000003902 lesions Effects 0.000 description 2
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229920002106 messenger RNA Polymers 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 108010045030 monoclonal antibodies Proteins 0.000 description 2
- 102000005614 monoclonal antibodies Human genes 0.000 description 2
- 235000013919 monopotassium glutamate Nutrition 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- UBWXUGDQUBIEIZ-QNTYDACNSA-N nandrolone phenpropionate Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@H]4CCC(=O)C=C4CC3)CC[C@@]21C)C(=O)CCC1=CC=CC=C1 UBWXUGDQUBIEIZ-QNTYDACNSA-N 0.000 description 2
- 229960000801 nelarabine Drugs 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 230000002020 noncytotoxic Effects 0.000 description 2
- 231100000065 noncytotoxic Toxicity 0.000 description 2
- 229960000572 olaparib Drugs 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 108010027841 pegademase bovine Proteins 0.000 description 2
- WBXPDJSOTKVWSJ-ZDUSSCGKSA-N pemetrexed Chemical compound C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 WBXPDJSOTKVWSJ-ZDUSSCGKSA-N 0.000 description 2
- 229960005079 pemetrexed Drugs 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 229960000952 pipobroman Drugs 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000000649 purine antagonist Substances 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- 239000010948 rhodium Substances 0.000 description 2
- 229950004707 rucaparib Drugs 0.000 description 2
- 238000000646 scanning calorimetry Methods 0.000 description 2
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000001235 sensitizing Effects 0.000 description 2
- 231100000202 sensitizing Toxicity 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000001187 sodium carbonate Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- XOGTZOOQQBDUSI-UHFFFAOYSA-M sodium;2-sulfanylethanesulfonate Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 2
- 238000000279 solid-state nuclear magnetic resonance spectrum Methods 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 229960003787 sorafenib Drugs 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-M stearate Chemical compound CCCCCCCCCCCCCCCCCC([O-])=O QIQXTHQIDYTFRH-UHFFFAOYSA-M 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 229960001796 sunitinib Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 2
- 229960005026 toremifene Drugs 0.000 description 2
- 229960005267 tositumomab Drugs 0.000 description 2
- 238000004450 types of analysis Methods 0.000 description 2
- 229960001055 uracil mustard Drugs 0.000 description 2
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 2
- 229960004276 zoledronic acid Drugs 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- VYXHVRARDIDEHS-QGTKBVGQSA-N (1Z,5Z)-cycloocta-1,5-diene Chemical compound C\1C\C=C/CC\C=C/1 VYXHVRARDIDEHS-QGTKBVGQSA-N 0.000 description 1
- PUSNGFYSTWMJSK-GSZQVNRLSA-N (2R,3R,4S,5R,6R)-2,3,4-trimethoxy-6-(methoxymethyl)-5-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxyoxane;1-[[(2R,3R,4S,5R,6S)-3,4,5-tris(2-hydroxypropoxy)-6-[(2R,3R,4S,5R,6R)-4,5,6-tris(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)oxan- Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](OC)O[C@@H]1COC.CC(O)CO[C@@H]1[C@@H](OCC(C)O)[C@H](OCC(C)O)[C@@H](COCC(O)C)O[C@H]1O[C@H]1[C@H](OCC(C)O)[C@@H](OCC(C)O)[C@H](OCC(C)O)O[C@@H]1COCC(C)O PUSNGFYSTWMJSK-GSZQVNRLSA-N 0.000 description 1
- RQHVNNWVDLRULK-PHEQNACWSA-N (6E)-6-[[2-[[(E)-(6-oxocyclohexa-2,4-dien-1-ylidene)methyl]amino]ethylamino]methylidene]cyclohexa-2,4-dien-1-one Chemical compound O=C1C=CC=C\C1=C/NCCN\C=C/1C(=O)C=CC=C\1 RQHVNNWVDLRULK-PHEQNACWSA-N 0.000 description 1
- VVIAGPKUTFNRDU-STQMWFEESA-N (6S)-5-formyltetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1C=O)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-STQMWFEESA-N 0.000 description 1
- KMSKQZKKOZQFFG-YXRRJAAWSA-N (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-6-methyl-5-[(2R)-oxan-2-yl]oxyoxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@@H]1CCCCO1 KMSKQZKKOZQFFG-YXRRJAAWSA-N 0.000 description 1
- UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-Trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 description 1
- AVFZOVWCLRSYKC-UHFFFAOYSA-N 1-methylpyrrolidine Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 description 1
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 1
- 108040005185 1-phosphatidylinositol-3-kinase activity proteins Proteins 0.000 description 1
- 238000004482 13C cross polarization magic angle spinning Methods 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- GCSJOZFHZGHGTJ-UHFFFAOYSA-N 2-[2-[3,4-bis(2-hydroxyethoxy)oxolan-2-yl]-2-(2-hydroxyethoxy)ethoxy]ethyl formate Chemical compound O=COCCOCC(OCCO)C1OCC(OCCO)C1OCCO GCSJOZFHZGHGTJ-UHFFFAOYSA-N 0.000 description 1
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 1
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2S)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
- AOPBDRUWRLBSDB-UHFFFAOYSA-N 2-bromoaniline Chemical compound NC1=CC=CC=C1Br AOPBDRUWRLBSDB-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N 2-stearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- WUIABRMSWOKTOF-PATWWPTKSA-N 3-[[2-[2-[2-[[(2R,3R)-2-[[(2R,3R,4S)-4-[[(2S)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2R)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2S,3R,4R,5R,6R)-3-[(2R,3S,4S,5R,6R)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan- Chemical compound OS([O-])(=O)=O.N([C@H](C(=O)N[C@@H](C)[C@H](O)[C@@H](C)C(=O)N[C@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)C(O[C@@H]1[C@@H]([C@H](O)[C@@H](O)[C@@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-PATWWPTKSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-M 3-cyclopentylpropanoate Chemical compound [O-]C(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-M 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- 125000002103 4,4'-dimethoxytriphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)(C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H])C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- LZPWAYBEOJRFAX-UHFFFAOYSA-N 4,4,5,5-tetramethyl-1,3,2$l^{2}-dioxaborolane Chemical compound CC1(C)O[B]OC1(C)C LZPWAYBEOJRFAX-UHFFFAOYSA-N 0.000 description 1
- XJPZKYIHCLDXST-UHFFFAOYSA-N 4,6-dichloropyrimidine Chemical compound ClC1=CC(Cl)=NC=N1 XJPZKYIHCLDXST-UHFFFAOYSA-N 0.000 description 1
- COBZMDPXIDGRHY-QFIQSOQBSA-N 4,6-dideuterio-2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine Chemical compound [2H]C1=NC(C)=NC([2H])=C1B1OC(C)(C)C(C)(C)O1 COBZMDPXIDGRHY-QFIQSOQBSA-N 0.000 description 1
- JVYNJRBSXBYXQB-UHFFFAOYSA-N 4-[3-(4-carboxyphenoxy)propoxy]benzoic acid;decanedioic acid Chemical compound OC(=O)CCCCCCCCC(O)=O.C1=CC(C(=O)O)=CC=C1OCCCOC1=CC=C(C(O)=O)C=C1 JVYNJRBSXBYXQB-UHFFFAOYSA-N 0.000 description 1
- HYNBNUYQTQIHJK-UHFFFAOYSA-N 4-[[4-fluoro-3-(4-methoxypiperidine-1-carbonyl)phenyl]methyl]-2H-phthalazin-1-one Chemical compound C1CC(OC)CCN1C(=O)C1=CC(CC=2C3=CC=CC=C3C(=O)NN=2)=CC=C1F HYNBNUYQTQIHJK-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- YJISHJVIRFPGGN-UHFFFAOYSA-N 5-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy-6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)O)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 YJISHJVIRFPGGN-UHFFFAOYSA-N 0.000 description 1
- 101710025088 66 Proteins 0.000 description 1
- ILYBMUDLGFMEMU-UHFFFAOYSA-N 7-$l^{1}-oxidanyl-2,3,4,5,6,7-hexaoxoheptan-1-olate Chemical compound [O]C(=O)C(=O)C(=O)C(=O)C(=O)C(=O)C[O-] ILYBMUDLGFMEMU-UHFFFAOYSA-N 0.000 description 1
- WKFLNVQGWQBFBD-UHFFFAOYSA-N 8-bromo-N-methylquinoline-4-carboxamide Chemical compound C1=CC=C2C(C(=O)NC)=CC=NC2=C1Br WKFLNVQGWQBFBD-UHFFFAOYSA-N 0.000 description 1
- AFDUIUOATSXDFH-UHFFFAOYSA-N 8-bromoquinoline-2-carbaldehyde Chemical compound C1=C(C=O)N=C2C(Br)=CC=CC2=C1 AFDUIUOATSXDFH-UHFFFAOYSA-N 0.000 description 1
- HLEBPQHZLBSIJC-UHFFFAOYSA-N 8-bromoquinoline-4-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=NC2=C1Br HLEBPQHZLBSIJC-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N AI2O3 Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 101710027066 ALB Proteins 0.000 description 1
- VJZITPJGSQKZMX-XDPRQOKASA-N AMRUBICIN Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 description 1
- 101710034857 ATIC Proteins 0.000 description 1
- 230000035533 AUC Effects 0.000 description 1
- 229940028652 Abraxane Drugs 0.000 description 1
- 229960004176 Aclarubicin Drugs 0.000 description 1
- 229940060205 Adagen Drugs 0.000 description 1
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
- 208000009956 Adenocarcinoma Diseases 0.000 description 1
- 229940009456 Adriamycin Drugs 0.000 description 1
- 229940064305 Adrucil Drugs 0.000 description 1
- 229940110282 Alimta Drugs 0.000 description 1
- 229940098174 Alkeran Drugs 0.000 description 1
- 229940045714 Alkyl sulfonate alkylating agents Drugs 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N Aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 229940063655 Aluminum stearate Drugs 0.000 description 1
- 229960001097 Amifostine Drugs 0.000 description 1
- JKOQGQFVAUAYPM-UHFFFAOYSA-N Amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 description 1
- 229960003896 Aminopterin Drugs 0.000 description 1
- 229960001220 Amsacrine Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N Amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 208000000058 Anaplasia Diseases 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 206010059512 Apoptosis Diseases 0.000 description 1
- 240000005781 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 229940078010 Arimidex Drugs 0.000 description 1
- 229940087620 Aromasin Drugs 0.000 description 1
- 229940014583 Arranon Drugs 0.000 description 1
- 229940009098 Aspartate Drugs 0.000 description 1
- 229940120638 Avastin Drugs 0.000 description 1
- 210000003719 B-Lymphocytes Anatomy 0.000 description 1
- LNHWXBUNXOXMRL-VWLOTQADSA-N Belotecan Chemical compound C1=CC=C2C(CCNC(C)C)=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 LNHWXBUNXOXMRL-VWLOTQADSA-N 0.000 description 1
- 229950011276 Belotecan Drugs 0.000 description 1
- YTKUWDBFDASYHO-UHFFFAOYSA-N Bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 1
- 229940050390 Benzoate Drugs 0.000 description 1
- 229940108502 BiCNU Drugs 0.000 description 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N Bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
- 230000035639 Blood Levels Effects 0.000 description 1
- 229920002799 BoPET Polymers 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N Bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 241000219193 Brassicaceae Species 0.000 description 1
- 229940112133 Busulfex Drugs 0.000 description 1
- 210000001217 Buttocks Anatomy 0.000 description 1
- 102100005858 CCNA2 Human genes 0.000 description 1
- 102100003755 CCNO Human genes 0.000 description 1
- 101700047412 CCNO Proteins 0.000 description 1
- 101700067048 CDC13 Proteins 0.000 description 1
- 101700024634 CDK16 Proteins 0.000 description 1
- 102100019396 CDK2 Human genes 0.000 description 1
- 108060006647 CHEK2 Proteins 0.000 description 1
- 102100019698 CHEK2 Human genes 0.000 description 1
- FVLVBPDQNARYJU-KYZUINATSA-N CHEMBL1967746 Chemical compound C[C@H]1CC[C@H](NC(=O)N(CCCl)N=O)CC1 FVLVBPDQNARYJU-KYZUINATSA-N 0.000 description 1
- 102100006400 CSF2 Human genes 0.000 description 1
- 102100006435 CSF3 Human genes 0.000 description 1
- 229960003563 Calcium Carbonate Drugs 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L Calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 240000002804 Calluna vulgaris Species 0.000 description 1
- 235000007575 Calluna vulgaris Nutrition 0.000 description 1
- DSSYKIVIOFKYAU-UHFFFAOYSA-N Camphor Chemical compound C1CC2(C)C(=O)CC1C2(C)C DSSYKIVIOFKYAU-UHFFFAOYSA-N 0.000 description 1
- 229940088954 Camptosar Drugs 0.000 description 1
- SHHKQEUPHAENFK-UHFFFAOYSA-N Carboquone Chemical compound O=C1C(C)=C(N2CC2)C(=O)C(C(COC(N)=O)OC)=C1N1CC1 SHHKQEUPHAENFK-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 229940047495 Celebrex Drugs 0.000 description 1
- 229920002301 Cellulose acetate Polymers 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008943 Chronic leukaemia Diseases 0.000 description 1
- 229940103380 Clolar Drugs 0.000 description 1
- IAKHMKGGTNLKSZ-INIZCTEOSA-N Colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 1
- 210000002808 Connective Tissue Anatomy 0.000 description 1
- 229940088547 Cosmegen Drugs 0.000 description 1
- 108010068192 Cyclin A Proteins 0.000 description 1
- 102000003909 Cyclin E Human genes 0.000 description 1
- 108090000257 Cyclin E Proteins 0.000 description 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N DL-aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- UZZWBUYVTBPQIV-UHFFFAOYSA-N DME dimethoxyethane Chemical compound COCCOC.COCCOC UZZWBUYVTBPQIV-UHFFFAOYSA-N 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 101700038723 DOHH Proteins 0.000 description 1
- 101700011961 DPOM Proteins 0.000 description 1
- 108010019673 Darbepoetin alfa Proteins 0.000 description 1
- 229940041983 Daunorubicin Liposomal Drugs 0.000 description 1
- 229940070968 DepoCyt Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 Dexamethasone Drugs 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K Dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N Diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L Dipotassium phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 108010092799 EC 2.7.7.49 Proteins 0.000 description 1
- 229940034984 ENDOCRINE THERAPY ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS Drugs 0.000 description 1
- 102100016655 ERN1 Human genes 0.000 description 1
- 101700036757 ERN1 Proteins 0.000 description 1
- 101700014948 ERN2 Proteins 0.000 description 1
- 229940047652 Ear Drops Drugs 0.000 description 1
- 229940053594 Eligard Drugs 0.000 description 1
- 229940087477 Ellence Drugs 0.000 description 1
- 229940120655 Eloxatin Drugs 0.000 description 1
- 229940073038 Elspar Drugs 0.000 description 1
- 229940000733 Emcyt Drugs 0.000 description 1
- 229940088598 Enzyme Drugs 0.000 description 1
- 108010074604 Epoetin Alfa Proteins 0.000 description 1
- 229960003388 Epoetin alfa Drugs 0.000 description 1
- 229940089118 Epogen Drugs 0.000 description 1
- 229940082789 Erbitux Drugs 0.000 description 1
- 229960001842 Estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N Estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N EtOAc EtOAc Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N Ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940047887 Etopophos Drugs 0.000 description 1
- 230000036826 Excretion Effects 0.000 description 1
- 229940012356 Eye Drops Drugs 0.000 description 1
- 108060000495 FBXW7 Proteins 0.000 description 1
- 102100020077 FBXW7 Human genes 0.000 description 1
- 229940043168 Fareston Drugs 0.000 description 1
- 229940087861 Faslodex Drugs 0.000 description 1
- 229940087476 Femara Drugs 0.000 description 1
- 229960004177 Filgrastim Drugs 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N Flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 230000035521 G2 Phase Effects 0.000 description 1
- 230000010337 G2 phase Effects 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 229940020967 Gemzar Drugs 0.000 description 1
- 229940084910 Gliadel Drugs 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N Glycerol 3-phosphate Chemical compound OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101710035962 HB1 Proteins 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 206010073071 Hepatocellular carcinoma Diseases 0.000 description 1
- 229940022353 Herceptin Drugs 0.000 description 1
- 229940003183 Hexalen Drugs 0.000 description 1
- 229960003911 Histrelin acetate Drugs 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229940088597 Hormone Drugs 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006822 Human Serum Albumin Proteins 0.000 description 1
- 229940088013 Hycamtin Drugs 0.000 description 1
- 229940096120 Hydrea Drugs 0.000 description 1
- 241000282619 Hylobates lar Species 0.000 description 1
- 102100005044 IL11 Human genes 0.000 description 1
- SYJRVVFAAIUVDH-UHFFFAOYSA-N IPA isopropanol Chemical compound CC(C)O.CC(C)O SYJRVVFAAIUVDH-UHFFFAOYSA-N 0.000 description 1
- 101700085586 IRE1A Proteins 0.000 description 1
- 101700019719 IRE1B Proteins 0.000 description 1
- 229940099279 Idamycin Drugs 0.000 description 1
- 229940090411 Ifex Drugs 0.000 description 1
- 229960003685 Imatinib mesylate Drugs 0.000 description 1
- 229940060367 Inert Ingredients Drugs 0.000 description 1
- 229950002133 Iniparib Drugs 0.000 description 1
- 229940102223 Injectable Solution Drugs 0.000 description 1
- 229940102213 Injectable Suspension Drugs 0.000 description 1
- 229960003521 Interferon Alfa-2a Drugs 0.000 description 1
- 229960003507 Interferon Alfa-2b Drugs 0.000 description 1
- 229940047124 Interferons Drugs 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 229940047122 Interleukins Drugs 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 210000000936 Intestines Anatomy 0.000 description 1
- 229940084651 Iressa Drugs 0.000 description 1
- 210000001630 Jejunum Anatomy 0.000 description 1
- 244000232488 Jessenia polycarpa Species 0.000 description 1
- 235000002407 Jessenia polycarpa Nutrition 0.000 description 1
- 101710033922 KRAS Proteins 0.000 description 1
- 229940065223 Kepivance Drugs 0.000 description 1
- 102000015335 Ku Autoantigen Human genes 0.000 description 1
- 108010025026 Ku Autoantigen Proteins 0.000 description 1
- 229940001447 Lactate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N Lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229940063725 Leukeran Drugs 0.000 description 1
- 229940087875 Leukine Drugs 0.000 description 1
- 229940008250 Leuprolide Drugs 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 229950008991 Lobaplatin Drugs 0.000 description 1
- 229940100029 Lysodren Drugs 0.000 description 1
- 101710007526 MAP3K14 Proteins 0.000 description 1
- 101710029649 MDV043 Proteins 0.000 description 1
- 102100013322 MTOR Human genes 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L Magnesium hydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N Maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- UUVIQYKKKBJYJT-ZYUZMQFOSA-N Mannosulfan Chemical compound CS(=O)(=O)OC[C@@H](OS(C)(=O)=O)[C@@H](O)[C@H](O)[C@H](OS(C)(=O)=O)COS(C)(=O)=O UUVIQYKKKBJYJT-ZYUZMQFOSA-N 0.000 description 1
- 229960000733 Mannosulfan Drugs 0.000 description 1
- 229940087732 Matulane Drugs 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N MeOH methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 229940090004 Megace Drugs 0.000 description 1
- 229960004296 Megestrol Acetate Drugs 0.000 description 1
- GPKJTRJOBQGKQK-UHFFFAOYSA-N Mepacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 229940087004 Mustargen Drugs 0.000 description 1
- 239000005041 Mylar™ Substances 0.000 description 1
- 229940090009 Myleran Drugs 0.000 description 1
- FGNGTWFJQFTFGN-UHFFFAOYSA-N N,N,N',N'-tetramethylethane-1,2-diamine Chemical compound CN(C)CCN(C)C.CN(C)CCN(C)C FGNGTWFJQFTFGN-UHFFFAOYSA-N 0.000 description 1
- XFAZZQREFHAALG-UHFFFAOYSA-N N-{1-amino-6-[(5-nitro-2-furoyl)amino]-1-oxohexan-2-yl}-23-(indol-3-yl)-20-oxo-4,7,10,13,16-pentaoxa-19-azatricosan-1-amide Chemical compound C=1NC2=CC=CC=C2C=1CCCC(=O)NCCOCCOCCOCCOCCOCCC(=O)NC(C(=O)N)CCCCNC(=O)C1=CC=C([N+]([O-])=O)O1 XFAZZQREFHAALG-UHFFFAOYSA-N 0.000 description 1
- 102100018379 NEIL2 Human genes 0.000 description 1
- 101700036395 NEIL2 Proteins 0.000 description 1
- 101710033916 NRAS Proteins 0.000 description 1
- 102100001119 NRAS Human genes 0.000 description 1
- 229940086322 Navelbine Drugs 0.000 description 1
- QZGIWPZCWHMVQL-UIYAJPBUSA-N Neocarzinostatin Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 1
- 229940071846 Neulasta Drugs 0.000 description 1
- 229940082926 Neumega Drugs 0.000 description 1
- 229940029345 Neupogen Drugs 0.000 description 1
- 229940080607 Nexavar Drugs 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N Nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- 229940109551 Nipent Drugs 0.000 description 1
- 229940085033 Nolvadex Drugs 0.000 description 1
- 229950007318 OZOGAMICIN Drugs 0.000 description 1
- 229940049964 Oleate Drugs 0.000 description 1
- 229940099216 Oncaspar Drugs 0.000 description 1
- 229940100027 Ontak Drugs 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229940098901 POLIFEPROSAN 20 Drugs 0.000 description 1
- 101700044505 PUB33 Proteins 0.000 description 1
- 101700045570 PUB34 Proteins 0.000 description 1
- 101700046887 PUB35 Proteins 0.000 description 1
- 101700066160 PUB51 Proteins 0.000 description 1
- 101700067511 PUB52 Proteins 0.000 description 1
- 101700068819 PUB53 Proteins 0.000 description 1
- 101700086326 PUB70 Proteins 0.000 description 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N Pamidronic acid Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 235000003177 Panax trifolius Nutrition 0.000 description 1
- 229940096763 Panretin Drugs 0.000 description 1
- SHGAZHPCJJPHSC-UHFFFAOYSA-N Panrexin Chemical compound OC(=O)C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229960001373 Pegfilgrastim Drugs 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 229940109328 Photofrin Drugs 0.000 description 1
- IIMIOEBMYPRQGU-UHFFFAOYSA-L Picoplatin Chemical compound N.[Cl-].[Cl-].[Pt+2].CC1=CC=CC=N1 IIMIOEBMYPRQGU-UHFFFAOYSA-L 0.000 description 1
- 229950005566 Picoplatin Drugs 0.000 description 1
- 229940023488 Pill Drugs 0.000 description 1
- IVDFJHOHABJVEH-UHFFFAOYSA-N Pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 1
- 229950010765 Pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N Pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229940063179 Platinol Drugs 0.000 description 1
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 1
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000004698 Polyethylene (PE) Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 229920001451 Polypropylene glycol Polymers 0.000 description 1
- 229960004293 Porfimer Sodium Drugs 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M Potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- 241000048284 Potato virus P Species 0.000 description 1
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 1
- 229940087463 Proleukin Drugs 0.000 description 1
- 229950008679 Protamine sulfate Drugs 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 108060006633 Protein Kinases Proteins 0.000 description 1
- 229940117820 Purinethol Drugs 0.000 description 1
- 102100008299 RBBP8 Human genes 0.000 description 1
- 101710036782 RBBP8 Proteins 0.000 description 1
- 101700054624 RF1 Proteins 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- AHHFEZNOXOZZQA-ZEBDFXRSSA-N Ranimustine Chemical compound CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O AHHFEZNOXOZZQA-ZEBDFXRSSA-N 0.000 description 1
- 229960000424 Rasburicase Drugs 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 210000000664 Rectum Anatomy 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N Retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229940120975 Revlimid Drugs 0.000 description 1
- 229940003641 Rituxan Drugs 0.000 description 1
- 108010001645 Rituximab Proteins 0.000 description 1
- 230000036191 S Phase Effects 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- HNMATTJJEPZZMM-BPKVFSPJSA-N S-[(2R,3S,4S,6S)-6-[[(2R,3S,4S,5R,6R)-5-[(2S,4S,5S)-5-[acetyl(ethyl)amino]-4-methoxyoxan-2-yl]oxy-6-[[(2S,5Z,9R,13E)-13-[2-[[4-[(2E)-2-[1-[4-(4-amino-4-oxobutoxy)phenyl]ethylidene]hydrazinyl]-2-methyl-4-oxobutan-2-yl]disulfanyl]ethylidene]-9-hydroxy-12-(m Chemical compound C1[C@H](OC)[C@@H](N(CC)C(C)=O)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@@](C/3=C/CSSC(C)(C)CC(=O)N\N=C(/C)C=3C=CC(OCCCC(N)=O)=CC=3)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HNMATTJJEPZZMM-BPKVFSPJSA-N 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 210000003296 Saliva Anatomy 0.000 description 1
- 229940053186 Sclerosol Drugs 0.000 description 1
- 210000002966 Serum Anatomy 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N Silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M Sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- UKLNMMHNWFDKNT-UHFFFAOYSA-M Sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 1
- 240000001016 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229940075582 Sorbic Acid Drugs 0.000 description 1
- JNYAEWCLZODPBN-CTQIIAAMSA-N Sorbitan Chemical compound OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 description 1
- 229960001052 Streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N Streptozotocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L Sulphite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 229940034785 Sutent Drugs 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 229940120982 Tarceva Drugs 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N Tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- 229940061353 Temodar Drugs 0.000 description 1
- 210000001685 Thyroid Gland Anatomy 0.000 description 1
- 108010010691 Trastuzumab Proteins 0.000 description 1
- 229950001353 Tretamine Drugs 0.000 description 1
- 229960001727 Tretinoin Drugs 0.000 description 1
- SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 description 1
- PXSOHRWMIRDKMP-UHFFFAOYSA-N Triaziquone Chemical compound O=C1C(N2CC2)=C(N2CC2)C(=O)C=C1N1CC1 PXSOHRWMIRDKMP-UHFFFAOYSA-N 0.000 description 1
- 229960004560 Triaziquone Drugs 0.000 description 1
- 229940086984 Trisenox Drugs 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- UMKFEPPTGMDVMI-UHFFFAOYSA-N Trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 description 1
- HWKQNAWCHQMZHK-UHFFFAOYSA-N Trolnitrate Chemical compound [O-][N+](=O)OCCN(CCO[N+]([O-])=O)CCO[N+]([O-])=O HWKQNAWCHQMZHK-UHFFFAOYSA-N 0.000 description 1
- 229940035893 Uracil Drugs 0.000 description 1
- 229940001814 Uvadex Drugs 0.000 description 1
- 229940054937 Valstar Drugs 0.000 description 1
- 229950011257 Veliparib Drugs 0.000 description 1
- 229940065658 Vidaza Drugs 0.000 description 1
- 229960000237 Vorinostat Drugs 0.000 description 1
- 210000002268 Wool Anatomy 0.000 description 1
- QXKHYNVANLEOEG-UHFFFAOYSA-N XANTHOTOXIN Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 1
- 102100009954 XRCC6 Human genes 0.000 description 1
- 101700032709 XRCC6 Proteins 0.000 description 1
- 229940053867 Xeloda Drugs 0.000 description 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Yamafur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
- 241000209149 Zea Species 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 229940099232 Zinecard Drugs 0.000 description 1
- 229940061261 Zolinza Drugs 0.000 description 1
- 229940002005 Zometa Drugs 0.000 description 1
- FBTUMDXHSRTGRV-ALTNURHMSA-N Zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1
- 229940088909 Zyloprim Drugs 0.000 description 1
- YCPOZVAOBBQLRI-PHDIDXHHSA-N [(2R,3R)-2,3-dihydroxy-4-methylsulfonyloxybutyl] methanesulfonate Chemical compound CS(=O)(=O)OC[C@@H](O)[C@H](O)COS(C)(=O)=O YCPOZVAOBBQLRI-PHDIDXHHSA-N 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N [(8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- XSMVECZRZBFTIZ-UHFFFAOYSA-M [2-(aminomethyl)cyclobutyl]methanamine;2-oxidopropanoate;platinum(4+) Chemical compound [Pt+4].CC([O-])C([O-])=O.NCC1CCC1CN XSMVECZRZBFTIZ-UHFFFAOYSA-M 0.000 description 1
- SRNWOUGRCWSEMX-KEOHHSTQSA-N [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-3,4,5-trihydroxyoxolan-2-yl]methyl hydrogen phosphate Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=CN=C(C=2N=C1)N)OP(O)(=O)OP(O)(=O)OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O SRNWOUGRCWSEMX-KEOHHSTQSA-N 0.000 description 1
- 229960002184 abarelix Drugs 0.000 description 1
- 108010023617 abarelix Proteins 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 231100000494 adverse effect Toxicity 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229960005310 aldesleukin Drugs 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960002550 amrubicin Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 229960003473 androstanolone Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003474 anti-emetic Effects 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 108090001123 antibodies Proteins 0.000 description 1
- 102000004965 antibodies Human genes 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229940027983 antiseptics and disinfectants Quaternary ammonium compounds Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- 125000005228 aryl sulfonate group Chemical group 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 229960002707 bendamustine Drugs 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 1
- KSBFFOYIOAYXEH-UHFFFAOYSA-N benzoic acid;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)CC(O)(C(O)=O)CC(O)=O KSBFFOYIOAYXEH-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-M camphorsulfonate anion Chemical compound C1CC2(CS([O-])(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-M 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M caproate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229960002115 carboquone Drugs 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 229960003261 carmofur Drugs 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000003197 catalytic Effects 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229910052570 clay Inorganic materials 0.000 description 1
- 230000003021 clonogenic Effects 0.000 description 1
- 230000005025 clonogenic survival Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 230000002860 competitive Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005824 corn Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- RRKODOZNUZCUBN-UHFFFAOYSA-N cycloocta-1,3-diene Chemical compound C1CCC=CC=CC1 RRKODOZNUZCUBN-UHFFFAOYSA-N 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 229960005029 darbepoetin alfa Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000032459 dedifferentiation Effects 0.000 description 1
- 230000002939 deleterious Effects 0.000 description 1
- 238000006392 deoxygenation reaction Methods 0.000 description 1
- BDAGIHXWWSANSR-PFUFQJKNSA-N deuterio deuterioformate Chemical compound [2H]OC([2H])=O BDAGIHXWWSANSR-PFUFQJKNSA-N 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- YDVNLQGCLLPHAH-UHFFFAOYSA-N dichloromethane;hydrate Chemical compound O.ClCCl YDVNLQGCLLPHAH-UHFFFAOYSA-N 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide DMF Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-M dodecyl sulfate Chemical compound CCCCCCCCCCCCOS([O-])(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-M 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 238000009261 endocrine therapy Methods 0.000 description 1
- 210000002919 epithelial cells Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960004750 estramustine phosphate Drugs 0.000 description 1
- ADFOJJHRTBFFOF-RBRWEJTLSA-N estramustine phosphate Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 ADFOJJHRTBFFOF-RBRWEJTLSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000001605 fetal Effects 0.000 description 1
- 229960005304 fludarabine phosphate Drugs 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000004868 gas analysis Methods 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 231100000446 genotoxin Toxicity 0.000 description 1
- 238000009650 gentamicin protection assay Methods 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000001963 growth media Substances 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- AEMXANZTBWZJBY-UHFFFAOYSA-N hexanedioic acid Chemical compound OC(=O)CCCCC(O)=O.OC(=O)CCCCC(O)=O.OC(=O)CCCCC(O)=O AEMXANZTBWZJBY-UHFFFAOYSA-N 0.000 description 1
- 229960002193 histrelin Drugs 0.000 description 1
- HHXHVIJIIXKSOE-QILQGKCVSA-N histrelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 HHXHVIJIIXKSOE-QILQGKCVSA-N 0.000 description 1
- BKEMVGVBBDMHKL-VYFXDUNUSA-N histrelin acetate Chemical compound CC(O)=O.CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 BKEMVGVBBDMHKL-VYFXDUNUSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000002431 hydrogen Chemical group 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
- 108010061572 ibritumomab tiuxetan Proteins 0.000 description 1
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910001410 inorganic ion Inorganic materials 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 101700052395 ire-1 Proteins 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-M isethionate Chemical compound OCCS([O-])(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-M 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M isothiocyanate Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M laurate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 108010054155 lysyllysine Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004962 mammalian cells Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- JBVNBBXAMBZTMQ-CEGNMAFCSA-N megestrol Chemical compound C1=CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 JBVNBBXAMBZTMQ-CEGNMAFCSA-N 0.000 description 1
- 229960001786 megestrol Drugs 0.000 description 1
- URXWVWVPMJSAJD-KOORYGTMSA-N megestrol acetate Chemical compound C1=CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 URXWVWVPMJSAJD-KOORYGTMSA-N 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229960000901 mepacrine Drugs 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M methanoate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 229960005485 mitobronitol Drugs 0.000 description 1
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 229960000060 monoclonal antibodies Drugs 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000000869 mutational Effects 0.000 description 1
- 229960001133 nandrolone phenpropionate Drugs 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 101700077936 ncsA Proteins 0.000 description 1
- 230000001613 neoplastic Effects 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
- 229960001840 oprelvekin Drugs 0.000 description 1
- 108010046821 oprelvekin Proteins 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000003431 oxalo group Chemical group 0.000 description 1
- 229960002502 paclitaxel protein-bound Drugs 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M palmitate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N palmityl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229960001218 pegademase Drugs 0.000 description 1
- 229940048111 pegademase bovine Drugs 0.000 description 1
- 229960001744 pegaspargase Drugs 0.000 description 1
- 108010001564 pegaspargase Proteins 0.000 description 1
- 108010044644 pegfilgrastim Proteins 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- NYDXNILOWQXUOF-GXKRWWSZSA-L pemetrexed disodium Chemical compound [Na+].[Na+].C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 NYDXNILOWQXUOF-GXKRWWSZSA-L 0.000 description 1
- 229960003349 pemetrexed disodium Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000000737 periodic Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 239000000546 pharmaceutic aid Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229930001140 podophyllotoxin Natural products 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229960004694 prednimustine Drugs 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000750 progressive Effects 0.000 description 1
- 230000001737 promoting Effects 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L propanedioate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 238000002661 proton therapy Methods 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 239000003790 pyrimidine antagonist Substances 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 230000000191 radiation effect Effects 0.000 description 1
- 230000002285 radioactive Effects 0.000 description 1
- 230000000637 radiosensitizating Effects 0.000 description 1
- 229960002185 ranimustine Drugs 0.000 description 1
- 108010084837 rasburicase Proteins 0.000 description 1
- 230000003014 reinforcing Effects 0.000 description 1
- 230000000268 renotropic Effects 0.000 description 1
- 230000003362 replicative Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000028617 response to DNA damage stimulus Effects 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229960002530 sargramostim Drugs 0.000 description 1
- 108010038379 sargramostim Proteins 0.000 description 1
- 229960003440 semustine Drugs 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 230000003007 single stranded DNA break Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229960002218 sodium chlorite Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- WSWCOQWTEOXDQX-UHFFFAOYSA-N sorbic acid Chemical compound CC=CC=CC(O)=O WSWCOQWTEOXDQX-UHFFFAOYSA-N 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 235000019527 sweetened beverage Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- FQZYTYWMLGAPFJ-OQKDUQJOSA-N tamoxifen citrate Chemical compound [H+].[H+].[H+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 FQZYTYWMLGAPFJ-OQKDUQJOSA-N 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- AGEABOYQYKWDAI-UHFFFAOYSA-N tert-butyl N-[2-[4-(methylcarbamoyl)quinolin-8-yl]prop-2-enyl]carbamate Chemical compound C1=CC=C2C(C(=O)NC)=CC=NC2=C1C(=C)CNC(=O)OC(C)(C)C AGEABOYQYKWDAI-UHFFFAOYSA-N 0.000 description 1
- IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran THF Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 231100000730 tolerability Toxicity 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229960003181 treosulfan Drugs 0.000 description 1
- IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 description 1
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 description 1
- BLYVBOMCZVHBIS-UHFFFAOYSA-L triplatin(4+) Chemical compound [NH3+][Pt-2]([NH3+])(Cl)[NH2+]CCCCCC[NH2+][Pt-2]([NH3+])([NH3+])[NH2+]CCCCCC[NH2+][Pt-2]([NH3+])([NH3+])Cl BLYVBOMCZVHBIS-UHFFFAOYSA-L 0.000 description 1
- 239000011778 trisodium citrate Substances 0.000 description 1
- 229960000875 trofosfamide Drugs 0.000 description 1
- 230000001573 trophoblastic Effects 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-M undecanoate Chemical compound CCCCCCCCCCC([O-])=O ZDPHROOEEOARMN-UHFFFAOYSA-M 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-M valerate Chemical class CCCCC([O-])=O NQPDZGIKBAWPEJ-UHFFFAOYSA-M 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- KDQAABAKXDWYSZ-JKDPCDLQSA-N vincaleukoblastine sulfate Chemical compound OS(O)(=O)=O.C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 KDQAABAKXDWYSZ-JKDPCDLQSA-N 0.000 description 1
- CILBMBUYJCWATM-IJDPFCGHSA-N vinorelbine L-tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-IJDPFCGHSA-N 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 235000016804 zinc Nutrition 0.000 description 1
- 229950009268 zinostatin Drugs 0.000 description 1
- 229960000641 zorubicin Drugs 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N β-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
- A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/14—Adipic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/265—Citric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
- C07C63/04—Monocyclic monocarboxylic acids
- C07C63/06—Benzoic acid
- C07C63/08—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Abstract
The present invention relates to compositions and co-crystals each comprising a compound of formula I having the structure: wherein each of R1 and R2 is H or 2H and a co-crystal former selected from adipic acid, citric acid, fumaric acid, maleic acid, succinic acid, or benzoic acid. The co-crystals of (S)-N-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide with adipic acid are DNA-dependent protein kinase (DNA-PK) inhibitors which may be useful for the treatment of cancer. of (S)-N-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide with adipic acid are DNA-dependent protein kinase (DNA-PK) inhibitors which may be useful for the treatment of cancer.
Description
CO-CRYSTALS OF
(S)-N-METHYL-8—(1-((2'-METHYL-[4,5'-B|PYRIM|DIN]YL)AM|NO)PROPANYL)QUINO
LINECARBOXAMIDE AND DEUTERATED DERIVATIVES THEREOF AS DNA-PK
INHIBITORS
RELATED APPLICATIONS
The t ation claims priority to United States Provisional Application
No. 61/892,002 filed on October 17, 2013, the entire contents of which are incorporated by
reference herein.
TECHNICAL FIELD OF THE INVENTION
The present invention relates to co-crystals of DNA-dependent protein kinase
(DNA-PK) inhibitors. The invention also provides pharmaceutical itions f and
methods of using the co-crystals and compositions in the treatment of cancer.
BACKGROUND OF THE INVENTION
Ionizing radiation (IR) induces a variety of DNA damage of which double strand
breaks (DSBs) are the most cytotoxic. These DSBs can lead to cell death via apoptosis and/or
mitotic catastrophe if not rapidly and completely repaired. In on to IR, certain
chemotherapeutic agents including topoisomerase II inhibitors, bleomycin, and doxorubicin
also cause DSBs. These DNA lesions r a complex set of signals through the DNA
damage response network that function to repair the damaged DNA and maintain cell
viability and c stability. In mammalian cells, the predominant repair pathway for
DSBs is the Non-Homologous End Joining Pathway (NHEJ). This pathway functions
regardless of the phase of the cell cycle and does not require a template to re—ligate the
broken DNA ends. NHEJ requires nation of many proteins and signaling pathways.
The core NHEJ machinery consists of the Ku70/80 heterodimer and the catalytic subunit of
DNA-dependent protein kinase (DNA-PKcs), which together se the active DNA-PK
enzyme complex. cs is a member of the phosphatidylinositol 3-kinase-related kinase
(PIKK) family of serine/threonine protein kinases that also includes ataxia telangiectasia
mutated (ATM), ataxia telangiectasia and Rad3 -related (ATR), mTOR, and four PI3K
isoforms. However, while DNA-PKcs is in the same protein kinase family as ATM and ATR,
these latter kinases on to repair DNA damage through the Homologous Recombination
(HR) pathway and are restricted to the S and G2 phases of the cell cycle. While ATM is also
recruited to sites of DSBs, ATR is recruited to sites of single stranded DNA breaks.
NHEJ is thought to proceed through three key steps: recognition of the DSBs,
DNA processing to remove non-ligatable ends or other forms of damage at the termini, and
finally on of the DNA ends. Recognition of the DSB is carried out by binding of the Ku
heterodimer to the ragged DNA ends followed by recruitment of two molecules of DNA—
PKcs to adjacent sides of the DSB; this serves to protect the broken termini until onal
processing enzymes are recruited. Recent data ts the hypothesis that DNA—PKcs
phosphorylates the processing enzyme, Artemis, as well as itself to prepare the DNA ends for
additional processing. In some cases DNA polymerase may be required to synthesize new
ends prior to the ligation step. The auto—phosphorylation of DNA—PKcs is believed to induce
a conformational change that opens the central DNA binding cavity, releases DNA-PKcs
from DNA, and facilitates the ultimate re-ligation of the DNA ends.
It has been known for some time that DNA-PK'/' mice are hypersensitive to the
effects of IR and that some non-selective small molecule inhibitors of DNA-PKcs can
radiosensitize a variety of tumor cell types across a broad set of genetic backgrounds. While
it is expected that inhibition of DNA-PK will radiosensitize normal cells to some extent, this
has been observed to a lesser degree than with tumor cells likely due to the fact that tumor
cells s higher basal levels of endogenous replication stress and DNA damage
(oncogene—induced replication ) and DNA repair mechanisms are less efficient in tumor
cells. Most importantly, an improved therapeutic window with greater sparing of normal
tissue will be imparted from the combination of a DNA-PK inhibitor with recent advances in
precision delivery of d IR, including image—guide RT (IGRT) and intensity—modulated
RT (IMRT).
Inhibition of DNA-PK activity s effects in both cycling and non-cycling
cells. This is highly significant since the majority of cells in a solid tumor are not actively
replicating at any given moment, which limits the efficacy of many agents targeting the cell
cycle. y intriguing are recent reports that suggest a strong tion between
inhibition of the NHEJ pathway and the ability to kill esistant cancer stem cells (CSCs).
It has been shown in some tumor cells that DSBs in t CSCs predominantly te
DNA repair h the NHEJ pathway; it is believed that CSCs are usually in the quiescent
phase of the cell cycle. This may explain why half of cancer patients may experience local or
distant tumor relapse despite treatment as current strategies are not able to effectively target
CSCs. A DNA-PK inhibitor may have the ability to sensitize these potential metastatic
progenitor cells to the effects of IR and select DSB-inducing chemotherapeutic agents.
Given the involvement of DNA-PK in DNA repair processes, DNA-PK inhibitory
drugs may act as agents that enhance the efficacy of both cancer chemotherapy and
radiotherapy. The present invention features crystalline compositions of DNA-PK inhibitors
together with a co-crystal former (CCF), i.e., co-crystals. ed to their free form(s), the
co—crystals of the invention are advantageous as these compounds possess improved
dissolution, higher s solubility, and greater solid state physical stability than
amorphous dispersions. The co—crystals described herein also provide a reduced volume of
the dosage form and therefore lower pill burden since these co-crystals also exhibit higher
bulk densities relative to amorphous forms. Further, the co-crystals of the invention provide
manufacturing advantages relative to amorphous forms which require spray drying,
lyophilization, or precipitation.
BRIEF DESCRIPTION OF THE GS
Figure 1 shows an X-ray powder diffraction pattern of the co-crystal formed
between Compound 1 with adipic acid.
Figure 2 shows an X-ray powder diffraction pattern of the co-crystal formed
between Compound 2 with adipic acid.
Figure 3 shows an X-ray powder diffraction pattern of the co-crystal formed
between Compound 1 with citric acid.
Figure 4 shows an X-ray powder diffraction pattern of the co-crystal formed
between nd 1 and fumaric acid.
Figure 5 shows an X-ray powder diffraction pattern of the co-crystal formed
between Compound 1 and maleic acid.
Figure 6 shows an X-ray powder ction pattern of the co-crystal formed
n Compound 1 and succinic acid.
Figure 7 shows an X-ray powder diffraction n of the co-crystal formed
n Compound 1 and benzoic acid.
Figure 8 shows a thermogravimetric analysis thermogram of the co-crystal formed
between Compound 1 and adipic acid.
Figure 9 shows a thermogravimetric is thermogram of the co-crystal formed
n Compound 2 and adipic acid.
Figure 10 shows a differential scanning calorimetry thermogram of the stal
formed between Compound 1 and adipic acid.
Figure 11 shows a ential scanning calorimetry thermogram of the co-crystal
formed between Compound 2 with adipic acid.
Figure 12 shows a solid—state NMR spectrum of the co—crystal formed between
Compound 1 and adipic acid.
Figure 13 shows a solid—state NMR spectrum of the co—crystal formed between
nd 2 and adipic acid.
Figure 14 shows an X-ray powder diffraction pattern of polymorphic Form A of
the co—crystal formed between Compound 1 with adipic acid.
Figure 15 shows an X-ray powder diffraction pattern of polymorphic Form B of
the co—crystal formed between Compound 2 with adipic acid.
Figure 16 shows a solid—state NMR spectrum of polymorphic Form A of the co—
crystal formed between Compound 1 and adipic acid.
Figure 17 shows a solid—state NMR spectrum of polymorphic Form A of the co-
crystal formed between Compound 2 and adipic acid.
Figure 18 shows a solid—state NMR spectrum of polymorphic Form B of the co—
crystal formed n Compound 2 and adipic acid.
Figure 19 shows a binary phase diagram of Compound 2 and adipic acid.
Figure 20 shows a diagram of the calculated pH solubility of the co-crystal
formed n Compound 2 with adipic acid (by excess adipic acid content) and free form
Compound 2.
Figure 21 shows two stage dissolution es for: i) Compound 1:adipic acid co—
crystal prepared by hot melt extrusion and slurry crystallization; ii) HME 65:35: Compound
1: adipic acid co—crystal manufactured using hot melt extrusion with 65 % w:w Compound 1
and 35 % w:w adipic acid; iii) HME 75:25: Compound 1: adipic acid co—crystal manufactured
using hot melt extrusion with 75 % w:w Compound 1 and 25 % w:w adipic acid; iv) HME
80:20: Compound 1: adipic acid co—crystal ctured using hot melt extrusion with 80 %
w:w Compound 1 and 20 % w:w adipic acid; V) SC 80:20: slurry crystallized Compound 2
c acid co—crystal with final Compound 2 content of 79 % w:w Compound 2 and 21 %
w:w adipic acid; and Vi) Free Form: Compound 2 free form.
Figure 22 shows a predicted fraction absorbed for the co—crystal formed between
Compound 2 and adipic acid, and nd 2 free form.
Figure 23 shows a m summarizing Bliss analysis of Compound (2) in
combination with a panel of cytotoxic and non-cytotoxic agents.
Figure 24 shows a diagram summarizing Bliss analysis of Compound (2) in
combination with BMN-673 by tumor type.
Figure 25 shows a diagram summarizing Bliss analysis of Compound (2) in
combination with etoposide by tumor type.
Figure 26 shows a diagram summarizing Bliss analysis of nd (2) in
combination with bleomycin by tumor type.
Figure 27 shows a diagram summarizing Bliss analysis of Compound (2) in
ation with nib by tumor type.
Figure 28 shows a diagram summarizing Bliss analysis of Compound (2) in
combination with doxorubicin by tumor type.
Figure 29 shows a diagram izing Bliss analysis of Compound (2) in
combination with bleomycin by tumor type.
Figure 30 shows a diagram summarizing Bliss analysis of Compound (2) in
Combination with carboplatin by tumor type.
Figure 31 shows a diagram summarizing Bliss is of Compound 1 or
Compound 2 and standard of care combinations in primary human tumor chemosensitivity
assays.
1. SUMMARY OF THE INVENTION
In a first aspect, the invention features a co-crystal comprising a compound of
formula I
(I),
and a co-crystal former (CCF) selected from adipic acid, citric acid, fumaric acid, maleic acid,
ic acid, or benzoic acid, wherein each of R1 and R2 is hydrogen or deuterium.
[0039a] In a particular aspect, the present ion provides a co-crystal comprising a
compound of the formula
(I) and
a co-crystal former, wherein the stal former is adipic acid, wherein each of R1 and R2 is
independently hydrogen or deuterium.
In another aspect, the ion provides a pharmaceutical composition that
includes a co-crystal of a compound of formula I described above. In one embodiment, the
pharmaceutical composition further includes a diluent, t, excipient, or carrier.
In yet another aspect, the invention provides a ic solid composition comprising:
(a) a co-crystal comprising a compound of formula (I) and a co-crystal former selected from
adipic acid, wherein each of R1 and R2 is hydrogen or deuterium, and wherein the molar ratio of
the compound of a I to adipic acid is about 2 to 1; and (b) adipic acid. In yet another
aspect, the invention provides a pharmaceutical composition sing such a eutectic solid
composition. In one embodiment, the pharmaceutical composition further includes a diluent,
solvent, excipient, or carrier.
Another aspect of this invention provides a method of making a co-crystal of a
compound of formula I and adipic acid, citric acid, fumaric acid, maleic acid, succinic acid, or
benzoic acid. In one embodiment, the method comprises: providing the compound of formula I;
providing the co-crystal former; grinding, heating, co-subliming, ting, or contacting in
on the compound of formula I with the co-crystal former under crystallization ions so
as to form the co-crystal in solid phase; and then optionally isolating the stal formed
y. In another embodiment, the method comprises mixing a compound of formula (I) with
adipic acid, citric acid, fumaric acid, maleic acid, succinic acid, or benzoic acid at an elevated
temperature to form the co-crystal. In some embodiments, the making a co-crystal of a
[FOLLOWED BY PAGE 6a]
compound of formula I and the CCF includes providing the compound of formula I and adipic
acid, citric acid, fumaric acid, maleic acid, succinic acid, or benzoic acid in a molar ratio
between about 1 to 1.2 to about 1 to 3.6, respectively.
[0042a] In another particular aspect, the present invention provides a method of making a cocrystal
comprising:
grinding, heating, co-subliming, co-melting, or contacting either (S)-N-methyl(1-((2'-
methyl-[4,5'-bipyrimidin]yl)amino)propanyl)quinolinecarboxamide or (S)-N-methyl
(1-((2'-methyl-4',6'-dideutero-[4,5'-bipyrimidin]yl)amino)propanyl)quinoline
carboxamide with a co-crystal former under crystallization conditions so as to form the cocrystal
in solid phase, wherein the co-crystal former is adipic acid.
[0042b] In a yet further particular aspect, the present invention provides a method of making a
co-crystal comprising providing a pre-existing co-crystal as a seed to prepare the co-crystal,
wherein the pre-existing co-crystal comprises: (i) either (S)-N-methyl(1-((2'-methyl-[4,5'-
bipyrimidin]yl)amino)propanyl)quinolinecarboxamide or (S)-N-methyl(1-((2'-
methyl-4',6'-dideutero-[4,5'-bipyrimidin]yl)amino)propanyl)quinolinecarboxamide; and
(ii) adipic acid; or the co-crystal to be formed comprises: (i) either (S)-N-methyl(1-((2'-
methyl-[4,5'-bipyrimidin]yl)amino)propanyl)quinolinecarboxamide or (S)-N-methyl
(1-((2'-methyl-4',6'-dideutero-[4,5'-bipyrimidin]yl)amino)propanyl)quinoline
carboxamide; and (ii) adipic acid.
In yet r aspect, the invention provides a method for ting a chemical
or physical property of st (such as melting point, solubility, dissolution, copicity, and
bioavailability) of a co-crystal containing a compound of formula I and adipic acid, citric acid,
fumaric acid, maleic acid, succinic acid, or benzoic acid. The method es the steps of
ing the chemical or al property of interest for the compound of formula I and CCF;
determining the mole fraction of the compound of formula I and CCF that will result in the
desired tion of the chemical or physical property of interest; and preparing the co-crystal
with the molar fraction as determined.
The compositions and stals of this invention can be used for treating
diseases implicated by or associated with the inhibition of DNA-PK. In particular, the invention
es a method of sensitizing a cell to an agent that induces a DNA lesion sing
contacting the cell with a co-crystal of the ion or pharmaceutical composition thereof.
[FOLLOWED BY PAGE 7]
2014/061102
The invention further provides methods of potentiating a therapeutic regimen for
treatment of cancer comprising administering to an individual in need thereof an effective
amount of a co-crystal of the ion or pharmaceutical composition thereof. In one
embodiment, the therapeutic regimen for treatment of cancer includes radiation therapy.
The present invention also provides methods of treating cancer in an animal that
includes administering to the animal an effective amount of a co-crystal or pharmaceutical
composition of the invention. The invention further is directed to methods of inhibiting
cancer cell growth, including processes of cellular proliferation, invasiveness, and metastasis
in biological systems. s include use of such a co—crystal or pharmaceutical
composition to inhibit cancer cell growth.
The invention provides a method of inhibiting DNA-PK activity in a biological
sample that includes contacting the ical sample with a co-crystal or pharmaceutical
composition of the invention.
Also within the scope of this invention is a method of treating diseases described
herein, such as cancer, which comprising stering to a subject in need thereof a
eutically effective amount of a co-crystal of this invention or a composition of this
invention.
DETAILED DESCRIPTION OF THE INVENTION
In one aspect, the ion is directed to co—crystals comprising a compound of
and a co—crystal former (CCF) selected from adipic acid, citric acid, fumaric acid, maleic
acid, succinic acid, or c acid, wherein each of R1 and R2 is hydrogen or deuterium.
In one embodiment, the compound of formula I is (S)—N—methyl—8—(l—((2'—methyl-
[4,5'-bipyrimidin]yl)amino)propanyl)quinolinecarboxamide (Compound 1).
WO 58067
In r embodiment, the compound of formula I is (S)-N—methyl(1-((2'-
methyl-4',6'-dideutero-[4,5'-bipyrimidin]yl)amino)propanyl)quinolinecarboxamide
(Compound 2).
In one embodiment, the invention provides a co—crystal that includes a compound
of formula I and adipic acid as the CCF. In a further embodiment, the X-ray powder
diffraction (XRPD) pattern of this co-crystal exhibits peaks at about 6.46, 7.91, 11.92, 12.26,
12.99, 14.19, 18.68, and 19.07-Theta. In another embodiment, the XRPD pattern of this co-
crystal exhibits peaks as shown in Figure 1. In yet another ment, the XRPD pattern of
this stal exhibits peaks as shown in Figure 2. In yet another further embodiment, its
differential scanning calorimetry (DSC) thermogram shows g points at about 1950 C.
and about 2450 C.
In one embodiment, the invention provides a co—crystal that includes a compound
of formula I and citric acid as the CCF. In one embodiment, the XRPD pattern of this co-
l exhibits peaks at about 7.44, 8.29, 11.35, 13.26, 15.49, 21.55, and 23.57—Theta. In
r embodiment, the XRPD pattern of this co-crystal exhibits peaks as shown in Figure
3. In yet another embodiment, a compound of formula I and the CCF are both in the solid
state (e.g., crystalline) and are bonded non—covalently (i.e., by hydrogen bonding).
In one embodiment, the invention provides a co—crystal that includes a compound
of a I and fumaric acid as the CCF. In one embodiment, the XRPD pattern of this co-
crystal exhibits peaks at about 8.26, 10.11, 14.97, 16.61, 17.22, 25.20, and 26.01-Theta. In
another embodiment, the XRPD pattern of this co-crystal exhibits peaks as shown in Figure
4. In yet another embodiment, a compound of formula I and the CCF are both in the
solid state (e. g., crystalline) and are bonded non—covalently (i.e., by hydrogen bonding).
In one embodiment, the invention provides a co—crystal that includes a nd
of formula I and maleic acid as the CCF. In one ment, the XRPD pattern of this co-
crystal exhibits peaks at about 6.21, 10.43, 11.28, 12.41, 13.26, 18.87, and 21.08-Theta. In
another embodiment, the XRPD pattern of this co-crystal exhibits peaks as shown in Figure
. In yet another embodiment, a compound of formula I and the CCF are both in the solid
state (e.g., crystalline) and are bonded non—covalently (i.e., by en bonding).
In one embodiment, the invention provides a co—crystal that es a compound
of formula I and succinic acid as the CCF. In one embodiment, the XRPD pattern of this co-
crystal exhibits peaks at about 8.02, 12.34, 14.78, 17.32, 19.56, and 20.06-Theta. In another
embodiment, the XRPD pattern of this co-crystal exhibits peaks as shown in Figure 6. In
another embodiment, a compound of formula I and the CCF are both in the solid state (e. g.,
crystalline) and are bonded non—covalently (i.e., by hydrogen bonding).
In yet another embodiment, the invention provides a stal that includes a
compound of formula I and benzoic acid as the CCF. In one embodiment, the XRPD n
ofthis co—crystal exhibits peaks at 8.70, 13.90, 15.62, 17.65, 18.15, 20.77, and 24.72—Theta.
In another embodiment, the XRPD n of this co-crystal exhibits peaks as shown in
Figure 7. In another embodiment, a nd of formula I and the CCF are both in the solid
state (e.g., crystalline) and are bonded non—covalently).
In one embodiment, the invention provides co—crystals of the formula und
1)n:(AA)m, wherein n is 1 and m is between 0.4 and 2.1. In one embodiment, n is 1 and m is
between 0.9 and 3.1. In one embodiment for co—crystals comprising adipic acid, n is about 2
and m is about 1. In one embodiment for co-crystals comprising adipic acid, n is about 2 and
m is about 1.
In another embodiment, the invention provides co-crystals of the formula
(Compound 2)n:(AA)m, wherein n is 1 and m is n 0.4 and 2.1 In one embodiment for
co—crystals comprising adipic acid, n is about 2 and m is about 1.
In another embodiment, the invention provides a co—crystal of a compound of
formula I and CCF adipic acid, citric acid, fumaric acid, maleic acid, succinic acid, or
c acid, wherein the co-crystal is a solid at the room temperature and the nd of
a I and CCF interact by noncovalent bonds. In n embodiments, the non-covalent
bond interactions between the compound of formula I and CCF include hydrogen bonding
and van der Waals interactions. In one embodiment, the CCF is adipic acid.
In one embodiment, the invention provides a co—crystal of Compound (1) and
CCF adipic acid, wherein the molar ratio of Compound (1) to adipic acid is about 2:1.
In another embodiment, the invention provides a co-crystal of Compound (2) and
CCF adipic acid, wherein the molar ratio of Compound (2) to adipic acid is about 2:1.
In r embodiment, the co—crystal of Compound (2) and CCF adipic acid
(adipic acid co—crystal of Compound (2)) is in polymorphic Form A or B. Polymorphic
Forms A and B are two conformational rphs of the adipic acid co-crystal of
Compound (2). In yet another embodiment, the co-crystal of Compound (1) and CCF adipic
acid (adipic acid co—crystal of Compound (1)) is in polymorphic Form A or B. Polymorphic
Forms A and B are two conformational polymorphs of the adipic acid stal of
Compound (1), and their 13C solid state nuclear magnetic resonance oscopies are
essentially the same as those for Polymorphic Forms A and B of Compound (2).
In a specific embodiment, the rphic Form A is characterized by 13C solid
state nuclear magnetic resonance spectroscopy peaks at about 117.1, 96.8, 95.7, 27.6, 14.8
13C solid
ppm. In another specific embodiment, the polymorphic Form A is characterized by
state nuclear ic resonance spectroscopy peaks at about 161.6, 154.5, 117. 1, 96.8, 95.7,
51.5, 50.2, 27.6, 25.6, 18.5, and 14.8 ppm. In yet another specific embodiment, the
polymorphic Form A is characterized by 13C solid state nuclear magnetic resonance
spectroscopy peaks at about 179.4, 168.4, 161.6, 158.3, 154.5, 147.8, 145.7, 143.2, 141.8,
124.6, 117.1, 96.8, 95.7, 51.5, 50.2, 31.2, 30.1, 27.6, 25.6, 18.5, and 14.8 ppm. In yet another
specific embodiment, the polymorphic Form A is characterized by 13C solid state nuclear
magnetic resonance spectroscopy peaks as shown in Figure 16 or 17.
13C solid
In a specific embodiment, the polymorphic Form B is characterized by
state nuclear magnetic resonance spectroscopy peaks at about 117.9, 97.3, 94.0, 26.7, and
.7 ppm. In another specific embodiment, the polymorphic Form B is characterized by 13C
solid state nuclear magnetic resonance spectroscopy peaks at about 161.7, 153.8, 117.9, 97.3,
94.0, 50.7, 25.3, 26.7, 18.8, and 15.7 ppm. In yet another specific embodiment, the
polymorphic Form B is characterized by 13C solid state nuclear magnetic resonance
spectroscopy peaks at about 179.1, 168.3, 158.1, 147.2, 142.4, 125.8, 124.5, 117.9, 97.3,
94.0, 32.3, 30.1, 26.7, and 15.7 ppm. In yet another ic embodiment, the polymorphic
13C solid
Form B is characterized by state r magnetic resonance spectroscopy peaks as
shown in Figure 17.
In yet another embodiment, the co—crystal of Compound (2) and CCF adipic acid
c acid stal of Compound (2)) is in a mixture of polymorphic Forms A and B. In
yet another embodiment, the stal of Compound (1) and CCF adipic acid (adipic acid
co—crystal of Compound (1)) is in a mixture of polymorphic Forms A and B.
The present invention encompasses the co—crystals of a compound of formula I
and CCF described above in isolated, pure form, or in a mixture as a solid composition when
d with other materials, for example, free form of compound of formula I or free CCF.
In one embodiment, the ion provides pharmaceutically acceptable itions
comprising the co—crystals of a compound of formula I and the CCF described above and an
additional free CCF. In a specific ment, the compositions comprise the co—crystals of
Compound (1) or (2) and CCF adipic acid described above and additional adipic acid. In
some specific embodiments, the l molar ratio of the compound of formula I to CCF
(both part of the co-crystals and free CCF, e. g., adpic acid in the co-crystals and free adipic
acid) in such compositions is in a range from about 1: 0.55 to about 1:100. In other specific
embodiments, the overall molar ratio of the compound of formula I to CCF in such
itions is in a range from about 1:0.55 to about 1: 50. In other specific embodiments,
the overall molar ratio of the compound of formula I to CCF in such compositions is in a
range from about 1:0.55 to about 1: 10. In some specific embodiments, the overall weight
ratio of the compound of formula I to CCF in such compositions is in a range from about 85
wt% : 15 wt% to about 60 wt% : 40 wt%. In other ic embodiments, the overall weight
ratio of the compound of formula I to CCF is in a range from about 70 wt% :30 wt% to about
60 wt% : 40 wt%. In yet other embodiments, the overall weight ratio of the compound of
formula I to CCF is about 65 wt% :35 wt%.
In another embodiment, the invention provides eutectic solid compositions
comprising: (a) a co-crystal sing a compound of formula (I), and a CCF selected from
adipic acid, n each of R1 and R2 is hydrogen or deuterium, and wherein the molar ratio
of the compound of formula I to adipic acid is about 2 to l; and (b) adipic acid. As used
herein, the term tic solid” means a solid al resulting from a ic reaction
known in the art. Without being bound to a particular theory, an eutectic reaction is defined
as follows:
at eutectic temperature
. . Liquid ‘——~ Sohd phase A + Sohd phase B
In the eutection reaction, a single liquid phase and two solid phases all co-exist at the same
time and are in chemical equilibrium. It forms a super-lattice or microstructure on cooling
which releases at once all its components into a liquid mixture (melts) at a specific
temperature (the eutectic temperature).
In one ment, the overall weight ratio of the compound of formula I to
adipic acid in the eutectic solid compositions is in a range from about 70 wt% :30 wt% to
about 60 wt% : 40 wt%. In yet another embodiment, the overall weight ratio of the
nd of formula I to adipic acid is in a range from about 65 wt% :35 wt%. In yet
another embodiment, the molar ratio of the co-crystal of a compound of a I to adipic
acid is about 1 to 1.03.
The pure form means that the particular co-crystal or polymorphic form comprises
over 95% (w/w), for example, over 98% (w/w), over 99% (w/w %), over 99.5% (w/w), or
over 99.9% (w/w).
More specifically, the present invention also provides pharmaceutically acceptable
compositions where each of the co—crystals or polymorphic forms are in the form of a
composition or a mixture of the polymorphic form with one or more other crystalline, solvate,
ous, or other rphic forms or their combinations thereof. For example, in one
embodiment, the itions comprise Form A of the adipic acid stal of Compound
(2) along with one or more other polymorphic forms of Compound (2), such as amorphous
form, hydrates, solvates, and/or other forms or their combinations thereof. In a specific
embodiment, the compositions comprise Form A of the adipic acid co—crystal of Compound
(2) along with Form B of the adipic acid co-crystal of Compound (2). More specifically, the
ition may comprise from trace amounts up to 100% of the specific polymorphic form
or any amount, for example, in a range of0.1% — 0.5%, 0.1% — 1%, 0.1% — 2%, 0.1% — 5%,
0.1% — 10%, 0.1% — 20%, 0.1% — 30%, 0.1% — 40%, 0.1% — 50%, 1% — 50%, or 10% — 50% by
weight based on the total amount of the compound of formula I in the composition.
Alternatively, the ition may comprise at least 50%, 60%, 70%, 80%, 90%, 95%, 97%,
98%, 99%, 99.5% or 99.9% by weight of specific polymorphic form based on the total
amount of the compound of formula I in the composition.
In one embodiment, the compounds in accordance with the present invention are
provided in the form of a single enantiomer at least 95%, at least 97% and at least 99% free
of the corresponding enantiomer.
In a further embodiment, the compounds in accordance with the present invention
are in the form of the (--) enantiomer at least 95% free of the corresponding (-) enantiomer.
In a further embodiment, the compounds in accordance with the present invention
are in the form of the (--) enantiomer at least 97% free of the corresponding (-) omer.
In a further embodiment, the compounds in accordance with the present invention
are in the form of the (--) enantiomer at least 99% free of the corresponding (-) enantiomer.
In a further embodiment, the compounds in accordance with the t invention
are in the form of the (-) enantiomer at least 95% free of the corresponding (--) enantiomer.
In a further embodiment, the compounds in accordance with the present invention
are in the form of the (-) enantiomer at least 97% free of the ponding (--) enantiomer.
In a further embodiment the compounds in accordance with the present invention
are in the form of the (-) enantiomer at least 99% free of the corresponding (--) enantiomer.
The present ion also provides methods of making the co—crystals described
above. In one embodiment, the methods comprises grinding, g, co—subliming, co-
melting, or contacting either (S)-N—methyl(1-((2'-methyl-[4,5'-bipyrimidin]
yl)amino)propanyl)quinolinecarboxamide or (S)-N—methyl(1-((2'-methyl-4',6'-
ero-[4,5'-bipyrimidin]yl)amino)propanyl)quinolinecarboxamide with the cocrystal
former under crystallization conditions so as to form the co-crystal in solid phase,
wherein the co-crystal former is ed from adipic acid, citric acid, fumaric acid, maleic
acid, succinic acid, or benzoic acid.
In another embodiment, the methods comprises mixing a nd of formula (I)
with a CCF selected from adipic acid, citric acid, fumaric acid, maleic acid, succinic acid, or
c acid at an elevated ature to form the co-crystal. The compound of formula (I)
can be mixed with the CCF to generate a mixture of the compound and CCF, and then the
mixture of the compound and CCF are heated at an elevated ature to form the co-
crystal. Alternatively, the mixing and heating steps can be performed at the same time.
In one specific embodiment, the CCF is adipic acid, and the compound of formula
(I) is mixed with adipic acid at an elevated temperature in a range of about 110 0C and about
195°C to form the co—crystal. In another specific embodiment, the elevated temperature is in
a range of about 130 °C and about 180°C, or in a range of about 140 °C and about 160°C.
In another ic embodiment, the CCF is adipic acid, and 10 wt% to about 85
wt% of the compound (I) and about 90 wt% to 15wt% of adipic acid are mixed. In yet
another specific embodiment, about 30 wt% to about 80 wt% and the adipic acid is about 70
wt% to about 20 wt%. In yet another specific embodiment, the compound (I) is about 50
wt% to about 80 wt% and the adipic acid is about 50 wt% to about 20 wt%. In yet another
specific embodiment, the compound (I) is about 60 wt% to70 wt% and the adipic acid is
about 40 wt% to about 30 wt%. In yet another specific ment, the compound (I) is
about 65 wt% and the adipic acid is about 35 wt%.
In yet another embodiment, the s include: providing the compound of
formula 1; providing the co-crystal former; grinding, heating, co-subliming, co-melting, or
contacting in solution the compound of formula I with the co-crystal former under
crystallization conditions so as to form the stal in solid phase; and then optionally
isolating the co-crystal formed thereby. In some specific ments, the making a co-
crystal of a compound of formula I and the CCF es providing the compound of formula
I and adipic acid, citric acid, fumaric acid, maleic acid, succinic acid, or benzoic acid in a
molar ratio between about 1 to 0.55 to about 1 to 3.6, respectively. In some ic
embodiments, the making a co-crystal of a compound of formula I and the CCF includes
providing the compound of formula I and adipic acid, citric acid, fumaric acid, maleic acid,
succinic acid, or benzoic acid in a molar ratio between about 1 to 1.2 to about 1 to 3.6,
respectively.
In yet another embodiment, the invention provides methods for modulating a
al or physical property of interest (such as melting point, solubility, dissolution,
copicity, and bioavailability) of a co-crystal containing a compound of formula I and
adipic acid, citric acid, fumaric acid, maleic acid, succinic acid, or benzoic acid. The
methods include: measuring the chemical or physical property of interest for the compound
of formula I and CCF; ining the mole fraction of the compound of formula I and CCF
that will result in the desired tion of the chemical or physical property of interest; and
preparing the co-crystal with the molar fraction as determined.
As used herein, the following definitions shall apply unless otherwise indicated.
For purposes of this invention, the chemical elements are identified in accordance with the
Periodic Table of the Elements, CAS version, and the Handbook of Chemistry and Physics,
75th Ed. 1994. Additionally, general principles of organic chemistry are bed in
“Organic Chemistry,” Thomas Sorrell, University Science Books, Sausalito: 1999, and
“March’s Advanced Organic Chemistry,” 5th Ed., Smith, MB. and March, J eds. John Wiley
& Sons, New York: 2001, the entire contents of which are hereby incorporated by reference/
For XRPD peak assignments, the term “about” means a range of +/- 0.2 relative to
the stated value. For 13C solid state NMR spectra, the term “about” means a range of +/- 0.1
relative to the stated value. Otherwise, the term “about” means a value of +/— 10% of the
stated value. When this term is followed by a series of numbers it applies to each of the
numbers in the series.
For compounds of the invention in which R1 or R2 is deuterium, the deuterium to
hydrogen ratio is at least 5 to 1. In some embodiments, the deuterium to hydrogen ratio is at
least 9 to 1. In other embodiments, the deuterium to hydrogen ratio is at least 19 to 1.
s for preparing and characterizing a stal are well documented in the
literature. See, e.g., Trask et al., Chem. Commun, 2004, 1; and 0. Almarsson and M. J.
Zaworotko, Chem. Commun, 2004, 896. These methods in general are also suitable
for preparing and terizing co-crystals of this invention.
es of preparing co-crystals with an active pharmaceutical ingredient and a
CCF include hot-melt extrusion, ball-milling, melting in a reaction block, evaporating
solvent, slurry conversion, blending, ation, or ng. In the ball-milling method,
certain molar ratios of the components of the co—crystal (e. g., a compound of interest, such as
a compound of formula I of this invention, and a CCF) are mixed and milled with balls.
Optionally, a solvent such as methyl ethyl ketone, chloroform, and/or water can be added to
the mixture being ball milled. After milling, the e can be dried under vacuum either at
the room temperature or in the heated condition, which typically gives a powder t. In
the melting method, the components of a co-crystal (e. g., a CCF and a compound of formula
I) are mixed, ally with a solvent such as acetonitrile. The mixture is then placed in a
reaction block with the lid closed, and then heated to the endotherm. The ing mixture is
then cooled off and solvent, if used, removed. In the solvent—evaporation method, each
component of a co—crystal is first dissolved in a solvent (e. g., a solvent e, such as
methanol/dichloromethane ope, or toluene/acetonitrile (e.g., 50/50 by volume)), and the
solutions are then mixed er. The mixture is then allowed to sit and solvent to evaporate
to dryness, to yield the co—crystal. In the hot—melt extrusion (HME) method, a new material
(the extrudate) is formed by forcing it through an orifice or die (extruder) under controlled
conditions, such as temperature, mixing, feed-rate and pressure. An extruder typically
comprises a platform that supports a drive system, an ion barrel, a rotating screw
arranged on a screw shaft and an extrusion die for defining product shape. Alternatively, the
extrusion die can be removed and the product can be shaped by other means. Typically,
process parameters are controlled via connection to a central electronic control unit. The
extrusion drive system generally comprises motor, gearbox, e and thrust bearings,
whereas the barrel and screw is commonly utilized in a modular configuration. Any le
HME technologies known in the art, for example, Gavin P. Andrews et al., “Hot-melt
extrusion: an emerging drug delivery logy”, Pharmaceutical Technology Europe,
volume 21, Issue 1 (2009), can be used in the invention. In one embodiment, the stals
of the invention are prepared by hot-melt ion.
Examples of characterization methods include thermogravimetric analysis (TGA),
differential scanning metry (DSC), X-ray powder diffraction (XRPD), solid-state
nuclear magnetic resonance spectroscopy (ss—NMR), solubility analyses, dynamic vapor
on, infrared off-gas analysis, and suspension stability. TGA can be used to investigate
the presence of residual solvents in a co—crystal sample and to identify the temperature at
which decomposition of each co—crystal sample occurs. DSC can be used to look for
thermotransitions ing in a co-crystal sample as a function of temperature and determine
the g point of each co-crystal sample. XRPD can be used for structural
characterization of the co-crystal. Solubility analysis can be performed to reflect the changes
in the physical state of each co—crystal . Suspension stability analysis can be used to
determine the chemical stability of a co-crystal sample in a t.
Pharmaceutically Acceptable Salts
The present invention also covers co—crystals formed with pharmaceutically
acceptable salts of the compounds of formula I. Also, the combination therapy of the
invention discussed below includes administering the compounds of a I and
pharmaceutically acceptable salts thereof, and their co—crystals described herein. The
compounds of formula I can exist in free form for treatment, or where appropriate, as a
pharmaceutically acceptable salt.
A “pharmaceutically able salt” means any non-toxic salt of a compound of
this invention that, upon stration to a recipient, is capable of providing, either ly
or indirectly, a compound of this invention or an inhibitorily active metabolite or residue
thereof. As used herein, the term "inhibitorily active metabolite or residue thereof' means
that a metabolite or residue thereof is also a DNA-PK inhibitor.
Pharmaceutically acceptable salts are well known in the art. For example, S. M.
Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical
es, 1977, 66, l—l9, incorporated herein by reference. ceutically acceptable salts
of the compounds of this invention include those derived from suitable nic and organic
acids and bases. These salts can be prepared in situ during the final ion and purification
of the compounds. Acid addition salts can be prepared by l) reacting the purified compound
in its free-based form with a suitable organic or inorganic acid and 2) isolating the salt thus
formed.
Examples of pharmaceutically able, nontoxic acid addition salts are salts of
an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid,
phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid,
oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using
other methods used in the art such as ion ge. Other pharmaceutically acceptable salts
include adipate, alginate, ate, aspartate, benzenesulfonate, benzoate, bisulfate, borate,
butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, onate,
dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate,
glycolate, gluconate, glycolate, hemisulfate, oate, hexanoate, hydrochloride,
hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl
sulfate, , maleate, malonate, methanesulfonate, 2—naphthalenesulfonate, nicotinate,
nitrate, oleate, oxalate, palmitate, palmoate, pectinate, persulfate, 3-phenylpropionate,
phosphate, picrate, pivalate, propionate, salicylate, stearate, succinate, sulfate, tartrate,
thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like.
Base addition salts can be prepared by l) ng the purified compound in its
acid form with a suitable organic or inorganic base and 2) isolating the salt thus formed.
Salts derived from appropriate bases include alkali metal (e. g., sodium, lithium, and
potassium), alkaline earth metal (e.g., ium and m), ammonium and
N+(C1_4alkyl)4 salts. This invention also envisions the quatemization of any basic nitrogen-
containing groups of the compounds disclosed herein. Water or oil—soluble or dispersible
products may be obtained by such quatemization.
Further pharmaceutically acceptable salts include, when appropriate, nontoxic
ammonium, quaternary um, and amine cations formed using counterions such as
halide, ide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl
sulfonate. Other acids and bases, while not in themselves pharmaceutically acceptable, may
be employed in the preparation of salts useful as intermediates in obtaining the compounds of
the invention and their pharmaceutically acceptable acid or base addition salts.
Uses ofthe co-crystals andpharmaceutical compositions ofthe invention
An effective amount of a co-crystal or pharmaceutical composition of the
invention can be used to treat diseases implicated or associated with the cancer. An effective
amount is the amount which is required to confer a therapeutic effect on the treated subject,
e.g. a patient. As used , the terms ct" and "patien are used interchangeably.
The terms "subject" and "patient" refer to an animal (e. g., a bird such as a chicken, quail or
turkey, or a ), specifically a l" ing a non-primate (e. g., a cow, pig,
horse, sheep, rabbit, guinea pig, rat, cat, dog, and mouse) and a primate (e. g., a monkey,
chimpanzee and a human), and more ically a human. In one embodiment, the subject is
a non—human animal such as a farm animal (e. g., a horse, cow, pig or sheep), or a pet (e. g., a
dog, cat, guinea pig or ). In a preferred embodiment, the subject is a "human".
The precise amount of compound administered to a subject will depend on the
mode of administration, the type and severity of the cancer and on the characteristics of the
subject, such as general health, age, sex, body weight and tolerance to drugs. The skilled
artisan will be able to ine appropriate dosages depending on these and other factors.
When co—administered with other agents, e.g., when co-administered with an anti-cancer
medication, an "effective amount" of the second agent will depend on the type of drug used.
Suitable dosages are known for approved agents and can be adjusted by the skilled artisan
according to the condition of the subject, the type of condition(s) being treated and the
amount of a compound described herein being used. In cases where no amount is expressly
noted, an ive amount should be assumed. Generally, dosage regimens can be selected
in accordance with a variety of factors including the disorder being treated and the severity of
the disorder; the activity of the ic compound employed; the ic composition
employed; the age, body weight, general health, sex and diet of the patient; the time of
administration, route of stration, and rate of excretion of the specific compound
employed; the renal and c function of the subject; and the particular compound or salt
thereof employed, the duration of the treatment; drugs used in combination or coincidental
with the specific compound employed, and like s well known in the medical arts. The
d artisan can readily determine and ibe the effective amount of the compounds
described herein required to treat, to prevent, inhibit (fully or partially) or arrest the progress
of the e.
The effective amount of a co-crystal or pharmaceutical composition of the
invention is between about 0.1 to about 200 mg/kg body weight/day. In one ment, the
effective amount of a co-crystal or pharmaceutical composition of the invention is between
about 1 to about 50 mg/kg body weight/day. In another embodiment, the effective amount of
a stal or pharmaceutical composition of the invention is between about 2 to about 20
mg/kg body weight/day. Effective doses will also vary, as recognized by those skilled in the
art, dependent on route of administration, excipient usage, and the possibility of co—usage
with other therapeutic ents including use of other therapeutic agents and/or therapy.
The co—crystals or pharmaceutical compositions of the ion can be
administered to the subject in need f (e. g., cells, a tissue, or a patient (including an
animal or a human) by any method that permits the delivery of a compound of formula I, e. g.,
orally, intravenously, or erally. For instance, they can be administered via pills, tablets,
capsules, aerosols, suppositories, liquid formulations for ingestion or injection.
As described above, the pharmaceutically acceptable compositions of the present
invention additionally comprise a pharmaceutically acceptable carrier, nt, or vehicle,
which, as used herein, includes any and all ts, diluents, or other liquid vehicle,
dispersion or sion aids, surface active agents, isotonic , thickening or
fying agents, preservatives, solid binders, lubricants and the like, as suited to the
particular dosage form desired. In Remington: The Science and Practice ofPharmacy, 21st
edition, 2005, ed. D.B. Troy, Lippincott Williams & Wilkins, Philadelphia, and Encyclopedia
ofPharmaceutical Technology, eds. J. Swarbrick and J. C. Boylan, 1988—1999, Marcel
Dekker, New York, the contents of each of which is incorporated by reference herein, are
disclosed various carriers used in formulating pharmaceutically acceptable compositions and
known techniques for the preparation thereof. Except insofar as any conventional carrier
medium is incompatible with the compounds of the invention, such as by producing any
undesirable biological effect or otherwise interacting in a deleterious manner with any other
component(s) of the pharmaceutically acceptable composition, its use is contemplated to be
within the scope of this invention.
A pharmaceutically acceptable r may contain inert ingredients which do not
unduly inhibit the biological activity of the compounds. The pharmaceutically acceptable
carriers should be biocompatible, e. g., non-toxic, non-inflammatory, non-immunogenic or
devoid of other undesired reactions or side—effects upon the administration to a subject.
Standard pharmaceutical formulation techniques can be employed.
Some examples of materials which can serve as pharmaceutically able
carriers include, but are not limited to, ion exchangers, alumina, aluminum stearate, in,
serum ns (such as human serum albumin), buffer substances (such as twin 80,
phosphates, glycine, sorbic acid, or potassium e), l glyceride mixtures of saturated
ble fatty acids, water, salts or electrolytes (such as protamine sulfate, disodium
hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, or zinc salts), colloidal
silica, magnesium trisilicate, polyvinyl idone, polyacrylates, waxes, polyethylene—
polyoxypropylene—block polymers, methylcellulose, hydroxypropyl methylcellulose, wool
fat, sugars such as lactose, glucose and sucrose; starches such as corn starch and potato
starch; cellulose and its tives such as sodium carboxymethyl cellulose, ethyl cellulose
and cellulose acetate; powdered anth; malt; gelatin; talc; excipients such as cocoa butter
and suppository waxes; oils such as peanut oil, cottonseed oil; safflower oil; sesame oil; olive
oil; corn oil and soybean oil; glycols; such a propylene glycol or polyethylene glycol; esters
such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide
and um ide; alginic acid; pyrogen-free water; isotonic saline; 's solution;
ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible
lubricants such as sodium lauryl sulfate and magnesium te, as well as coloring agents,
releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives
and antioxidants can also be present in the ition, according to the judgment of the
formulator.
In one specific example, the pharmaceutically acceptable compositions of the
invention comprise methylcellulose, such as about 0.5 wt% methylcellulose. In another
specific example, the pharmaceutically acceptable compositions of the invention comprise
methylcellulose and benzoic acid, such as about 0.5 wt% methylcellulose and about 0.2 wt%
benzoic acid. In r specific example, the pharmaceutically acceptable compositions
comprise methylcellulose and benzoic acid, such as about 0.5 wt% cellulose, about 0.1
wt% benzoic acid about 0.1 wt% sodium benzoate. In some embodiments, the pharmaceutical
WO 58067
compositions further se free adipic acid (free CCF that is not a CCF of the co-crystals
of the invention). Such adipic acid is in a concentration of, for example, about 5 mg/[g
vehicle] to about 10 mg/[g e], such as about 8.8 mg/[g vehicle].
Any orally acceptable dosage form including, but not limited to, capsules, tablets,
aqueous suspensions or ons, can be used for the oral administration. In the case of
s for oral use, carriers commonly used include, but are not limited to, lactose and corn
starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral
administration in a capsule form, useful diluents include lactose and dried arch. When
aqueous sions are required for oral use, the active ingredient is combined with
emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring
agents may also be added.
Liquid dosage forms for oral administration e, but are not limited to,
pharmaceutically able emulsions, microemulsions, solutions, suspensions, syrups and
elixirs. In addition to the active compounds, the liquid dosage forms may contain inert
diluents commonly used in the art such as, for example, water or other solvents, solubilizing
agents and emulsifiers such as ethyl l, pyl alcohol, ethyl carbonate, ethyl acetate,
benzyl l, benzyl benzoate, propylene glycol, l,3-butylene glycol, dimethylformamide,
oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils),
glycerol, ydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan,
and es thereof. Besides inert diluents, the oral compositions can also include adjuvants
such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and
perfuming agents.
Solid dosage forms for oral administration include capsules, tablets, pills,
powders, and granules. In such solid dosage forms, the active compound is mixed with at
least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or
dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose,
mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates,
gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d)
disintegrating agents such as agar--agar, calcium carbonate, potato or tapioca starch, alginic
acid, certain silicates, and sodium carbonate, e) solution retarding agents such as in, f)
absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as,
for example, cetyl alcohol and glycerol monostearate, h) ents such as kaolin and
bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid
polyethylene s, sodium lauryl sulfate, and mixtures thereof. In the case of capsules,
tablets and pills, the dosage form may also comprise buffering agents.
Solid compositions of a similar type may also be employed as fillers in soft and
hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high
molecular weight hylene glycols and the like. The solid dosage forms of tablets,
dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric
coatings and other gs well known in the pharmaceutical formulating art. They may
optionally n opacifying agents and can also be of a composition that they release the
active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally,
in a delayed manner. Examples of embedding compositions that can be used include
polymeric substances and waxes. Solid itions of a similar type may also be ed
as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar
as well as high molecular weight hylene glycols and the like.
ncapsulated forms with one or more excipients as noted above can also be
used in the invention. The solid dosage forms of tablets, dragees, capsules, pills, and
granules can be prepared with coatings and shells such as enteric coatings, release controlling
coatings and other coatings well known in the pharmaceutical formulating art. In such solid
dosage forms the active compound may be admixed with at least one inert diluent such as
sucrose, e or starch. Such dosage forms may also comprise, as is normal practice,
additional substances other than inert diluents, e.g., tableting lubricants and other tableting
aids such a ium stearate and microcrystalline cellulose. In the case of capsules,
tablets and pills, the dosage forms may also comprise buffering agents. They may optionally
contain opacifying agents and can also be of a composition that they release the active
ingredient(s) only, or entially, in a certain part of the intestinal tract, optionally, in a
delayed manner. Examples of embedding compositions that can be used include polymeric
substances and waxes.
able preparations, for example, sterile injectable aqueous or oleaginous
suspensions may be formulated ing to the known art using suitable dispersing or
wetting agents and ding agents. The sterile inj ectable preparation may also be a sterile
inj ectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or
solvent, for example, as a solution in l,3-butanediol. Among the acceptable vehicles and
solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium
de solution. In addition, sterile, fixed oils are conventionally employed as a solvent or
suspending medium. For this purpose any bland fixed oil can be employed including
synthetic mono— or diglycerides. In addition, fatty acids such as oleic acid are used in the
preparation of inj es.
Injectable formulations can be sterilized, for example, by filtration through a
bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid
compositions which can be dissolved or dispersed in sterile water or other sterile injectable
medium prior to use.
Sterile able forms may be aqueous or oleaginous suspension. These
suspensions may be formulated according to techniques known in the art using suitable
dispersing or wetting agents and suspending agents. The sterile inj ectable preparation may
also be a sterile injectable on or suspension in a non-toxic parenterally-acceptable
diluent or solvent, for example as a solution in l,3-butanediol. Among the acceptable
vehicles and ts that may be employed are water, Ringer's solution and isotonic sodium
chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or
suspending . For this purpose, any bland fixed oil may be employed including
synthetic mono— or di—glycerides. Fatty acids, such as oleic acid and its glyceride derivatives
are useful in the ation of inj ectables, as are natural ceutically-acceptable oils,
such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil
solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as
carboxymethyl cellulose or similar dispersing agents which are commonly used in the
formulation of pharmaceutically acceptable dosage forms including emulsions and
suspensions. Other commonly used surfactants, such as Tweens, Spans and other
emulsifying agents or bioavailability enhancers which are commonly used in the manufacture
of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the
purposes of ation.
In order to prolong the effect of the active compounds stered, it is often
desirable to slow the absorption of the nd from subcutaneous or uscular
injection. This may be accomplished by the use of a liquid suspension of lline or
ous material with poor water solubility. The rate of absorption of the compound then
depends upon its rate of dissolution that, in turn, may depend upon crystal size and crystalline
form. atively, delayed absorption of a parenterally administered compound form is
accomplished by dissolving or suspending the compound in an oil vehicle. Injectable depot
forms are made by forming microencapsule matrices of the active compound in
biodegradable polymers such as polylactide—polyglycolide. Depending upon the ratio of the
active compound to polymer and the nature of the ular polymer employed, the rate of
WO 58067
compound release can be controlled. Examples of other biodegradable polymers include
poly(orthoesters) and poly(anhydrides). Depot inj ectable formulations are also prepared by
entrapping the compound in liposomes or microemulsions that are compatible with body
tissues.
When desired the above described formulations adapted to give sustained e
of the active ingredient may be employed.
Compositions for rectal or vaginal administration are specifically suppositories
which can be prepared by mixing the active compound with suitable non-irritating excipients
or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at
ambient temperature but liquid at body temperature and therefore melt in the rectum or
vaginal cavity and release the active compound.
Dosage forms for topical or transdermal administration include ointments, pastes,
creams, lotions, gels, powders, ons, sprays, inhalants or patches. The active ent
is admixed under sterile conditions with a pharmaceutically acceptable carrier and any
needed preservatives or buffers as may be required. lmic formulation, eardrops, and
eye drops are also plated as being within the scope of this invention. onally,
ermal patches, which have the added age of providing controlled delivery of a
compound to the body, can also be used. Such dosage forms can be made by dissolving or
dispensing the nd in the proper medium. Absorption enhancers can also be used to
increase the flux of the compound across the skin. The rate can be controlled by either
providing a rate controlling membrane or by dispersing the compound in a polymer matrix or
gel.
Alternatively, the active compounds and pharmaceutically acceptable
compositions thereof may also be administered by nasal aerosol or inhalation. Such
compositions are prepared ing to techniques well-known in the art of pharmaceutical
ation and may be prepared as solutions in saline, employing benzyl alcohol or other
suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or
other conventional solubilizing or dispersing agents.
] The co-crystals or pharmaceutical compositions of the invention also can be
delivered by implantation (e. g., surgically) such with an implantable device. es of
implantable devices include, but are not d to, stents, delivery pumps, vascular s,
and implantable control release compositions. Any implantable device can be used to deliver
a compound of formula I as the active ingredient in the co-crystals or pharmaceutical
compositions of this invention, provided that l) the device, compound of formula I, and any
pharmaceutical composition including the compound are biocompatible, and 2) that the
device can deliver or release an ive amount of the nd to confer a therapeutic
effect on the treated patient.
ry of therapeutic agents via stents, delivery pumps (e g., mini-osmotic
pumps), and other table devices is known in the art. See, e.g., "Recent pments
in Coated Stents" by Hofma et al., published in Current Interventional Cardiology Reports,
2001, 3: 28—3 6, the entire ts of which, including references cited therein, are
incorporated herein. Other descriptions of implantable devices, such as stents, can be found
in US. Pat. Nos. 6,569, 195 and 6,322,847, and PCT International Publication Numbers WO
04/0044405, WO 04/0018228, WO 03/0229390, WO 8346, WO 03/0225450, WO
03/0216699, and WO 03/0204168, each of which (as well as other publications cited herein)
is incorporated herein in its entirety.
The active compounds and pharmaceutically acceptable compositions f can
be formulated in unit dosage form. The term “unit dosage form” refers to physically discrete
units suitable as unitary dosage for subjects undergoing treatment, with each unit containing a
predetermined quantity of active material calculated to produce the desired therapeutic effect,
optionally in association with a suitable pharmaceutical carrier. The unit dosage form can be
for a single daily dose or one of multiple daily doses (e.g., about 1 to 4 or more times per
day). When multiple daily doses are used, the unit dosage form can be the same or different
for each dose. The amount of the active compound in a unit dosage form will vary ing
upon, for example, the host treated, and the particular mode of administration, for example,
from about 0.1 to about 200 mg/kg body weight/day.
In one embodiment, the invention is directed to methods for potentiating a
therapeutic n for treatment of cancer. The methods comprise the step of administering
to an individual in need thereof an ive amount of a stal of the invention or
pharmaceutical composition thereof. The compounds of a I and co-crystals thereof,
without being bound to a particular , can inhibit DNA-PK. DNA-PK plays an
important role in cellular survival, for example, of cancer cells, after DNA damage via its
activity repairing double strand breaks (DSBs) by non—homologous end joining (NHEJ).
Targeting DNA-PK therefore can improve cancer patient outcomes ally in cancer
patients who receive therapies to induce DSBs in tumor cells since the DSBs in the tumor
cells cannot be repaired and rapidly lead to cell death. In some embodiments, the methods of
the invention potentiate therapeutic n to induce DSBs. Examples of such therapies
include radiation therapy (RT) and certain chemotherapies such as topoisomerase I inhibitors
(e. g., topotecan, irinotecan/SN3 8, can and other derivatives), topoisomerase II
inhibitors (e. g., etoposide and , DNA intercalators (e.g., doxorubicin or epirubicin),
radiomimetics (e.g., bleomycin), PARP inhibitors (e. g., BMN-673), DNA-repair inhibitors
(e. g., carboplatin), DNA cross-linkers (e.g., cisplatin), inhibitors of thymidylate synthase
(e. g., fluorouracil (5-FU)), mitotic inhibitors (e. g., paclitaxel), EGFR inhibitors (e. g.,
nib), and EGFR onal antibodies (e. g., cetuximab).
In one specific embodiment, said potentiated therapeutic regimen for treatment
cancer includes at least one chemotherapy selected from a topoisomerase I inhibitor,
omerase II inhibitor, DNA intercalator, radiomimetic, PARP inhibitor, DNA-repair
inhibitor, DNA cross-linkers, inhibitor of thymidylate synthase, mitotic inhibitor, EGFR
inhibitor, EGFR monoclonal antibody, or radiation. In another specific embodiment, the
therapeutic regimen for treatment of cancer includes radiation therapy. The co-crystals or
pharmaceutical compositions of the ion are useful in instances where radiation therapy
is indicated to enhance the therapeutic benefit of such treatment. In on, ion
therapy frequently is indicated as an adjuvant to surgery in the treatment of cancer. In
general a goal of radiation therapy in the adjuvant setting is to reduce the risk of recurrence
and enhance disease-free survival when the primary tumor has been controlled. For example,
adjuvant radiation therapy is indicated in cancers, including but not limited to, breast cancer,
colorectal cancer, c-esophageal cancer, fibrosarcoma, glioblastoma, hepatocellular
carcinoma, head and neck squamous cell carcinoma, melanoma, lung cancer, atic
cancer, and prostate cancer as bed below. In yet another specific embodiment, the
therapeutic regimen for treatment of cancer includes both radiation therapy and a
chemotherapy of at least one chemotherapy agents selected from topoisomerase I inhibitors,
topoisomerase II inhibitors, DNA alators, radiomimetics, PARP inhibitors, DNA-repair
inhibitors, DNA linkerss, inhibitors of ylate synthase, mitotic inhibitors, EGFR
inhibitors, or EGFR monoclonal dies.
In another embodiment, the invention provides methods of inhibiting or
preventing repair of DNA—damage by homologous recombination in cancerous cells.
Another embodiment provides methods of promoting cell death in cancerous cells. Yet
another embodiment provides s or preventing cell repair of DNA-damage in
cancerous cells.
The invention further relates to izing (e. g., radiosensitizing) tumor cells by
utilizing a co-crystal or pharmaceutical composition of the ion. Accordingly, such a
co-crystal or pharmaceutical composition can “radiosensitize” a cell when administered to
2014/061102
animals in therapeutically effective amount to increase the sensitivity of cells to
electromagnetic radiation and/or to promote the treatment of diseases that are treatable with
electromagnetic radiation (e.g., X-rays). Diseases that are treatable with electromagnetic
radiation include neoplastic es, benign and malignant tumors, and cancerous cells. In
some embodiments, the invention further relates to sensitizing tumor cells to DNA-damaging
agents.
The present invention also provides methods of treating cancer in an animal that
includes administering to the animal an effective amount of a compound of formula (I) or a
co-crystal thereof, or a pharmaceutical composition of the invention. The invention further is
directed to methods of inhibiting cancer cell , including processes of cellular
proliferation, invasiveness, and metastasis in biological systems. Methods include use of
such a co-crystal or pharmaceutical composition to inhibit cancer cell growth. Preferably, the
methods are ed to inhibit or reduce cancer cell growth, invasiveness, metastasis, or
tumor incidence in living animals, such as mammals. s of the invention also are
readily adaptable for use in assay systems, e.g., assaying cancer cell growth and properties
thereof, as well as identifying compounds that affect cancer cell growth.
Tumors or neoplasms include growths of tissue cells in which the multiplication
of the cells is uncontrolled and progressive. Some such growths are benign, but others are
termed “malignant” and can lead to death of the sm. Malignant sms or
“cancers” are distinguished from benign growths in that, in addition to exhibiting aggressive
ar eration, they can invade surrounding tissues and metastasize. Moreover,
malignant neoplasms are characterized in that they show a greater loss of differentiation
er “dedifferentiation”) and their organization relative to one another and their
surrounding tissues. This property is also called “anaplasia.”
Neoplasms treatable by the present invention also include solid tumors, i.e.,
carcinomas and sarcomas. Carcinomas include those ant neoplasms d from
epithelial cells which infiltrate (invade) the surrounding tissues and give rise to ases.
Adenocarcinomas are carcinomas derived from glandular tissue, or from tissues which form
izable glandular structures. Another broad category of s includes sarcomas,
which are tumors whose cells are embedded in a lar or homogeneous substance like
embryonic connective tissue. The invention also enables treatment of cancers of the myeloid
or lymphoid systems, including leukemias, lymphomas, and other cancers that typically do
not present as a tumor mass, but are distributed in the ar or lymphoreticular systems.
DNA-PK activity can be associated with various forms of cancer in, for example,
adult and pediatric oncology, growth of solid tumors/malignancies, myxoid and round cell
carcinoma, locally advanced tumors, metastatic cancer, human soft tissue sarcomas, including
Ewing's sarcoma, cancer metastases, including lymphatic metastases, squamous cell
carcinoma, particularly of the head and neck, esophageal squamous cell carcinoma, oral
carcinoma, blood cell malignancies, including multiple myeloma, leukemias, including acute
lymphocytic leukemia, acute nonlymphocytic leukemia, chronic lymphocytic leukemia,
chronic myelocytic leukemia, and hairy cell leukemia, effusion lymphomas (body cavity
based mas), thymic lymphoma lung cancer, including small cell oma, cutaneous
T cell ma, Hodgkin's ma, non-Hodgkin's lymphoma, cancer of the adrenal
cortex, roducing tumors, all cell cancers, breast cancer, including small cell
carcinoma and ductal carcinoma, gastrointestinal cancers, including stomach cancer, colon
cancer, colorectal cancer, polyps associated with colorectal neoplasia, pancreatic cancer, liver
cancer, urological cancers, including bladder cancer, including primary superficial bladder
tumors, invasive transitional cell carcinoma of the bladder, and muscle—invasive bladder
cancer, prostate , malignancies of the female genital tract, including n
carcinoma, primary peritoneal epithelial sms, cervical carcinoma, uterine endometrial
cancers, vaginal cancer, cancer of the vulva, uterine cancer and solid tumors in the ovarian
follicle, malignancies of the male genital tract, including ular cancer and penile cancer,
kidney cancer, including renal cell carcinoma, brain cancer, ing sic brain tumors,
neuroblastoma, astrocytic brain , gliomas, metastatic tumor cell invasion in the central
nervous system, bone cancers, including osteomas and osteosarcomas, skin cancers, including
malignant melanoma, tumor progression of human skin keratinocytes, squamous cell cancer,
thyroid cancer, retinoblastoma, neuroblastoma, peritoneal effusion, malignant pleural
on, mesothelioma, Wilms's tumors, gall bladder cancer, trophoblastic sms,
hemangiopericytoma, and Kaposi's sarcoma. Thus, also within the scope of this ion is
a method of treating such diseases, which comprising administering to a subject in need
thereof a therapeutically effective amount of a stal of this invention or a
pharmaceutical ition of this invention.
In some embodiments, the invention is employed for treating lung cancer (e.g.,
non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), or extensive—disease
small cell lung cancer (ED-SCLC)), breast cancer (e.g., triple negative breast cancer),
prostate cancer, heme malignancies (e.g., acute myeloid ia (AML)), myeloma (e.g.,
plasma cell myeloma , gastro-esophageal junction cancer (GEJ), ovarian cancer,
colon cancer, pharynx cancer, pancreatic cancer, gastric , esophageal cancer,
lymphoma (e. g., diffuse large B-cell ma (DLBL)), or lung fibroblast. In some
specific embodiments, the invention is employed for treating lung cancer (e.g., non-small cell
lung cancer (NSCLC), small cell lung cancer (SCLC), or extensive-disease small cell lung
cancer (ED-SCLC)), breast cancer (e.g., triple negative breast cancer), prostate cancer, acute
myeloid leukemia, myeloma, gastro-esophageal junction cancer (GEJ), or ovarian cancer. In
some specific embodiments, the invention is employed for ng lung cancer such as non—
small cell lung cancer (NSCLC) or small cell lung cancer, such as extensive—disease small
cell lung cancer (ED—SCLC). In some specific embodiments, the invention is employed for
treating breast cancer, such as triple ve breast cancer. In some specific embodiments,
the invention is ed for treating gastro-esophageal junction cancer (GEJ). In some
ic embodiments, the invention is employed for treating acute myeloid leukemia (AML).
The invention also provides a method of inhibiting DNA-PK activity in a
biological sample that includes contacting the biological sample with a co-crystal or
pharmaceutical composition of the invention. The term “biological sample,” as used herein,
means a sample outside a living organism and includes, without limitation, cell cultures or
extracts thereof; biopsied material obtained from a mammal or extracts thereof; and blood,
saliva, urine, feces, semen, tears, or other body fluids or extracts thereof. Inhibition of kinase
activity, particularly DNA-PK ty, in a ical sample is useful for a variety of
purposes known to one of skill in the art. An example includes, but is not limited to, the
inhibition of DNA-PK in a biological assay. In one embodiment, the method of inhibiting
DNA-PK activity in a biological sample is d to non-therapeutic methods.
The term "biological sample", as used herein, includes, without limitation, cell
cultures or extracts f; biopsied material obtained from a mammal or extracts thereof;
blood, , urine, feces, semen, tears, or other body fluids or extracts f
Combination Therapies
The present invention also provides combination of herapy with a
compound or composition of the ion, or with a combination of another anticancer
therapy, such as ncer agent or radiation y (or radiotherapy). In some
embodiments, the compounds of formula I and co—crystals thereof are used in combination
with another ncer therapy, such as anticancer drug or radiation therapy. As used herein,
the terms "in combination" or "co-administration" can be used interchangeably to refer to the
use of more than one therapy (e.g., one or more prophylactic and/or therapeutic agents). The
use of the terms does not restrict the order in which therapies (e. g., prophylactic and/or
therapeutic agents) are administered to a subject.
In some embodiments, said another anticancer therapy is an anti-cancer agent. In
other embodiments, said another anticancer therapy is a DNA-damaging agent. In yet other
embodiments, said r anticancer therapy is selected from radiation therapy. In a
specific embodiment, the radiation therapy is ionizing radiation.
Examples of DNA-damaging agents that may be used in ation with the
compounds of formula I and co—crystals thereof include, but are not limited to platinating
agents, such as carboplatin, nedaplatin, satraplatin and other derivatives; topoisomerase I
inhibitors, such as can, irinotecan/SN3 8, can and other derivatives;
antimetabolites, such as folic family (methotrexate, exed and relatives); purine
antagonists and pyrimidine antagonists (thioguanine, fludarabine, cladribine, cytarabine,
gemcitabine, 6-mercaptopurine, rouracil (SFU) and relatives); alkylating agents, such
as nitrogen mustards (cyclophosphamide, lan, chlorambucil, mechlorethamine,
ifosfamide and relatives); nitrosoureas (e. g. carmustine); triazenes (dacarbazine,
temozolomide); alkyl sulphonates (eg busulfan); procarbazine and aziridines; antibiotics,
such as hydroxyurea, anthracyclines (doxorubicin, daunorubicin, epirubicin and other
derivatives); anthracenediones (mitoxantrone and relatives); streptomyces family (bleomycin,
mitomycin C, actinomycin); and ultraviolet light.
Other therapies or anticancer agents that may be used in combination with the
inventive agents of the present invention include surgery, radiotherapy (in but a few
examples, ionizaing radiation (IR), gamma-radiation, neutron beam herapy, electron
beam radiotherapy, proton therapy, therapy, and systemic radioactive isotopes, to
name a few), endocrine therapy, biologic response modifiers (interferons, interleukins, and
tumor is factor (TNF) to name a few), hermia and cryotherapy, agents to
attenuate any adverse effects (e. g., antiemetics), and other approved chemotherapeutic drugs,
including, but not d to, the DNA damaging agents listed herein, spindle s
(vinblastine, vincristine, vinorelbine, paclitaxel), podophyllotoxins (etoposide, ecan,
vopotecan), nitrosoureas (varmustine, lomustine), inorganic ions (cisplatin, carboplatin),
enzymes (vsparaginase), and hormones (tamoxifen, leuprolide, flutamide, and megestrol),
GleevecTM, adriamycin, dexamethasone, and cyclophosphamide.
Additional examples of the therapeutic agents for the co-therapy of the invention
include: abarelix (Plenaxis depot®); aldesleukin ne®); eukin (Proleukin®);
zumabb th®); alitretinoin (Panretin®); allopurinol (Zyloprim®); altretamine
(Hexalen®); amifostine l®); anastrozole (Arimidex®); arsenic trioxide (Trisenox®);
ginase (Elspar®); azacitidine (Vidaza®); bevacuzimab (Avastin®); bexarotene
capsules (Targretin®); bexarotene gel (Targretin®); bleomycin (Blenoxane®); bortezomib
de®); busulfan intravenous (Busulfex®); busulfan oral (Myleran®); calusterone
(Methosarb®); capecitabine (Xeloda®); carboplatin (Paraplatin®); carmustine (BCNU®,
BiCNU®); carmustine (Gliadel®); carmustine with Polifeprosan 20 Implant el
Wafer®); celecoxib (Celebrex®); cetuximab (Erbitux®); chlorambucil (Leukeran®);
tin (Platinol®); cladribine (Leustatin®, 2-CdA®); clofarabine (Clolar®);
cyclophosphamide (Cytoxan®, Neosar®); cyclophosphamide (Cytoxan Inj ection®);
cyclophosphamide (Cytoxan Tablet®); cytarabine (Cytosar-U®); bine liposomal
(DepoCyt®); dacarbazine (DTIC-Dome®); dactinomycin, actinomycin D (Cosmegen®);
Darbepoetin alfa sp®); daunorubicin liposomal (DanuoXome®); daunorubicin,
daunomycin (Daunorubicin®); daunorubicin, daunomycin (Cerubidine®); ukin
diftitox (Ontak®); dexrazoxane (Zinecard®); docetaxel (Taxotere®); doxorubicin
(Adriamycin PFS®); doxorubicin mycin®, Rubex®); doxorubicin (Adriamycin PFS
Injection®); doxorubicin liposomal (Doxil®); dromostanolone propionate
stanolone®); dromostanolone propionate (masterone injection®); Elliott's B Solution
(Elliott's B Solution®); icin (Ellence®); Epoetin alfa (epogen®); nib (Tarceva®);
ustine (Emcyt®); etoposide phosphate (Etopophos®); etoposide, VP—l6 (Vepesid®);
exemestane (Aromasin®); Filgrastim (Neupogen®); floxuridine arterial) (FUDR®);
fludarabine (Fludara®); fluorouracil, 5-FU (Adrucil®); fulvestrant (Faslodex®); gefitinib
(Iressa®); gemcitabine (Gemzar®); umab ozogamicin (Mylotarg®); goserelin acetate
(Zoladex Implant®); goserelin acetate (Zoladex®); histrelin acetate (Histrelin implant®);
yurea (Hydrea®); Ibritumomab Tiuxetan (Zevalin®); idarubicin (Idamycin®);
ifosfamide (IFEX®); imatinib mesylate ec®); interferon alfa 2a (Roferon A®);
Interferon alfa-2b n A®); irinotecan (Camptosar®); lenalidomide (Revlimid®);
letrozole (Femara®); leucovorin (Wellcovorin®, Leucovorin®); lide Acetate
(Eligard®); levamisole (Ergamisol®); lomustine, CCNU (CeeBU®); meclorethamine,
nitrogen mustard (Mustargen®); megestrol acetate (Megace®); melphalan, L-PAM
(Alkeran®); mercaptopurine, 6-MP (Purinethol®); mesna (Mesnex®); mesna (Mesnex
tabs®); methotrexate (Methotrexate®); salen (Uvadex®); mitomycin C
(Mutamycin®); mitotane (Lysodren®); mitoxantrone (Novantrone®); nandrolone
phenpropionate (Durabolin-50®); nelarabine (Arranon®); momab (Verluma®);
Oprelvekin (Neumega®); oxaliplatin (Eloxatin®); paclitaxel (Paxene®); paclitaxel (Taxol®);
paclitaxel protein-bound particles (Abraxane®); rmin (Kepivance®); onate
(Aredia®); pegademase (Adagen (Pegademase Bovine)®); pegaspargase (Oncaspar®);
Pegfilgrastim (Neulasta®); pemetrexed disodium (Alimta®); pentostatin (Nipent®);
pipobroman (Vercyte®); plicamycin, mithramycin (Mithracin®); porfimer sodium
(Photofrin®); procarbazine (Matulane®); rine (Atabrine®); Rasburicase k®);
Rituximab (Rituxan®); mostim (Leukine®); Sargramostim (Prokine®); sorafenib
(Nexavar®); ozocin ar®); sunitinib maleate (Sutent®); talc (Sclerosol®);
tamoxifen (Nolvadex®); temozolomide (Temodar®); teniposide, VM—26 (Vumon®);
testolactone (Teslac®); anine, 6-TG (Thioguanine®); thiotepa (Thioplex®); can
(Hycamtin®); toremifene (Fareston®); Tositumomab (Bexxar®); Tositumomab/I-l3l
momab (Bexxar®); Trastuzumab (Herceptin®); tretinoin, ATRA (Vesanoid®); Uracil
Mustard (Uracil Mustard es®); valrubicin (Valstar®); vinblastine (Velban®);
vincristine (Oncovin®); vinorelbine (Navelbine®); zoledronate (Zometa®) and vorinostat
(Zolinza®).
For a hensive discussion of updated cancer therapies see, nci.nih. gov, a list
of the FDA approved oncology drugs at fda.gov/cder/cancer/druglistframe.htm, and The
Merck , Seventeenth Ed. 1999.
Some embodiments comprising administering to said t an additional
therapeutic agent ed from a DNA-damaging agent, wherein said additional therapeutic
agent is appropriate for the disease being treated, and said additional therapeutic agent is
administered together with said compound as a single dosage form or separately from said
compound as part of a multiple dosage form.
In some embodiments, said DNA—damaging agent is selected from at least one
from radiation, (e. g., ionizing radiation), radiomimetic neocarzinostatin, a platinating agent, a
topoisomerase 1 inhibitor, a topoisomerase II inhibitor, an antimetabolite, an alkylating agent,
an alkyl sulphonates, an antimetabolite, a PARP inhibitor, or an antibiotic. In other
embodiments, said DNA-damaging agent is selected from at least one from ionizing
radiation, a platinating agent, a topoisomerase 1 inhibitor, a topoisomerase II inhibitor, a
PARP inhibitor, or an antibiotic.
Examples of platinating agents include cisplatin, oxaliplatin, carboplatin,
nedaplatin, satraplatin and other derivatives. Other platinating agents include lobaplatin, and
triplatin. Other platinating agents include tetranitrate, picoplatin, latin, proLindac and
aroplatin.
Examples of topoisomerase 1 inhibitors include camptothecin, topotecan,
irinotecan/SN3 8, rubitecan and other derivatives. Other topoisomerase 1 inhibitors include
belotecan.
Examples of topoisomerase II inhibitors include ide, daunorubicin,
doxorubicin, mitoxantrone, aclarubicin, epirubicin, idarubicin, amrubicin, amsacrine,
pirarubicin, valrubicin, zorubicin and teniposide.
Examples of antimetabolites include members of the folic family, purine family
(purine antagonists), or pyrimidine family idine antagonists). Examples of the folic
family include methotrexate, exed and relatives; examples of the purine family include
thioguanine, fludarabine, cladribine, aptopurine, and relatives; examples of the
pyrimidine family include bine, gemcitabine, 5-fluorouracil (5FU) and relatives.
Some other specific examples of antimetabolites include aminopterin,
methotrexate, pemetrexed, rexed, pentostatin, cladribine, clofarabine, fludarabine,
thioguanine, mercaptopurine, uracil, capecitabine, tegafur, carmofur, floxuridine,
cytarabine, gemcitabine, azacitidine and hydroxyurea.
Examples of alkylating agents include nitrogen mustards, triazenes, alkyl
sulphonates, procarbazine and aziridines. Examples of nitrogen ds include
cyclophosphamide, melphalan, chlorambucil and relatives; es of nitrosoureas include
tine; examples of nes include dacarbazine and temozolomide; examples of alkyl
nates e busulfan.
Other specific examples of alkylating agents include mechlorethamine,
cyclophosphamide, ifosfamide, trofosfamide, chlorambucil, melphalan, prednimustine,
bendamustine, tine, estramustine, carmustine, lomustine, semustine, fotemustine,
nimustine, ranimustine, streptozocin, busulfan, mannosulfan, treosulfan, carboquone,
thioTEPA, triaziquone, triethylenemelamine, procarbazine, dacarbazine, lomide,
altretamine, mitobronitol, mycin, bleomycin, mitomycin and plicamycin.
Examples of antibiotics include mitomycin, hydroxyurea; anthracyclines,
anthracenediones, streptomyces family. Examples of cyclines include doxorubicin,
WO 58067
daunorubicin, epirubicin and other derivatives; examples of anthracenediones include
ntrone and relatives; examples of omyces family inclue bleomycin, mitomycin C,
and mycin.
Examples of PARP inhibitors e inhibitors of PARPl and PARP2. Specific
examples include olaparib (also known as AZD2281 or KU-0059436), iniparib (also known
as BSI-201 or SAR240550), veliparib (also known as ABT-888), rucaparib (also known as
PF—01367338), CEP—9722, INO—lOOl, MK—4827, E7016, 3, or AZD2461. In other
embodiments, the agent that inhibits or modulates PARPl or PARP2 is rib (also
known as ABT-888) or Rucaparib. In other embodiments, the agent that inhibits or
modulates PARPl or PARP2 is BMN—673.
In certain embodiments, said platinating agent is cisplatin or oxaliplatin; said
topoisomerase I inhibitor is camptothecin; said topoisomerase II inhibitor is etoposide; and
said antibiotic is mitomycin. In other embodiments, said platinating agent is selected from
cisplatin, oxaliplatin, latin, nedaplatin, or satraplatin; said topoisomerase I inhibitor is
selected from camptothecin, can, irinotecan/SN3 8, rubitecan; said topoisomerase II
inhibitor is selected from etoposide; said antimetabolite is selected from a member of the
folic family, the purine family, or the pyrimidine family; said alkylating agent is selected
from en mustards, nitrosoureas, triazenes, alkyl sulfonates, procarbazine, or aziridines;
and said antibiotic is selected from hydroxyurea, anthracyclines, anthracenediones, or
streptomyces family.
] In some embodiments, the additional therapeutic agent is ion (e. g., ionizing
radiation). In other embodiments, the onal therapeutic agent is cisplatin or carboplatin.
In yet other embodiments, the additional therapeutic agent is etoposide. In yet other
embodiments, the additional therapeutic agent is temozolomide.
In some embodiments, the additional eutic agents are selected from those
that inhibit or modulate a base excision repair protein. In a ic embodiment, the base
excision repair protein is selected from UNG, SMUGl, MBD4, TDG, OGGl, MYH, NTHl,
MPG, NEILl, NEILZ, NEIL3 (DNA glycosylases); APEl, APEX2 (AP endonucleases);
LIGl, LIG3 (DNA ligases I and III); XRCCl (LIG3 accessory); PNK, PNKP (polynucleotide
kinase and phosphatase); PARPl, PARP2 (Poly(ADP-Ribose) Polymerases); PolB, PolG
(polymerases); FENl (endonuclease) or Aprataxin. In another specific embodiment, the base
excision repair protein is selected from PARPl, PARP2, or PolB. In yet another
embodiment, the base excision repair protein is selected from PARPl or PARP2.
] In some embodiments, the method is used on a cancer cell having defects in the
ATM signaling cascade. In some embodiments, said defect is altered expression or activity
of one or more ofthe following: ATM, p53, CHK2, MREl l, RAD50, NBSl, 53BPl, MDCl,
H2AX, BRITl, CTIP, or SMCl. In other embodiments, said defect is altered
expression or activity of one or more of the following: ATM, p53, CHKZ, MREl l, RAD50,
NBSl, 53BPl, MDCl or H2AX. In another embodiment, the cell is a cancer cell expressing
DNA damaging nes. In some embodiments, said cancer cell has altered sion or
activity of one or more of the ing: K-Ras, N-Ras, H-Ras, Raf, Myc, Mos, E2F,
Cdc25A, CDC4, CDK2, Cyclin E, Cyclin A and Rb.
According to r embodiment, the method is used on a cancer, cancer cell, or
cell has a defect in a n ed in base excision repair (“base excision repair protein”).
There are many methods known in the art for determining r a tumor has a defect in
base excision repair. For example, sequencing of either the genomic DNA or mRNA products
of each base excision repair gene (e. g., UNG, PARPl, or LIGl) can be performed on a
sample of the tumor to establish whether mutations expected to modulate the function or
expression of the gene product are present (Wang et al., Cancer Research 52:4824 (1992)). In
addition to the mutational inactivation, tumor cells can modulate a DNA repair gene by
hypermethylating its promoter region, leading to reduced gene expression. This is most
commonly assessed using methylation—specific polymerase chain reaction (PCR) to quantify
methylation levels on the promoters of base excision repair genes of interest. Analysis of base
on repair gene promoter methylation is available commercially (e.g.,
sabiosciences.com/dna_methylation_product/HTML/MEAH—421A).
The expression levels of base excision repair genes can be assessed by ly
fying levels of the mRNA and protein products of each gene using standard techniques
such as quantitative reverse transcriptase-coupled polymerase chain reaction (RT-PCR) and
immunhohistochemistry (IHC), respectively (Shinmura et al., Carcinogenesis 25: 2311
(2004); Shinmura et al., Journal of Pathology 225:414 (2011)).
In some embodiments, the base excision repair protein is UNG, SMUGl, MBD4,
TDG, OGGl, MYH, NTHl, MPG, NEILl, NEIL2, NEIL3 (DNA glycosylases); APEl,
APEX2 (AP endonucleases); LIGl, LIG3 (DNA ligases I and III); XRCCl (LIG3 accessory);
PNK, PNKP (polynucleotide kinase and phosphatase); PARPl, PARP2 ADP-Ribose)
Polymerases); PolB, PolG (polymerases); FENl (endonuclease) or Aprataxin.
In some embodiments, the base excision repair protein is PARPl, PARP2, or
PolB. In other embodiments, the base excision repair protein is PARPl or PARP2.
2014/061102
In certain embodiments, the additional therapeutic agent is selected from one or
more of the following: cisplatin, carboplatin, gemcitabine, etoposide, temozolomide, or
ionizing ion.
In other embodiments, the additional therapeutic agents are selected from one or
more of the following: abine, cisplatin or carboplatin, and etoposide. In yet other
embodiments, the additional therapeutic agents are selected from one or more of the
ing: cisplatin or carboplatin, ide, and ionizing radiation. In some embodiments,
the cancer is lung cancer. In some embodiments, the lung cancer is non-small cell lung cancer
or small cell lung cancer.
In some embodiments, the anticancer therapies for the combination therapy of the
invention include DNA—damaging agents, such as topoisomerase inhibitors (e.g. etoposide
and doxil), DNA intercalators (e.g., doxorubicin, daunorubicin, and epirubicin),
radiomimetics (e.g., bleomycin), PARP inhibitors (e. g., BMN—673), DNA-repair inhibitors
(e. g., carboplatin), DNA cross-linkers (e.g., cisplatin), inhibitors of thymidylate synthase
(e. g., fluorouracil (5-FU)), mitotic inhibitors (e. g., paclitaxel), EGFR inhibitors (e. g.,
nib), EGFR monoclonal antibodies (e. g., cetuximab), and radiation (e. g., ionizing
radiation). Specific es include etoposide, doxil, gemcitabine, paclitaxel, cisplatin,
latin, 5—FU, etoposide, doxorubicin, daunorubicin, epirubicin, cin, BMN—673,
carboplatin, erlotinib, tin, carboplatin, fluorouracil cetuximab, and radiation (e. g.,
ionizing ion). In some embodiments, compounds of formula I and co—crystals thereof
are used in combination with at least one anticancer drug selected from etoposide, doxil,
gemcitabine, axel, cisplatin, carboplatin, 5—FU, etoposide, doxorubicin, daunorubicin,
epirubicin, cin, BMN—673, carboplatin, erlotinib, cisplatin, carboplatin, fluorouracil,
or cetuximab, and with or without radiation. In some specific embodiments, compounds of
formula I and co-crystals thereof are used in combination with etoposide and cisplatin, with
or without radiation (e. g., ionizing radiation). In some specific embodiments, compounds of
formula I and co-crystals thereof are used in combination with paclitaxel and cisplatin, with
or without radiation (e. g., ionizing ion). In some specific embodiments, compounds of
formula I and co-crystals thereof are used in combination with paclitaxel and carboplatin,
with or without radiation (e.g., ionizing radiation). In some specific ments,
compounds of formula I and co—crystals thereof are used in combination with cisplatin and 5—
Fu, with or without ion (e. g., ionizing radiation).
Specific examples of cancers for the combination y are as described above.
In some embodiments, the invention is ed for treating lung cancer (e. g., non-small cell
WO 58067
lung cancer (NSCLC), extensive—disease small cell lung cancer (ED—SCLC)), breast cancer
(e.g., triple negative breast cancer), prostate cancer, acute d leukemia, myeloma,
esophageal cancer (e. g., —esophageal junction cancer (GED), n cancer, colon
cancer, pharynx cancer, pancreatic cancer, lung fibroblast, and gastric cancer. In some
specific embodiments, the invention is employed for treating lung cancer (e.g., non-small cell
lung cancer (NSCLC), ive—disease small cell lung cancer (ED—SCLC)), breast cancer
(e.g., triple negative breast cancer), prostate , acute myeloid leukemia, myeloma,
gastro-esophageal junction cancer (GEJ), pancreatic cancer, and ovarian cancer.
In some specific embodiments, the invention provides co—therapy of the
compounds of formula I and co-crystals thereof in combination with standard of care (e.g.,
doxorubicin, etoposide, axel, and/or carboplatin), with or without radiation(e.g.,
ionizing radiation), for treating lung cancer, such as non-small cell lung cancer (NSCLC) or
extensive—disease small cell lung cancer (ED—SCLC).
In some specific embodiments, the ion provides co—therapy of the
compounds of formula I and co-crystals thereof in combination with standard of care (e.g.
cisplatin, 5-FU, carboplatin, paclitaxel, and/or etoposide), with or without radiation (e. g.,
ng radiation), is employed for treating -esophageal junction cancer (GEJ).
In some specific embodiments, the invention provides co—therapy of the
compounds of formula I and co-crystals thereof in combination with rd of care (e.g.,
doxorubicin and/or vincristine), with or without radiation (e.g., ionizing radiation), in acute
myeloid leukemia or chronic lymphocytic leukemia.
In some specific ments, the invention provides co—therapy of the
compounds of formula I and co-crystals thereof in combination with standard of care (e.g.,
doxorubicin and/or epirubicin), with or without radiation (e.g., ionizing radiation), in breast
cancer, such as triple negative breast cancer.
In some specific ments, the ion provides combination therapy of the
compounds of formula I and co-crystals thereof in combination with ion (or ionizing
radiation); cisplatin, etoposide, paclitaxel, doxorubicin or cetuximab, with or without
radiation (e. g., ionizing radiation); cisplatin and etoposide, with or without radiation (e.g.,
ionizing radiation); or cisplatin and paclitaxel, with or without radiation (e. g., ionizing
radiation), for lung cancer, such as non-small cell lung cancer (NSCLC), small cell lung
cancer, or ive—disease small cell lung cancer (ED—SCLC).
In some specific embodiments, the invention provides combination therapy of the
compounds of a I and stals thereof in combination with radiation (e. g., ionizing
radiation); cisplatin with or without radiation (e. g., ionizing radiation); etoposide with or
without radiation (e. g., ng radiation); carboplatin with or without radiation (e.g.,
ionizing radiation); 5-FU with or without radiation (e. g., ionizing ion); tin and
paclitaxel, with or without radiation (e. g., ionizing radiation); cisplatin and 5-FU, with or
without radiation (e. g., ionizing radiation); or carboplatin and paclitaxel, with or without
radiation (e. g., ionizing radiation), for gastro-esophageal on cancer (GEJ).
In some c embodiments, the invention provides ation y of the
compounds of formula I and co—crystals thereof in combination with doxorubicin or
epirubicin, with or without radiation (e.g., ionizing radiation), for breast cancer, such as triple
negative breast cancer.
r embodiment provides a method of treating breast cancer with the
compounds of formula I and co-crystals thereof in combination with a ating agent, with
or without radiation (e. g., ionizing radiation). In some embodiments, the breast cancer is
triple negative breast cancer. In other embodiments, the platinating agent is cisplatin.
In some specific embodiments, the invention provides combination therapy of the
compounds of a I and co—crystals thereof in combination with cetuximab, with or
without ion (e. g., ionizing radiation); or cisplatin with or without radiation (e. g.,
ng radiation), for x cancer, for pharynx cancer.
In some specific embodiments, the ion provides combination therapy of the
compounds of formula I and co-crystals thereof in combination with: cisplatin with or
without radiation (e. g., ionizing radiation); etoposide with or without radiation (e. g., ionizing
ion); cisplatin and 5-FU, with or without radiation (e. g., ionizing radiation); or
paclitaxel with or without radiation (e. g., ionizing radiation), for lung fibroblast.
In some specific embodiments, the invention provides combination therapy of the
compounds of formula I and co-crystals thereof in combination with: radiation (e. g., ionizing
radiation); bleomycin, doxorubicin, cisplatin, carboplatin, etoposide, paclitaxel or 5-FU, with
or without radiation (e. g., ionizing radiation) for lung cancer, such as NSCLC, pancreatic
cancer, esophageal cancer, or gastric cancer.
Another ment provides methods for treating pancreatic cancer by
administering a compound described herein in combination with r known pancreatic
cancer treatment. One aspect of the ion includes administering a compound described
herein in combination with gemcitabine.
inistration in the combination therapies encompasses administration of the
first and second s of the compounds/therapies of the co—administration in an
essentially simultaneous manner (such as in a single pharmaceutical composition, for
example, e or tablet having a fixed ratio of first and second amounts, or in multiple,
te capsules or s for each) or in a sequential manner in either order.
When co-administration involves the separate administration of the first amount of
a compound of the invention and a second amount of an additional therapeutic agent/therapy,
they are administered iently close in time to have the desired therapeutic effect. The
invention also can be practiced by including another anti-cancer herapeutic agent in a
therapeutic regimen for the treatment of cancer, with or without radiation therapy. The
combination of a co-crystal or ceutical composition of the invention with such other
agents can iate the chemotherapeutic protocol. For example, the tor compound of
the invention can be administered with etoposide, bleomycin, doxorubicin, epirubicin,
daunorubicin, or analogs thereof, agents known to cause DNA strand ge.
In some embodiments, the compounds of formula I and co—crystals thereof used in
combination with a DNA-damaging agent (e. g., etoposide, radiation), and the compounds of
formula I and co-crystals thereof are administered after the administration of the DNA-
damaging therapy. Specific examples of maging agents are described above.
In some embodiments, the ntioned one or more additional anticancer agent
or therapy is employed with Compound (1) or a pharmaceutically acceptable salt thereof. In
some embodiments, the forementioned one or more additional anticancer agent or therapy is
employed with Compound (2) or a pharmaceutically acceptable salt thereof. In some
embodiments, the forementioned one or more additional anticancer agent or therapy is
employed with the adipic acid co—crystal of Compound (1) (e. g., 2:1 Compound (1) to adipic
acid). In some embodiments, the forementioned one or more additional anticancer agent or
therapy is employed with the adipic co—crystal of nd (2) (e. g., 2:1 Compound (2) to
adipic acid).
In some embodiments, the forementioned one or more onal anticancer agent
or therapy is employed with the pharmaceutical compositions of the invention described
above.
Described below are es of preparing and characterizing co-crystals of this
invention, which are meant to be only illustrative and not to be limiting in any way.
Example 1: Preparation ofcompounds 0fthe invention
As used herein, all abbreviations, symbols and conventions are consistent with
those used in the contemporary scientific literature. See, e. g., Janet S. Dodd, ed., The ACS
Style Guide: A Manualfor Authors and Editors, 2nd Ed, Washington, DC: American
Chemical y, 1997. The following definitions describe terms and abbreviations used
herein:
BPin pinacol boronate ester
Brine a saturated NaCl solution in water
DCM dichloromethane
DIEA diisopropylethylamine
DMA dimethylacetamide
DME dimethoxyethane
DMF dimethylformamide
DMSO methylsulfoxide
EtDuPhos )- l - [2- [(2R,5R)-2,5 ylphospholan- l -yl]phenyl]—2,5 -
diethylphospholane
ESMS electrospray mass spectrometry
EtZO ethyl ether
EtOAc ethyl acetate
EtOH ethyl alcohol
HPLC high performance liquid tography
IPA isopropanol
LC-MS liquid chromatography-mass spectrometry
Me methyl
MeOH methanol
MTBE methyl t—butyl ether
NMP N—methylpyrrolidine
PdClz[P(cy)3]2 dichloro-bis(tricyclohexylphosphoranyl)-palladium
Ph phenyl
RT or rt room temperature
TBME tert—butylmethyl ether
tBu tertiary butyl
THF tetrahydrofuran
TEA triethylamine
TMEDA tetramethylethylenediamine
Example A. Preparation of 2-methyl(4,4,5,5—tetramethyl-l,3,2-dioxaborolan
yl)pyrimidine—4,6-d2 (Compound 1003)
Pd (black),TEA
C' 2
2HCOZZH H
1. tBuONO, 2H
\N (2H)3COZH HZNIKN CH3CN
/ BrfN
CI NJ\CH3 (Step 1_i) 2H N/J\CH 2. CUZBF 2
3 H 3
(step 1-ii)
H3C CH3
H3O ‘ H30 CH3
H30 0’ 9
H3C ,B
—2. H30 0
PdC|2[P(CY)3]2, 11
2H N/ CH3
KOAC, 2-MeTHF
100°C [1°03]
(step1-iii)
Schemel
As shown in step l—i of Scheme 1, to a solution of 4,6—dichloromethyl—
dinamine (14.04 g, 78.88 mmol) stirred in methanol—d4 (140.4 mL) was added
formic acid—d2 (7.77 g, 161.7 mmol) and Pd black (765 mg, 7.19 mmol, wetted in methanol—
d4), followed by ylamine (16.36 g, 22.53 mL, l6l.7 mmol). The reaction e was
sealed in a tube and stirred at RT overnight. The mixture was then filtered and concentrated
under reduced pressure. EtZO (250 mL) was added and the mixture d for 1 hour at RT.
The resulting solids were filtered and washed with EtZO (x2). The filtrate was concentrated
under reduced pressure to yield 4,6—dideutero—2—methyl—pyrimidin—5—amine (Compound 1001,
.65g, 65% yield) as a light yellow solid: 1H NMR (300 MHz, DMSO—d6) 5 5.25 (s, 2H), 2.40
(s, 3H). This compound was used in subsequent steps without further purification.
As shown in step l—ii of Scheme 1, to 4,6—dideutero—2—methyl—pyrimidin—5—amine
(5.35 g, 48.14 mmol) in CH3CN (192.5 mL) was added ocopper (16.13 g, 3.38 mL,
72.21 mmol) followed by t-butylnitrite (8.274 g, 9.54 mL, 72.21 mmol). After 1 hour, the
reaction was filtered through diatomaceous earth with dichloromethane. The te was
washed with water/brine (1:1), the organic layer ted, the aqueous layer extracted with
dichloromethane (2x), and the combined organic layers filtered through diatomaceous earth
and concentrated under reduced pressure. The crude product was purified by medium
pressure silica gel column chromatography (0—10% EtOAc/hexanes) to yield 5—bromo—4,6—
dideuteromethyl-pyrimidine (Compound 1002, 4.1 g, 49 % yield): 1H NMR (300 MHz,
methanol-d4) 5 2.64 (s, 3H).
As shown in step l—iii of Scheme 1, a e of 5-bromo-4,6-dideuteromethyl-
pyrimidine (8.5 g, 48.57 mmol), bis(pinacolato)diboron (13.57 g, 53.43 mmol), and KOAc
(14.30 g, 145.7 mmol) in 2-methyltetrahydrofuran (102.0 mL) was ed by flushing with
nitrogen. To this was added dichloro-bis(tricyclohexylphosphoranyl)-palladium
(PdClz[P(cy)3]2, 1.01 g, 1.364 mmol) and the reaction mixture stirred in a sealed tube
overnight at 100 0C. The mixture was filtered and the filtrate stirred with nd® DMT
silica (SiliCycle, Inc., 0.58mmol/g, 3.53 g) for 1 hour. The mixture was filtered and
concentrated under reduced pressure to yield 2—methyl—4,6—dideutero—5—(4,4,5,5—tetramethyl—
l,3,2-dioxaborolanyl)pyrimidine (Compound 1003, 13.6 g, 72% purity, the major
contaminant being pinacol) as a light yellow oil: 1H NMR (300 MHZ, CDCl3) 5 2.75 (s, 3H),
1.30 (s, 12H). This compound was used in uent steps without r purification.
Example B. Preparation of (S)(1-((6-chloropyrimidinyl)amino)propanyl)-N-
methquuinoline-4—carboxamide (Compound 1013)
0 1. M6803?, CH0
8602 \
HZN NaCIOz, NaH2PO4
HOAc 90 C I
Br CH2 dioxane, THF, H20,
2 NaOH (aq)B
H20 reflux Br 5°C to RT
(step 2-i) [1004] (step 2- ii) [1005] (step 2-iii)
1. (00002,
co H2 CH
\ DMF, DCM, 10 Co \ / 3
| | M Bo“NW —»Bpin Pd(dppf)C|2, N82C03
N N
2. MeNH2 (aq), CH2 dioxane, H20, reflux
Br THF 5°C to RT Br [1003] (step 2-v)
O(step 2-iv) [1007]
H3003)3'1 EztiH ””013 H2 cyclooctadiene, 100 psi
Rh(COD((RR)—EtDuPhos*OTf
Boc\N 2- A020 NaHCOBH
MeOH 50°C 14 hours
H20 THF
CH2 CH2 [1010] (step 2-vii)
(step 2--vi)
60°C-70°C HNZ ' HN
*2HCI
CH3 [1011] 14 hours TN:|:/Hco2g)
(ste 2-viii ) I 1012 I fiCHakl [1°13]
66°C
(step 2-ix)
Scheme 2
As shown in step 2—i of Scheme 2, 2—bromoaniline (520 g, 3.02 mol) was melted at
50°C in an oven and then added to a reaction vessel containing stirring acetic acid (3.12 L).
Methanesulfonic acid (871.6 g, 588.5 mL, 9.07 mol) was then added over 15 minutes. The
reaction mixture was heated to 60°C and methyl vinyl ketone (377 mL, 1.5 equiv.) was added
over 5 minutes and the reaction mixture stirred for 1 hour at 90°C. After this time another 50
mL (0.2 equiv.) of methyl vinyl ketone was added and the reaction mixture d for an
additional 16 hours. The resulting dark brown solution was cooled with an ter bath
and poured portion—wise into a stirring solution of 50% w/w aq. NaOH (3.894 L, 73.76 mol)
and ice (1 kg) also cooled with an ice—water bath. onal ice was added as required
during addition to maintain the reaction temperature below 25°C. After addition was
complete the reaction mixture (pH > 10) was stirred for 30 minutes whilst g in an
ice/water bath. A precipitate formed which was collected by ion, washed with water (2
L x 3), and dissolved in DCM (4 L). The organics were washed with water (2 L) and the
aqueous phase back—extracted with DCM (1 L). The combined organics were dried over
NazSO4, d h a pad of silica gel (about 2 L), eluted with DCM and then 3%
EtOAc/DCM until all of the product came through the plug. The volatiles of the filtrate were
removed at reduced pressure and the residue was triturated with hexanes (about 500 mL).
The resulting solid was collected by filtration, washed with hexanes (4 x 500 mL), and dried
under vacuum to yield 8—bromo—4—methquuinoline (Compound 1004, 363 g, 54% yield) as a
light tan solid: LC-MS = 222.17 (M+H); 1H NMR (300 MHz, CDCl3) 5 8.91 (d, J: 4.3 Hz,
1H), 8.06 (d, J= 7.4 Hz, 1H), 7.99 (d, J= 8.4 Hz, 1H), 7.42 (t, J= 7.9 Hz, 1H), 7.30 (d, J=
4.2 Hz, 1H), 2.73 (s, 3H).
As shown in step 2—ii of Scheme 2, selenium dioxide (764.7 g, 6.754 mol) was
taken up in 3.25 L of dioxane and 500 mL of water. The d solution was heated to 77°C
and 8—bromo—4-methquuinoline (compound 1004, 500 g, 2.251 mol) was added in one
portion. The reaction mixture was stirred at reflux for 30 minutes and then cooled with a
water bath to about 45°C, at which temperature a precipitate was observed. The suspension
was filtered h diatomaceous earth which was subsequently washed with the hot THF to
dissolve any residual solids. The filtrate was concentrated to a minimum volume under
d pressure and 2M NaOH (2.81 L, 5.63 mol) was added to achieve a pH of 8 to 9. The
reaction mixture was stirred at this pH for 30 minutes. A precipitate resulted which was
collected by filtration and air-dried overnight to produce 8-bromoquinoline—4—carbaldehyde
(compound 1005) as an yellowish solid: MS = 236.16 (M+H); 1H NMR (300 MHz, CDCl3) 5
.52 (s, 1H), 9.34 (d, J= 4.2 Hz, 1H), 9.05 (dd, J= 8.5, 1.2 Hz, 1H), 8.18 (dd, J= 7.5, 1.3
Hz, 1H), 7.88 (d, J= 4.2 Hz, 1H), 7.60 (dd, J= 8.5, 7.5 Hz, 1H). This material was used as is
in subsequent reactions.
As shown in step 2—iii of Scheme 2, to a stirred suspension of 8—bromoquinoline—
aldehyde (531.4 g, 2.25 mol) in THF (4.8 L) was added water (4.8 L) and monosodium
phosphate (491.1 g, 4.05 mol). The mixture was cooled to 5°C and, keeping the reaction
temperature below 15°C, sodium chlorite (534.4 g, 4.727 mol) was slowly added portionwise
as a solid over about 1 hour. After addition was complete the reaction mixture was stirred at
°C for 1 hour followed by the portionwise addition of 1N Na2S203 (1.18 L) whilst keeping
the temperature below 20°C. The reaction mixture was d at RT followed by the removal
of the THF under reduced pressure. The resulting aqueous solution containing a precipitate
was treated with sat’d NaHCO3 (about 1 L) until a pH of 3 to 4 was achieved. This mixture
was stirred an additional 15 minutes and the solid was collected by filtration, washed with
water (2 x 1 L), washed with tert—butyl methyl ether (2 x 500 mL), and dried in a convection
oven at 60°C for 48 hours. Additional drying under high vacuum provided 8—
uinoline—4—carboxylic acid (compound 1006, 530.7g, 94% yield from compound
1004) as a yellowish tan solid: LC—MS = 252.34 (M+H); 1H NMR (300 MHz, DMSO—d6) 5
14.09 (s, 1H), 9.16 (d, J= 4.4 Hz, 1H), 8.71 (dd, J= 8.6, 1.2 Hz, 1H), 8.25 (dd, J= 7.5, 1.2
Hz, 1H), 8.03 (d, J= 4.4 Hz, 1H), 7.64 (dd, J= 8.6, 7.5 Hz, 1H).
As shown in step 2—iv of Scheme 2, to a suspension of 8—bromoquinoline—4—
carboxylic acid (compound 1006, 779.4 g, 3.092 mol) in DCM (11.7 L) was added ous
DMF (7.182 mL, 92.76 mmol). The reaction mixture was cooled to 10° C and oxalyl chloride
(413 mL, 4.638 mol) was added dropwise over 30 minutes. The reaction e was stirred
an onal 30 minutes after addition was complete, transferred to an evaporation flask, and
the volatiles removed under reduced pressure. Anhydrous THF (2 L) was added and the
volatiles were once more removed under reduced pressure in order to remove any al
oxalyl de. Anhydrous THF was added to the residue under an atmosphere of nitrogen
and the resulting sion of ediate 8-bromoquinolinecarboxylic acid chloride
was stored for later use. tely, the original reaction flask was thoroughly flushed with
nitrogen gas to remove any residual oxalyl chloride and the flask charged with dry THF (1.16
L). After cooling to 5°C, aqueous methyl amine (2.14 L of 40% w/w MeNHz/water, 24.74
mol) was added followed by the addition of additional THF (1.16 L). To this solution was
added portionwise over 1 hour the intermediate acid chloride suspension, keeping the
reaction mixture temperature below 20°C during addition. The evaporation vessel used to
store the acid de was rinsed with anhydrous THF and aqueous MeNHz (500 mL) and
this added to the on mixture, which was allowed to come to room temperature over 16
hours. The organic volatiles were removed under reduced re and the remaining mostly
aqueous suspension diluted with water (1.5 L). The solids were collected by filtration,
washed with water until the filtrate had a pH of less than 11, washed with MTBE (2 x 800
mL), and dried in a convection oven at 60°C to provide o-N—methyl-quinoline
carboxamide (Compound 1007, 740.4 g, 90% yield) as a light brown solid: LC—MS = 265.04
(M+H); 1H NMR (300 MHz, DMSO-d6) 5 9.08 (d, J= 4.3 Hz, 1H), 8.78 (d, J= 4.7 Hz, 1H),
8.21 (dd, J= 7.5, 1.2 Hz, 1H), 8.16 (dd, J= 8.5, 1.3 Hz, 1H), 7.65 (d, J= 4.3 Hz, 1H), 7.58
(dd, J= 8.5, 7.5 Hz, 1H), 2.88 (d, J= 4.6 Hz, 3H).
As shown in step 2—v of Scheme 2, 8—bromo—N—methyl-quinoline—4—carboxamide
(Compound 1007, 722 g, 2.723 mol) and tert—butyl—N—[2—(4,4,5,5—tetramethyl—1,3,2—
dioxaborolan-2—yl)allyl]carbamate (Compound 1008, 925.4 g, 3.268 mol) were combined in a
reaction flask. NazCO3 (577.2 g, 5.446 mol) was added followed by the addition of water
(2.17 L). The e was stirred for 5 minutes, 1,4—dioxane (5.78 L) was added, and the
mixture was deoxygenated by bubbling in a stream of nitrogen gas for 30 s. Pd(dppf)
Clz/DCM (44.47 g, 54.46 mmol) was added and deoxygenation was continued as before for
an additional 30 minutes. The reaction mixture was stirred at reflux for 16 hours, allowed to
cool to 70°C, and water (5.42 L) was added. The mixture was cooled r with an ice—
water bath and stirring continued at <10o C for 2 hours. A precipitate resulted which was
collected by filtration, washed with water (3 x 1L), and washed with TBME (2 x IL). The
resulting precipitate cake was split into two equal portions. Each portion was dissolved in
THF/DCM (4 L) and poured onto a plug of Florisil® (3 L filtration funnel with about 1.5 L
of Florisil, using DCM to wet plug). The plug was subsequently washed with MeTHF until it
was determined by thin layer chromatography analysis that no product remained in the
filtrate. The filtrates from both cake portions were combined and concentrated under reduced
pressure to give an orange solid. TBME (1 L) was added and the ing suspension was
filtered. The collected solid was washed with 800 mL of TBME and dried under high
vacuum overnight to provide tert—butyl (2—(4—(methylcarbamoyl)quinolin—8—
yl)allyl)carbamate (Compound 1009, 653 g, 70% yield) as an off—white solid: LC—MS =
342.31 (M+H); 1H NMR (300 MHz, CDC13) 5 8.93 (d, J= 4.3 Hz, 1H), 8.17 (dd, J= 8.4, 1.6
Hz, 1H), 7.68 - 7.53 (m, 2H), 7.41 (d, J= 4.3 Hz, 1H), 6.09 (br. s, 1H), 5.54 (s, 1H), 5.28 (s,
1H), 5.10 (br. s, 1H), 4.33 (d, J= 6.0 Hz, 2H), 3.11 (d, J= 4.8 Hz, 3H), 1.38 (s, 9H).
Additional product (34.9 g, 74% total yield) was obtained by concentrating the filtrate under
reduced pressure, dissolving the residue in THF, filtering the on through a plug of
2014/061102
Florisil® as before, washing the plug with MeTHF, concentrating the filtrate under reduced
pressure, adding 250 mL of TBME, stirring for 0.5 hours, collecting the resulting precipitate
by filtration, washing the solid with EtOAc (40 mL), acetonitrile (50 mL), and drying the
solid under high vacuum overnight.
As shown in step 2—vi of Scheme 2, to a stirring suspension of tert—butyl (2-(4-
(methylcarbamoyl)quinolinyl)allyl)carbamate (Compound 1009, 425 g, 1.245 mol) in
EtOH (4.25 L) was added 5.5M HCl in iPrOH (1.132 L, 6.225 mol). The reaction mixture
was stirred at reflux (760 C internal temp) for 30 minutes and then over 90 minutes while it
was allowed to cool to 400 C. EtOAc (2.1 L) was added and the mixture was stirred for an
additional 2 hours. The solid was collected by filtration, washed with EtOAc, and dried
under high vacuum to provide 8—(3—acetamidopropen-2—yl)—N—methquuinoline—4—
carboxamide (Compound 1010, 357.9 g, 91% yield) as a tan solid: LC—MS = 242.12 (M+H);
1H NMR (300 MHz, methanol-d4) 5 9.07 (d, J: 4.6 Hz, 1H), 8.27 (dd, J: 8.5, 1.5 Hz, 1H),
7.89 (dd, J= 7.2, 1.5 Hz, 1H), 7.81 — 7.72 (m, 2H), 5.85 (s, 1H), 5.75 (s, 1H), 4.05 (s, 2H),
3.04 (s, 3H).
As shown in step 2—vii of Scheme 2, under an atmosphere of nitrogen 8—(3—
acetamidopropenyl)-N—methquuinolinecarboxamide (12.4 g, 43.77 mmol) and
cycloocta—1,5—diene/(2R,5R)—1-[2-[(2R,5R)—2,5 -diethylphospholanyl]phenyl]—2,5 -diethylphospholane
: rhodium(+1) cation - trifluoromethanesulfonate (Rh( COD)(R,R )-Et-DuPhos-
OTf, 316.3 mg, 0.4377 mmol) in ol (3 72.0 mL) were combined and warmed to 35—
40°C until the solids were solubilized. The reaction mixture was placed in a enation
apparatus, the atmosphere replaced with hydrogen, and the mixture agitated under 100 psi.
of hydrogen at 50°C for 14 hours. After cooling to RT, the mixture was filtered through a
bed of Florisil®, which was subsequently washed with MeOH (2 x 50 mL). The filtrate was
trated under d pressure and any trace water d via a DCM azeotrope
under reduced pressure. The e was triturated with 20% DCM in MTBE (2 x 100 mL)
to afford (1-acetamidopropanyl)-N—methquuinolinecarboxamide (Compound
1011, 11.0 g, 88 % yield, 96% e.e.) as an off—white solid: 1H—NMR (300 MHz, DMSO—d6) 5
8.97 (d, J = 4.3 Hz, 1H), 8.67 (d, J = 4.7 Hz, 1H), 7.97 (dd, J = 8.1, 1.5 Hz, 1H), 7.88 (t, J =
.6 Hz, 1H), 7.73—7.54 (m, 2H), 7.52 (d, J = 4.3 Hz, 1H), 4.31 (dd, J = 14.3, 7.1 Hz, 1H), 3.55
= 4.6 Hz, 3H), 1.76 (s, 3H), 1.28 (d, J = 7.0 Hz, 3H). The
— 3.32 (m, 3H), 2.86 (d, J
enantiomeric excess (e.e.) was determined by chiral HPLC (ChiralPac 1C, 0.46 cm x 25 cm],
flow rate 1.0 mL/min for 20 min at 30 OC (20:30:50 methanol/ l/ hexanes and 0.1 %
diethylamine) with a retention time for the (R)-enantiomer of 5.0 min, and for the (S)-
enantiomer of 6.7 min.
As shown in step 2-Viii of Scheme 2, (S)(1-acetamidopropanyl)-N—
methquuinolinecarboxamide (11.0 g, 38.55 mmol) in 6M aqueous HCl (192.7 mL, 1.156
mol) was warmed to 60° C. After stirring for 2 days at this ature, the reaction mixture
was cooled and an additional 20 mL of 6M HCl was added. Stirring was continued for an
additional 2 days at 70° C. The reaction mixture was cooled with an ice bath and the pH
adjusted to about 11 with 6M NaOH (aq.). The aqueous mixture was ted with 5%
MeOH/DCM and the combined organic extracts washed with water (60 mL), brine (100 mL),
dried over sodium e, filtered, and concentrated under reduced pressure to afford crude
product as a tan solid. This solid was suspended in EtOAc (200 mL), cooled to 3° C with an
ice bath, and 6M HCl/i—PrOH (30 mL) was added portionwise to e a white itate
which was collected by filtration. The solid was washed with EtOAc (100 mL) and dried
under high vacuum to provide (S)(1-aminopropanyl)-N—methquuinoline
carboxamide, dihydrochloride [Compound 1012, 7.8 g, 61% yield, 95% purity (5%
compound 1011)] as a white solid. This material was used as is in subsequent reactions.
As shown in step 2-ix of Scheme 2, 8-[(lS)—2—aminomethyl-ethyl]—N—methyl—
quinolinecarboxamide, hloride (compound 1012, 24.0 g, 72.86 mmol) was taken up
in THF (230 mL) and water (40 mL) and stirred for 5 minutes. Sodium carbonate (15.44g,
145.7 mmol) in 100 mL of water was added and the reaction mixture stirred for 10 minutes.
4,6-Dichloropyrimidine (12.18 g, 80.15 mmol) was added and the reaction mixture heated at
reflux at 66° C for 2 hours. The reaction mixture was cooled to RT, diluted with 200 mL of
EtOAc, the organic layer separated, and the aqueous layer ted with 100 mL EtOAc.
The combined organics were washed with water (60 mL), brine (100 mL), dried over
NaZSO4, filtered through a bed of silica gel (100 g), and concentrated under reduced pressure.
The resulting crude product was triturated with 20% DCM in MBTE (200 mL) then MBTE
(200 mL) to e (S)—8-(1-((6-chloropyrimidinyl)amino)propanyl)-N—
methquuinoline—4—carboxamide (Compound 1013, 23.15 g, 88% yield) as a white solid: 1H
NMR (300 MHz, DMSO—d6, 70°C) 5 8.97 (d, J = 4.3 Hz, 1H), 8.38 (s, 1H), 8.20 (s, 1H), 8.03
(d, J — 8.5 Hz, 1H), 7.71 (d, J = 6.8 Hz, 1H), 7.66—7.55 (m, 1H), 7.52 (d, J = 4.2 Hz, 2H), 6.63
(s, 1H), 4.46 (dd, J = 14.1, 7.1 Hz, 1H), 3.67 (s, 2H), 2.90 (d, J = 4.6 Hz, 3H), 1.40 (d, J = 7.0
Hz, 3H); [(411324 = 44.77 (c = 1.14, MeOH).
Example C. ation of methyl(1-((2'-methyl-[4,5'-bipyrimidin]yl-4',6'-
d2)amino)propanyl)quinolinecarboxamide (Compound 2)
H3C CH3 0
CH3 N82C03,
k | Silacat DPP Pd,
\N [1013]
CI dioxane
(step3-i)
Scheme 3
As shown in step 3—i of Scheme 3, (S)—8—(1—((6—chloropyrimidin—4-
yl)amino)propanyl)-N—methquuinolinecarboxamide (Compound 1013, 2.542 g, 7.146
mmol) , 2-methyl-4,6-dideutero(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)pyrimidine
(Compound 1003, 2.204 g, 7.146 mmol, 72% by weight) mL of 2 M (aq.),
, NazCO3 (10.72
21.44 mmol) and Silacat® DPP Pd (SiliCycle, lnc., 1.429 g, 0.3573 mmol) were taken up in
dioxane (30.00 mL), the solution flushed with nitrogen gas for 5 min, and the reaction
mixture stirred at 90°C for 16 hours. The mixture was filtered through diatomaceous earth,
concentrated under reduced re, dissolved in DMSO, and purified by reversed—phase
chromatography (IO—40% CH3CN/HZO, 0.1 % TFA). The product fractions were combined
and DCM and MeOH were added, followed by the addition of 1N NaOH until a pH of greater
than 7 was obtained. The product solution was extracted DCM (2x) and the combined
extracts dried over NaZSO4, filtered, and concentrated under reduced pressure to yield (S)—N—
methyl(1-((2'-methyl-4',6'-dideutero-[4,5'-bipyrimidin]yl)amino)propanyl)quinoline-
4-carboxamide und 2, 181 mg, 28 % yield) as an ite solid: 1H NMR (300
MHz, DMSO—dg, 70°C) 5 8.95 (d, J = 4.2 Hz, 1H), 8.47 (s, 1H), 8.35 (s, 1H), 8.01 (d, J = 8.4
Hz, 1H), 7.74 (d, J = 7.1 Hz, 1H), 7.59 (t, J = 7.8 Hz, 1H), 7.50 (d, J = 4.3 Hz, 1H), 7.30 (s,
1H), 7.03 (s, 1H), 4.51 (h, J = 7.2 Hz, 1H), 3.78 (m, 2H), 2.88 (d, J = 4.6 Hz, 3H), 2.68 (s,
3H), 1.41 (d, J = 7.0 Hz, 3H). When yl(4,4,5,5-tetramethyl-1,3,2-dioxaborolan
yl)pyrimidine was used in this reaction instead of deuterated nd 1003, Compound 1
was produced: LCMS = 414.40 (M+H); 1H NMR (300 MHz, DMSO—d6, 70°C) 5 9.14 (s,
2H), 8.95 (d, J= 4.3 Hz, 1H), 8.47 (s, 1H), 8.34 (br. s, 1H), 8.02 (d, J= 8.4 Hz, 1H), 7.74 (d,
J= 7.3 Hz, 1H), 7.59 (t, J= 7.8 Hz, 1H), 7.50 (d, J= 4.3 Hz, 1H), 7.28 (br. s, 1H), 7.04 (s,
2014/061102
1H), 4.52 (h, J: 7.0 Hz, 1H), 3.83 — 3.66 (m, 2H), 2.88 (d, J: 4.4 Hz, 3H), 2.68 (s, 3H), 1.42
(d, J: 6.9 Hz, 3H).
Example 2: Generalprocedurefor theformation 0fc0-crjystals ofa nd offormula I
and a CCF selectedfrom adipic acid, citric acid, fumaric acid), maleic acid), succinic
acid, or benzoic acid
In general, the Co-crystals of the ion can be prepared by slurry
crystallization or HME crystallization.
In one specific example, either Compound 1 or Compound 2 was weighed into
vials and mixed with a CCF at a ratio of about 1:12, respectively, and d in a suitable
solvent for 2 weeks. At the end of this time XRPD Analysis showed new crystalline patterns.
Table 1 izes the nd ratios and concentrations for the formation of co-crystals
of nd 1.
Table 1
Weight CCF Weight Compound 1
Coformer Solvent
(mg) (mg)
adipic acid 6.12 14.0 CH3CN
succinic acid 5.45 14.9 CH3CN
maleic acid 5.14 15.0 EtOAc
furmaric acid 5. 3 3 15.0 CH3CN
citric acid
benzoic acid
Example 3 : Preparation ofCompounds 1 & 2/adipic acid ystal
A 1 liter jacketed vessel (with overhead stirring) was charged with Compound 1
(36.04 g, 0.087 mol, 1.000 equiv.), adipic acid (16.65 g, 0.114 mol, 2.614 ), 1—propanol
(321.00 g, 5.342 mol, 122.564 equiv.) and the slurry stirred at 750 rpm. A seed of the co—
crystal (0.5% co—crystal seed) was added and the reaction mixture stirred at 25°C. Co—crystal
formation was monitored by removing aliquots and analyzing by Raman spectroscopy. After
114 hours it was determined that co-crystal formation was complete. The slurry was filtered
using a 600 mL Medium porosity fritted funnel until the solvent level was even with the wet
cake. The mother liquor was isolated, labeled and analyzed for content. The wet cake was
then washed with 1—propanol (270.0 mL, 7.49 vol.). The wet cake solids were weighed and
dried in a vacuum oven at 50°C. The final yield of Compound 1/adipic acid co—crystal was
21.7 g. A similar ure also produced a co—crystal of Compound 1 and adipic acid.
HPLC analyses indicated a stoichiometry of about 2:1 for Compound 1 or Compound 2 to
adipic acid.
Alternatively, the adipic acid co—crystals of Compound (1) was also prepared by
HME crystallization. The HME llization proof-of —concept was made at the 20g scale
on a 16mm extruder. Compound (1) freeform and neat adipic acid were extruded with high
shear mixing and elevated temperatures (e. g., 144°C or 155°) to generate cocrystal.
Certain physical properties of free base Compound (2) and its adipic co-crystal are
ized in Table 2 below.
Table 2: Material Properties of the Free Base and Adipic Acid Co—crystal of Compound
Material Free Form Adipic acid Adipic acid Adipic acid
Assessment cocrystal cocrystal (80% cocrystal (75%
Solvent Comp. 2:20% Comp. 2:25%
crystallization AA) (w/W) AA) (W/W)
s (80% Hot melt Hot melt
Comp. 2:20% ion extrusion
AA) (w/W) process s
Bulk Density 0.33 g/cc 0.14 g/cc 0.43 g/cc 0.62 g/cc
Tapped Density 0.47 g/cc 0.25 g/cc 0.60 g/cc 0.70 g/cc
Example 4: X-Ray powder diffraction characterization
The XRPD spectra for co—crystals of the invention (see s 1—7) were recorded
at room temperature in reflection mode using a Bruker D8 Advance diffractometer equipped
with a sealed tube Cu source and a Vantec PSD detector (Bruker AXS, n, WI). The
X-ray generator was operating at a voltage of 40 kV and a current of 40 mA. The powder
sample was placed in a silicon or PMM holder. The data were recorded over the range of 4°—
450 2 theta with a step size of 0.01400 and a dwell time of 1s per step. Fixed divergence slits
of 0.2 mm were used.
The XRPD pattern for co-crystals Form A and Form B of the invention (see
Figures 14 and 15) were recorded at room temperature in transmission mode using a
PANanalytical Empyrean diffractometer equipped with a sealed tube Cu source and a
PIXCel 1D detector. The X-ray generator was operating at a voltage of 45 kV and a current
of 40 mA. The powder sample was placed in a transmission holder and held in place with
Mylar thin films. The data were recorded over the range of 40-400 2-theta with a step size of
0.0070 and a dwell time of 1549 s per step. The diffractometer was setup with 0.020 Solar
slits, fixed 1/20 anti-scatter slits on the incident beam and U40 anti-scatter slits on the
diffracted side. Two scans were accumulated.
Figure 1 shows an X-ray powder diffraction (XRPD) n of the co-crystal
formed between Compound 1 with adipic acid. The XRPD pattern shows that the stal
is in a mixture of Forms A and B. Some specific XRPD peaks of the spectrum are
summaried below.
Table 3.
Pos. [°2Th.] Rel. Int. [%]
6.540282 61.33
7.858682 60.04
11.92977 52.67
12.2278 23.87
13.03317 29.49
14.22935 100
18.75679 59.81
8 19.0885 36.36
Figure 2 shows an X-ray powder ction n of the co-crystal formed
between Compound 2 with adipic acid. Some specific XRPD peaks of the pattern are
summaried below.
Pos. Rel.
[°2Th.] Int. [%]
6.459033 55.29
7.911365 51.42
11.91567 45.41
12.25639 24.61
12.98715 34.47
14.19256 100
92 38.85
19.06727 28.68
WO 58067
Figure 3 shows an X-ray powder diffraction pattern of the co-crystal formed
between Compound 1 with citric acid. Some specific XRPD peaks of the n are
summaried below.
Table 5.
No. Pos. [°2Th.] Rel. Int. [%]
7.435926 50.1
54 21.73
\ICD 21.55281 20.72
23.57031 30.18
Figure 4 shows an X-ray powder diffraction pattern of the co-crystal formed
between Compound 1 and fumaric acid. Some specific XRPD peaks of the pattern are
summaried below.
Table 6.
Pos.
No. [°2Th.] Rel. Int. [%]
8.264997
.1077
14.97012
16.60917 41.79
17.21781 100
.1975 67.75
26.01104 24.39
Figure 5 shows an X-ray powder diffraction pattern of the co-crystal formed
n Compound 1 and maleic acid. Some specific XRPD peaks of the pattern are
ied below.
Table 7.
Pos. [°2Th.]
6.205335
.43158
11.28478 40.95
12.41363 34.13
13.26101 19
18.86924 43.52
21.08017 31.35
Figure 6 shows an X-ray powder diffraction pattern of the co-crystal formed
n Compound 1 and succinic acid. Some specific XRPD peaks of the pattern are
summaried below.
Table 8.
Pos. Rel.
No. [°2Th.] Int. [%]
1 8.01725 26.29
2 12.33839 42.72
3 14.77709 37.21
4 17.31539 12.09
19.56132 13.66
6 20.05503 100
Figure 7 shows an X-ray powder diffraction pattern of the co-crystal formed
between Compound 1 and benzoic acid. Some specific XRPD peaks of the pattern are
ied below.
Table 9.
No. Pos. [°2Th.] Rel. Int. [%]
8.699594 88.63
13.90495 68.65
.6186 80.96
1 100
18.15049 41.75
.76838 39
24.72293 67.36
Example 5 .‘ Thermogravimetric Analysis
ThermograVimetric es (TGA) were conducted on a TA Instruments model
Q5000 thermograVimetric analyzer. Approximately l-4 mg of solid sample was placed in a
platinum sample pan and heated in a 90 mL/min nitrogen stream at 10°C/min to 300 0C. All
grams were analyzed using TA Instruments Universal Analysis 2000 re V4.4A.
The thermo graVimetric analysis curves for the co—crystals of Compound (1) and
adipic acid and for the co-crystals of nd (2) and adipic acid are shown in Figures 8
and 9, respectively. The figures show loss of adipic acid starting at about 150°C in both co—
crystals.
Example 6.‘ Differential Scanning Calorimetry
Differential Scanning metry (DSC) was ted on a TA Instruments
model Q2000 calorimetric analyzer. About l-4 mg of solid sample was placed in a crimped
aluminum pinhole pan and heated in a 50 mL/min nitrogen stream at 10°C/min to 300 0C. All
data were analyzed using TA Instruments Universal Analysis 2000 software V4.4A.
Representative differential scanning calorimetry thermograms are shown in
Figure 10 and Figure 11 for the co-crystals of Compound (1) and adipic acid and for the co—
crystals of Compound (2) and adipic acid, respectively.
Example 7.‘ Solid state nuclear magnetic resonance spectroscopy
] Solid state NMR spectra (ss—NMR) were acquired on the —Biospin 400
MHz e III wide-bore spectrometer equipped with Bruker-Biospin 4mm HFX probe.
Approximately 70 mg of each sample was packed into full volume -Biospin 4mm
Zr02 rotors. A magic angle spinning (MAS) speed of typically 12.5 kHz was applied. The
temperature of the probe head was set to 275°K to minimize the effect of frictional heating
during spinning. A relaxation delay of 30 s seconds was used for all experiments. The CP
contact time of 13C CPMAS experiment was set to 2 ms. A CP proton pulse with linear ramp
(from 50% to 100%) was employed. The Hartmann-Hahn match was optimized on external
reference sample ne). SPINAL 64 ling was used with the field strength of
approximately 100 kHz. The chemical shift was referenced against external standard of
adamantane with its upf1eld resonance set to 29.5 ppm.
ing washing with solvent, ss—NMR was used to investigate the co—crystal
complexes of nd 1 or Compound 2 with adipic acid. See Figures 12 and 13,
respectively. The absence of peaks characteristic of free Compound 1, Compound 2, or
adipic acid indicated pure cocrystal.
Example 8: ation ofPolymorphic Forms A and B ic Acid Co-crystals of
Compounds (1) and (2)
A. Preparation of Polymorphic Form A of Adipic Acid Co—crystal of Compound (1)
Polymorphic Form A of adipic acid co—crystal of Compound (1) can be obtained
by hot-melt crystallization of Compound (1) and adipic acid. A specific example of the
preparation of Form A by hot melt extrusion is described below.
Adipic acid was jet milled using a Fluid Energy Model 00 Jet—O—Mizer using
following settings:
Parameter Pressure
Air Supply 100
Grinding nozzle 60
Pusher nozzle 80
Compound (1) was screened h a #18 mesh screen. Compound (1) and jet milled adipic
acid were weighed to prepare binary blends at about 80, 75 and 65 % weight:weight
nd (1). The initial blends were prepared by passed h a #30 screen and
subsequent mixing in a turbular mixer for 5 s.
The blends were extruded using a Leistritz Nano l6 twin screw extruder with
three temperature zones and equipped with a plunger feeder. The screw design contained
conveying, pumping and 30° and 60° kneading elements. All experiments were performed
without a die installed on the extruder. Temperature, screw speed and temperature were set as
listed in the Table below. The temperature was set and controlled to the same value for all
three heating ts. During the extrusion the torque was monitored and the screw speed
was increased when the screw was at risk of seizing.
Parameter Setting
Feed Rate 1.5
[ml/min] 3.75
Screw speed 20 to 150
_[£m]—
Temperature [°C] 110
] The transmission XRPD pattern and 13CNMR spectrum of Form A of adipic acid
co—crystal of Compound (1) are shown in Figures 14 and 16, respectively. Certain peaks
observed in the 13C NMR spectrum are summarized below.
Table 10.
Shift $0.1 Intensity
Peak
[ppm] [% of max]
117.1 475
96-8 28.2
95-7 26.2
27-6 48.1
14.8 32.7
161.6 355
154.5 33_4
51-5 24.7
50.2 24.3
-6 99.2
18-5 33.7
179.4 54_4
168.4 55_9
158.3 83.5
147.8 455
145.7 279
143.2 44_1
141.8 432
124.6 100.0
31-2 31.7
.1 352
B. Preparation of rphic Form A of Adipic Acid Co—crystal of Compound (2)
Form A of adipic acid co—crystal of Compound (2) was prepared by acetone
slurry. 322 mg of a mixture of Form A and Form B compound 2:adipic acid co—crystal
prepared as described in Example 3 and 221 mg of adipic acid were stirred in 9.8 g of acetone
at 20 to 30 0C for 30 days. Approximately 50 mg of solid was isolated by filter centrifugation
through a 0.45 pm membrane filter using a centrifugal filter deVice and dried in vacuum at 20
to 30 0C for approximately 2 hours. Solid state NMR spectra were ted as described in
Example 7 with the exception that the sample amount was imately 50mg and the
relaxation delay was set to 5s. The 13CNMR spectrum of Form A of adipic acid co—crystal
of Compound (2) (see Figure 17) is ially the same as that of Form A of adipic acid co-
crystal of Compound (1). Certain peaks observed in the 13CNMR spectrum are summarized
below.
Table 11.
Shift $0.1 Intensity
Peak
[ppm] [% of max]
116.9 48.3
96.6 27.4
95.6 23.9
27.5 45.6
14.7 36.7
161.4 32.9
153.9 15.9
8 51.3 22.5
49.9 22.2
.4 100.0
18.3 35.8
179.2 55.6
168.2 49.5
158.2 48.2
147.6 46.0
145.5 27.1
143.1 45.7
141.6 44.6
124.4 91.9
31.0 30.9
29.9 33.4
C. ation of Polymorphic Form B of Adipic Acid Co—crystal of Compound (2)
Polymorphic Form B of adipic acid co—crystal of Compound (2) can be obtained
by employing spray drying. A specific example is bed below.
A solvent e for spray drying was prepared by weighing out 50g of methanol
and ll7.5g dichloromehane into a glass bottle and shaking. 500mg of Compound (2),
176.2mg of adipic acid and 19.3g of the methanol dichloromethane mixture were weighed
into a clear glass vial and stirred until all solids were dissolved. This solution was spray dried
using a Buchi mini spray drier B-290 using following setting:
Parameter Setting
Inlet Temp 99 °C
Aspirator 100%
Pump 40%
Condenser -5°C
Nozzle 1mm
Atomizer 35mm
Filter Pressure -60mbar
The isolated material completely recrystallized at room temperature to Compound (2):adipic
acid stal Form B over 2 months.
] The XRPD pattern and 13CNMR spectrum of Form B of adipic acid co—crystal of
Compound (2) are shown in s 15 and 18, respectively. Certain peaks observed in the
CNMR spectrum are summarized below.
Table 12.
Shift $0.1 Intensity
[ppm] [% of max]
Example 9: Binary Phase Diagram of Compound (2)/adipic acid co-crjystal
] Figure 18 is a depiction of an approximate phase diagram consistent with the
measured thermal data TAA: Melting temperature of adipic acid, Toox melting temperature of
the Compound (2): adipic acid co-crystal, Tp: peritectic temperature, TCMPDZ: Melting
temperature of Compound (2), TE1:Eutectic melt ature, P peritectic point, El eutectic
point, SAA: Solid adipic acid, L liquid, Seox:Solid Compound (2):Adipic Acid co—crystal,
SCMpD2:Solid Compound (2), Tm_E: metastable Eutectic melt temperature, m—E: metastable
Eutectic point.
The binary phase diagram was explored using ential scanning calorimetry on
mixtures of nd (2) and adipic acid and mixtures of Compound (2):Adipic acid and
stal. The stoichiometric composition of the co—crystal in % w:w Compound (2) was
calculated from the molar stoichiometry. A representative differential scanning calorimetry
thermogram is shown Figure 11. The thermogram of Compound (2):adipic acid stal
shows a melting endotherm at 196 OC :2 OC followed by a tallization exotherm which
is followed by a broad ution endotherm. Melting of Compound (2) is observed at 256
OC::2 OC when the adipic acid is allowed to fully decompose and evaporate. The observed
differential scanning calorimetry thermogram depends on the composition i.e., the solid
phases that are present in the material and is explained by the binary phase diagram.
Furthermore, it depends on other experimental details. A eutectic melt endotherm was
observed when excess adipic acid was present in addition to the co—crystal at 138 OC::2 °C.
The binary phase diagram of Compound (2) and adipic acid is consistent with the observed
differential scanning metry curves on compound 1: adipic acid co—crystal and
nd ic acid, adipic acid mixtures; an example is given in Figure 10.
Certain measured points of the phase diagram of Figure 19 are summarized below:
Table 13.
Composition
Point Tempereature [% w:w]
[ C] :2
compound 2
——.—
Example 9. Biopharmaceatical Analysis
The pH lity curve for Compound (2), Compound (2): adipic acid stal,
and Compound (2): adipic acid co—crystal in the presence of excess adipic acid were
calculated from the pKa values of Compound (2) and adipic acid, Compound (2):adipic acid
co-crystal KSp value, the binding constant of Compound (2) and adipic acid in aqueous buffer
and the Compound (1) self ation nt in s buffer and the solubility of
Compound (2) free form. The solubility of the adipic acid cocrystal of Compound (2) was
dependent on pH and the concentration of excess adipic acid. In general, as the tration
of adipic acid increased the apparent solubility of the cocrystal decreased. At low pH the
solubility of the cocrystal was less than the freebase Compound (2), but within the pH range
of the fasted human small intestine the cocrystal was much more soluble than the free form
(or free base) Compound (2), as shown in Figure 20. Simulations of oral dosing showed the
adipic acid cocrystal drived nearly complete absorption at doses up to 1.5 g, and at doses
exceeding 800 mg the negative impact of adipic acid on cocrystal lity decreased
exposure slightly (data not shown).
Example 10. Dissolution Analysis
In—vitro two stage dissolution experiments using simulated intestinal and gastric
fluids were used to evaluate and predict Compounds (1) and (2) and their co—crystals with
adipic acid in—vivo performance. Most commonly drug absorption can occur in the upper
intestine and high solubility generally indicates high in-vivo bioavailability after simulated
intestinal fluid is added in two stage dissolution ments for drugs with solubility limited
bioavailability. Figure 21 shows two stage ution profiles for: i) nd 1:adipic
acid stal prepared by hot melt ion and slurry crystallization; ii) HME 65:35:
Compound 1: adipic acid co—crystal manufactured using hot melt extrusion with 65 % w:w
Compound 1 and 35 % w:w adipic acid; iii) HME 75:25: Compound 1: adipic acid co—crystal
manufactured using hot melt extrusion with 75 % w:w Compound 1 and 25 % w:w adipic
acid; iv) HME 80:20: Compound 1: adipic acid co—crystal manufactured using hot melt
extrusion with 80 % w:w Compound 1 and 20 % w:w adipic acid; V) SC 80:20: slurry
llized Compound 2 :adipic acid co—crystal with final Compound 2 content of 79 % w:w
Compound 2 and 21 % w:w adipic acid; and vi) Free Form: Compound 2 free form. As
shown in Figure 21, the two stage dissolution data on Compound 1:adipic acid co—crystal and
Compound 2:adipic acid co—crystal showed higher nd 1 and Compound 2
concentrations than Compound 1 or nd 2 free form, respectively. Also, the
concentration of Compound 1 for Compound 1: adipic acid co—crystal prepared by hot melt
extrusion from Compound 1 and adipic acid at 65 % w:w and 35 % w:w performed better
than slurry crystallized Comopound 2: adipic acid co—crystal or Compound 1: adipic acid co—
crystal prepared by hot melt extrusion from Compound 1 and adipic acid at 75 % w:w and 25
% w:w and Compound 1: adipic acid co—crystal prepared by hot melt ion from
Compound c and adipic acid at 80 % w:w and 20 % w:w, respectively. Without being bound
to a particular theory, this is potentially due to the microstructure that was ed for the
eutectic solid.
] Two stage dissolution experiments were performed at least in duplicate. Fasted
state simulated gastric fluid (FaSSGF) was equilibrated for 30 minutes under stirring to 37°C
in a 100ml clear class vial using a water bath consisting of a ature lled jacketed
vessel. The compound 1:adipic acid co—crystal and compound 2:adipic acid co—crystal was
added and the suspension was stirred at about 130 rpm and 37 0C, respectively. Aliquots
(0.5ml) were taken at 5, 15, 30, and 60 minutes. Solids were separated by filter centrifugation
using centrifuge fllter units with a 0.45 pm membrane and spinning at 5000 rpm for 5
minutes on an Eppendorff Model 5418 centrifuge. The pH of the dissolution samples was
measured after ng at 15 and 60 minute time points. The supernatants of the filtered
samples were 10 fold diluted of with diluent for HPLC Analysis. At the 65 minute timepoint
fasted state simulated intestinal fluid FaSSIF equilibrated at 37 0C was added to the
suspension and the sion was continued to stir at 130 rpm. Aliquots (0.5 ml) were taken
at 75, 90, 120 and 180 minute timepoints. Solids were separated by filter centrifugation using
centrifuge filter units with a 0.45 pm membrane and spinning at 5000 rpm for 5 minutes on
an Eppendorff Model 5418 centrifuge. The pH of the dissolution samples was measured after
ng at 75, 90 and 180 minute time points. The supernatants of the filtered samples were
fold d of with diluent for HPLC Analysis. The amounts of material and simulated
fluids used are summarized below:
Material Weight [mg] Volume FaSSGF Volume FaSSIF
HME 65:35 43.5, 44.5 10 16
HME 75:25 40.8, 40.3 10 16
HME 80:20 38.3, 38.1 10 16
SC 80:20 31.7, 32.0, 31.6 8 12
Free Form 24.7, 25.1, 26.6 8 12
The concentrations of Compounds 1 and 2 were measured using following HPLC method,
tively:
Column "Xterra Phenyl 4.6 x 50 mm, 5.0um"
Column Temperature 30 0C
Flow Rate 1.5 ml/min
Injector Volume 10ul
Auto-sampler Temperature 25C
Total Run Time 3.0 mins
Detector Wavelength 240 nm
Needle Wash Solution Methanol
ng Rate 1 per sample
Data Acquisition Time 3
Mobile Phase A 0.1% TFA in Water
Mobile Phase B 0.1% TFA in Acetonitrile
Gradient 85 % Mobile Phase A 15 % Mobile
Phase B
Typical simulated fluid preparations were used for 2 stage dissolution
experiments: FaSSIF was prepared by adding about 1.80g of Sodium Hydroxide Pellets,
2.45 g of Maleic Anhydride, 6.3 7g of Sodium Chloride, 1.61g of Sodium Taurocholate and
618.8mg of in to 800ml water. The solution was stirred until all materials were
completely dissolved. Then the pH was adjusted to 6.5 using 1.0N HCl and 50% NaOH
Solution while the solution was being d. Water was added to a final volume of 1 l.
FaSSGF was prepared by adding 50.0mL of 1.0N HCl, about 1.0g of “800—2500 U/mg”
pepsin, 43mg of Sodium holate, 2.0g of Sodium Chloride (NaCl) to 800 ml water.
Water was added to a final volume of 1 l. The final pH was typically 1-2.
Example 12. Bioavailabilily ofthe stals ofthe Invention
The oral bioavailability of Compound 2:adipic acid co—crystal and Compound 2
free form in humans was predicted based on the calculated pH solubility curves in Figure 20
using GastroPlus, version 8.5.0002 Simulations Plus, Inc. A jejunum permeability of 1.67e-4
cm/s and particle radius of 10 microns was used. All other parameters were the default
settings of the software. The simulations predict 100 % fraction absorbed for oral doses up to
1500 mg Compound 2: adipic acid co—crystal and Compound 2; adipic acid stal with
additional adipic acid present whereas the predicted Compound 2 oral fraction absorbed
steeply decreases with increasing doses. As shown in Figure 22, the simulations te that
the compound 2:adipic acid co—crystal has superior oral bioavailability when compared to
Compound 2 free form to give sufficient re for human safety studies for doses up to
but not limited to 1500 mg and can result in larger safety margins for Compound 2.
Furthermore, high oral bioavailability will reduce the oral dose that is needed to reach
efficacious blood levels. Similar results are expected for Compound 1 based on the similarity
in the observed physical properties of Compound 1 and Compound 2.
Example 13. Biological cy ofCompound 2/adipic acid co-crystal
Example A. DNA-PK kinase inhibition assay
The adipic acid co—crystal of Compound 2 was screened for its ability to inhibit
DNA-PK kinase using a rd etric assay. Briefly, in this kinase assay the transfer
of the al 33P-phosphate in 33P-ATP to a peptide substrate is ogated. The assay
was carried out in 384-well plates to a final volume of 50 uL per well containing
approximately 6 nM DNA-PK, 50 mM HEPES (pH 7.5), 10 mM MgC12, 25 mM NaCl,
0.01% BSA, 1 mM DTT, 10 ug/mL sheared double-stranded DNA (obtained from Sigma),
0.8 mg/mL DNA-PK e (Glu-Pro-Pro-Leu-Ser-Gln-Glu-Ala—Phe-Ala-Asp-Leu-Trp-Lys-
Lys— Lys, obtained from American Peptide), and 100 ”M ATP. Accordingly, compounds of
the invention were dissolved in DMSO to make 10 mM initial stock solutions. Serial
ons in DMSO were then made to obtain the final ons for the assay. A 0.75 uL
aliquot of DMSO or inhibitor in DMSO was added to each well, followed by the addition of
ATP substrate solution containing 33P-ATP (obtained from Perkin Elmer). The reaction was
started by the addition of DNA-PK, peptide and ds-DNA. After 45 min, the reaction was
ed with 25 uL of 5% phosphoric acid. The reaction mixture was transferred to
MultiScreen HTS 384-well PH plates (obtained from Millipore), allowed to bind for one
hour, and washed three times with 1% phosphoric acid. Following the addition of 50 uL of
Ultima GoldTM high efficiency scintillant (obtained from Perkin Elmer), the samples were
counted in a Packard TopCount NXT Microplate Scintillation and Luminescence Counter
(Packard ence). The K values were calculated using Microsoft Excel Solver macros
to fit the data to the kinetic model for competitive binding inhibition. The adipic acid
stal of Compound (2) had a Ki of about 2 nM.
Example B: Efficacy of nds (1) and (2) in Combination with Whole Body IR
The in vivo efficacies of Compounds (1) and (2) in combination with whole body
IR were examined in the OD26749 primary NSCLC (non-small cell lung cancer) and the OE-
19 GEJ cell line xenograft models. The results are summarized in Tables 14 and 15. In these
studies, Compounds (1) and (2) were formulated with 16% captisol/1%PVP/1%HPMC E5
pH2.
B. 1. Efficacy of Compound (1) in Combination with IR in the OD26749 NSCLC Xenograft
Model
] The in vivo efficacy of Compound (1) was evaluated in the primary OD26749
NSCLC subcutaneous xenograft model. Compound (1) administered at 100 mg/kg tid on a
single day significantly enhanced the radiation effect of a single 2 Gy dose of whole body IR
in this model (%T/C 26 for the combination ed to %T/C of 80 for radiation alone,
P<0.001). Efficacy was ted using a regimen in which 2—Gy whole body IR was
administered twice, one week apart. Compound (1) was administered PO (tid at 0, 3, and 7
h) at 100 mg/kg alone or with a single 2 Gy dose of whole body IR at 3.25 h. Seven days
later, the same regimens were repeated. Compound (1) in combination with 2 Gy whole
body IR induced icant tumor regression (%T/Ti of -75; P<0.01) compared to IR alone.
nd (1) alone and IR alone did not induce cant (P>0.05) tumor
growth inhibition compared to vehicle controls (%T/C of 74 and 64, respectively). In this
primary tumor model, both groups exhibited some degree of body weight loss (6.7% and
8.7% maximal loss on Day 2 or Day 9 for the IR alone and combination group, respectively)
that recovered over the course of the study. The addition of a second administration of 2 Gy
IR in combination with Compound (1) resulted in a significant increase in time to tumor
doubling (TTD) with a 33.4 day TTD in the combination group compared to only 2 to 3 days
for the vehicle, IR and Compound (1) single agent groups.
B.2. Bridging Study: Compounds (1) and (2) in Combination with Two Cycles of Whole
Body IR in a Primary NSCLC Xenograft Model 49) in Nude Mice
The ies of Compounds (1) and (2) in combination with whole body IR (2
Gy) were evaluated in the OD26749 primary NSCLC aft model at a Compound (1)
dose level of 100 mg/kg PO bid (0 and 4 h) and Compound (2) dose levels of 50 mg/kg and
100 mg/kg PO bid (0 and 4 h). Two cycles of whole body IR (2 Gy) were given 15 min after
the first compound administration (0.25 hour). Control animals were administered vehicle PO
bid (0 and 4 h). Two cycles of treatment were performed on Day 0 and Day 7.
Two cycles of whole body radiation (2 Gy) alone did not inhibit tumor growth
compared to vehicle treated tumors (%T/C=106). r, efficacy was significantly
enhanced when Compounds (1) and (2) were combined with IR, as e tumor volumes in
all combination groups were significantly r than those in the IR only group (P<0.001).
In on, the Compounds (1) and (2) (100 mg/kg bid) combination groups demonstrated
very similar anti—tumor activity (%T/C= 4.80 and 7.80 respectively), blood exposure (AUC
65.8 and 58.2 ug*h/mL), and tolerability (maximum body weight change -2.40% and
2.70%). In addition, the average tumor volume in the 50-mg/kg combination group was
statistically different than those in the Compounds (1) and (2) 100 mg/kg combination groups
01).
B.3. Efficacy of Compounds (1) and (2) in Combination with IR in the OE-l9 Gasttro-
esophageal junction (GEJ) Cancer Xenograft Model
The OE—l9 cell line xenograft model was used to evaluate the efficacy of
Compounds (1) and (2) alone and in combination with IR. Two cycles of treatment were
administered (Day 0 and Day 7) as performed in the OD26749 model above. Two cycles of
2014/061102
whole body IR (2 Gy) alone exhibited minimal effect on tumor growth compared to vehicle
control (%T/C = 60.0) indicating that this tumor model is relatively resistant to IR. In
contrast, the combination of Compound (2) and 2 Gy whole body IR resulted in significant
tumor growth inhibition compared to the vehicle control with a %T/C of 8.00 (P<0.001). The
ation group also showed significant tumor growth inhibition compared to the IR only
group (P<0.001). nd (1) in combination with 2 Gy whole body IR also significantly
inhibited tumor growth in this model.
B.4. cy of Compounds (1) and (2) in a Primary NSCLC Xenograft Model
] The in vivo eff1cacies of Compounds (1) and (2) were evaluated alone and in
combination with three consecutive days of focused IR in the primary LU—01—0030 NSCLC
subcutaneous xenograft model. The dose—dependent umor activity of Compound (2)
alone and in combination with focused beam IR was evaluated in the LU—01—0030 model. In
this model, IR treatment alone resulted in significant tumor regression; however tumor re—
growth was observed approximately 20 days after the last day of treatment. On Day 34,
Compound (2) combination groups demonstrated statistically significant 01) anti-
tumor activity when compared to the e and IR only groups, with %T/Ti values of —96.3,
—67. 1, —96.9, and 1.6% for the 50 and 25 mg/kg bid and 50 and 25 mg/kg qd groups,
respectively. Mice in the combination treatment groups were monitored (without treatment)
for up to 90 days as some mice had no evidence of tumor burden. In all experimental
groups, ents were generally well tolerated as evidenced by maximum body weight
losses ranging from —1.11% to —6.93% 1 to 9 days after treatment initiation
B.5. Efficacy of Compounds (1) and (2) in Combination with IR in a Primary GEJ Cancer
Xenograft Model
The in vivo activities of Compounds (1) and (2) were compared in combination
with focused beam IR in a y gastric cancer subcutaneous xenograft model. In the ST
02 0004 model, focused IR was administered on three utive days alone and in
combination with Compound (1) or Compound (2). IR treatment alone ed in a slight
delay in tumor growth of approximately 7 days after the last day of treatment. Compounds (1)
and (2) combination groups demonstrated statistically signif1cant(P<0.001) anti tumor
activity when compared to the vehicle and IR only groups with a %T/Ti value of -2.8% for
the 100 mg/kg Compound (1) combination group and %T/C values of 9.2 and 17.4 for the
100 and 25 mg/kg Compound (2) combination groups, respectively. For all experimental
, treatment was generally well tolerated as evidenced by maximum body weight losses
ranging from -8.06% to -10.0% 10 to 48 days after treatment initiation
The anti-tumor activity of Compound (2) in combination with focused-beam IR
and the standard of care agents, axel and carboplatin, was also evaluated in the ST 02
0004 model. Treatment with paclitaxel, carboplatin, and IR was administered once per week
for three weeks alone or in combination with Compound (2). axel/carboplatin treatment
did not impact tumor growth nor did the combination of paclitaxel/carboplatin and 50 mg/kg
Compound (2). However, on Day 45, 25 and 50 mg/kg Compound (2) in combination with
paclitaxel/carboplatin and IR demonstrated a statistically significant difference (P<0.001) in
anti-tumor activity when compared to the vehicle group with %T/C values of 2.5 and 11.1 for
the 50 and 25 mg/kg Compound (2), axel/carboplatin, IR combination groups,
respectively. Further, the 50 and 25 mg/kg Compound (2), paclitaxel/carboplatin, IR
combination groups were statistically ent (P<0.05) from the paclitaxel/carboplatin,
paclitaxel/carboplatin/50 mg/kg Compound (2), and paclitaxel/carboplatin/IR groups.
Compound (2) blood exposures were 9.3 and 27 ug*h/mL for the 25 and 50 mg/kg
Compound (2) bid groups, respectively.
In Tables 14 and 15, for example, PO bid (0, 4h) indicates Compound (2) is
administered twice (bid) at time point 0 and then 4 hours after; IR (0.25h) qu3 indicates
radiation is administered 15 s (0.25h) after the administration of Compound (2) (Oh),
and once a day for 3 days (qu3); q7dx2 indicates once a week for two weeks; qod indicates
every other day twice (e. g., Day 1 and Day 3); and paclitaxel q7d x3 (—0.25h), carboplatin
q7dx3 (-0.25h) indicates administration of paclitaxel and carboplatin 15 minutes prior to the
administration of Compound (2), ed by additional stration of Compound (2)
after 4 hours after the first administration of Compound (2). In one specific example,
g paclitaxel q7dx3 (-0.25h), 25 mg/kg carboplatin q7dx3 (-0.25h), 2 Gy IR qu3
(0.25h), P0 50 mg/kg bid (0, 4h) qu3” indicates that 5mg/kg of paclitaxel and 25 mg/kg of
carboplatin are administered 15 minutes prior to the first administration of Compound (2); the
first stration of nd (2) is given; radiation is administered 15 minutes after the
first administration of Compound (2); and then the second administration of nd (2) is
provided 4 hours after the first administration of Compound (2).
Table 14: Summary of In Vivo Efficacy s with Compound (1)
Tumor Study Groups
Model,
Damaging
Agent
OD26749 %T c Da 20 %T Ti Da 20 Max. bod wt loss %
(Primary 2 Gy Radiation qul 80 - -6.90 (Day 2)
NSCLC) PO 100 mg/kg tid (0, 3, 7 h) qu1 101 - -2.40 (Day 2)
Whole PO 100 mg/kg tid (0, 3, 7 h) qu1, 2 Gy 26.0 - -9.70 (Day 2)
Body IR 25h)
OD26749 %T c Da 16 %T Ti Da 16 Max. bod wt loss %
(Primary 2 Gy Radiation q7dx2 64 -6.7 (Day 2)
NSCLC) PO 100 mg/kg tid (0, 3, 7 h) q7dx2 74 weight gain
Whole PO 100 mg/kg tid (0, 3, 7 h) q7dx2, 2
Body IR Gy q7dx2 (3.25 h) -8.7 (Day 9)
OD26749 %T c Da 22 %T Ti Da 22 Max. bod wt loss %
(Primary 2 Gy Radiation qu3 106 - -0.90 (Day 1)
NSCLC PO 100 mg/kg bid (0, 4 h), 2 Gy (0.25 4.8 - -2.40 (Day 1)
bridging h) qu3
study)*
Whole
BodyIR
OD26749 %T c Da 29 %T Ti Da 29 Max. bod wt loss %
(Primary 2 Gy Radiation q7dx2 42 - -3.50 (Day 1)
NSCLC) PO 200 mg/kg qd, 2 Gy IR (0.25 h) 6.5 - -6.10 (Day 1)
Whole q7dx2
Body IR po 100 mg/kg bid (0, 4 h), 2 Gy IR - —3.1 -3.70 (Day 8)
(0.25 h) q7dx2
P0 50 mg/kg bid (0, 4 h), 2 Gy IR (0.25 11_7 _ -550 (Day 8)
h) q7dx2
P0 25 mg/kg bid (0, 4 h), 2 Gy IR (0.25 25.6 _ _7_70 (Day 8)
h) q7dx2
LU %T c Da 30 %T Ti Da 30 Max. bod wt loss %
0030 2 Gy Radiation qu3 14.8 - -4.0 (Day 4)
(Primary PO 100 mg/kg tid (0, 3, 7 h) qu5 79.1 - -0.63 (Day 6)
NSCLC) PO 100 mg/kg tid (0, 3, 7 h) qu3, 2 Gy - -90.6 -1.58 (Day 4)
d IR (0.25 h) qu3
IR PO 100 mg/kg tid (0, 3, 7 h) qu5, 2 Gy - -91.6 -1.68 (Day 4)
IR (0.25 h) qu3
PO 100 mg/kg bid (0, 4 h) qu3, 2 Gy _ -85.6 .142 (Day 4)
IR (0.25 h) qu3
LU %T c Da 27 %T Ti Da 27 Max. bod wt loss %
0030 2 Gy Radiation qu3 16.1 - -7.44 (Day 3)
(Primary PO 100 mg/kg qu3, 2 Gy (0.25 h) IR - -76.5 -3.68 (Day 2)
NSCLC) qus
Focused
'R PO 100 mg/kg bid (0, 4 h) ddx3, 2 Gy - -90.1 -2.87 (Day 3)
(0.25 h) IR qu3
P0 50 mg/kg bid (0, 4 h) ddx3, 2 Gy — -87.8 -5.70 (Day 3)
(0.25 h) IR qu3
Tumor Study Groups
Model,
Agent
P0 25 mg/kg bid (0, 4 h) qu3, 2 Gy -80.3 -5.81 (Day 2)
(0.25 h) IR qu3
LU %T c Da 27 %T Ti Da 27 Max. bod wt loss %
0030
(Primary 2 Gy Radiation qu3 16.1 -7.44 (Day 3)
NSCLC) P0 50 mg/kg bid (0, 4 h) qu3, 2 Gy - -3.68 (Day 2)
Focused (0.25 h) IR qu3
IR P0 50 mg/kg bid (0, 4 h) qu2, 2 Gy -237 (Day 3)
(0.25 h) IR qu3
P0 25 mg/kg bid (0, 4 h) qu3, 2 Gy _5_70 (Day 3)
(0.25 h) IR qu3
P0 10 mg/kg bid (0, 4 h) qu3, 2 Gy -5.81 (Day 2)
(0.25 h) IR qu3
LU %T c Da 31 %T Ti Da 31 Max. bod wt loss %
0030
(Primary 2 Gy Radiation qu3 '4-46 (Day 2)
NSCLC) P0 10 mg.kg bid (0, 4 h) qu3, 2 Gy IR 33 (Day 3)
Focused (025 h)
'R P0 50 mg/kg qu3, 2 Gy IR (0.25 h) -2.07 (Day 1)
P0 50 mg/kg bid (0, 4 h) qu1, 2 Gy IR
(0-25 h) -0.59 (Day 1)
P0 50 mg/kg bid (0, 4 h) qu2, 2 Gy IR
(0-25 h) -1.7 -2.11 (Day 1)
P0 50 mg/kg bid (0, 4 h) qu3, 2 Gy IR
(0'25 h)
- -14.1 -0.94 (Day 3)
LU %T c Da 24 %T Ti Da 24 Max. bod wt loss
0030 2 Gy Radiation qu3 %
(Primary P0 10 mg/kg bid (0, 4 h) qu3, 2 Gv IR 26.7 -0.40 (Day 2)
NSCLC) qu3 (05 h) - -1.46 (Day 4)
Focused P0 25 mg/kg bid (0, 4 h) qu3, 2 Gy IR
IR qu3 (0.25 h)
_2-03 (Day 4)
P0 50 mg/kg bid (0, 4 h) qu3, 2 Gy IR.
qu3 (0.25 h)
'1'19 (Day 4)
P0 50 mg/kg bid (0, 4 h) qodx2, 2 Gy
IR qu3 (0.25 h)
-1.59 (Day 4)
OE-19 %T c Da 18 %T Ti Da 18 Max. bod wei ht
(GEJ cell 2 Gy Radiation qd7 x 2 M
line) PO 100 mg/kg bid (0, 4 h) qd7x 2 86.0 —1.90 (Day 1)
Whole PO 100 mg/kg bid (0, 4 h) qd7x2, 2 Gy 79.0 70 (Day 8)
Body IR IR qd7x2 (0.25 h) 24.0 -3.50 (Day 1)
ST %T c Da 34 %T Ti Da 34 Max. bod wei ht
0004 2 Gy Radiation qu3 M
(Primary po 100 mg/kg qu3 59.6 -8.06 (Day 48)
GEJ PO 100 mg/kg bid (0, 4 h) qu3, 2 Gy 95.6 -6.31 (Day 14)
tumor- IR (0.25 h) - -10.0 (Day 10)
bridging
study)*
Tumor Study Groups
Model,
Damaging
Agent
Focused
Table 15: Summary of In Vivo Efficacy Studies with nd (2)
Tumor Study Groups Results
Model, DNA
Damaging
Agent
OD26749 %T C Da 22 %T Ti Da 22 Max. bod wt loss
(Primary 2 Gy Radiation qu3 %
NSCLC-- PO 100 mg/kg bid (0, 4 h), 2 Gy (0.25 h) 106 - 90 (Day 1)
bridging qu3 7.8 - -2.70 (Day 1)
study) P0 50 mg/kg bid (0, 4 h), 2 Gy (0.25 h)
qu3 27.2 - -2.10 (Day 1)
LU-01—0030 %T C Da 34 %T Ti Da 34 Max. bod wt loss
(Primary 2 Gy Radiation qu3 %
NSCLC) P0 50 mg/kg bid (0, 4 h) qu3 16.9 - -4.93 (Day 3)
P0 50 mg/kg bid (0, 4 h) qu3, 2 Gy |R 98.3 - -1.11 (Day 9)
(0.25 h) qu3 - -96.3 -6.93 (Day 3)
P0 25 mg/kg bid (0, 4 h) qu3, 2 Gy |R
(025 h) qu3 - -67.1 -6.59 (Day 3)
P0 50 mg/kg qu3, 2 Gy |R (0.25 h)
qu3 - -96.9 -4.66 (Day 3)
P0 25 mg/kg qu3, 2 Gy IR (0.25 h)
qu3 - -1.6 -4.62 (Day 1)
OE-19 %T C Da 21 %T Ti Da 21 Max. bod wt loss
(GEJ cell 2 Gy Radiation q7dx2 %
Iine-- PO 100 mg/kg bid (0, 4 h) q7dx2, 2 Gy 60.0 - 80 (Day 1)
bridging IR q7dx2 (0.25 h) 8.0 - -6.50 (Day 7)
study)
0004 %T C Da 34 %T Ti Da 34 Max. bod wt loss
(Primary GE) 2 Gy Radiation qu3 %
tumor) PO 100 mg/kg bid (0, 4 h) qu3 56.9 - -8.06 (Day 48)
PO 100 mg/kg bid (0, 4 h) qu3, 2 Gy IR 67.6 - -7.61 (Day 34)
qu3 (0.25 h) 9.2 - -9.15 (Day 14)
P0 25 mg/kg bid (0, 4 h) qu3, 2 Gy IR
qu3 (0.25 h) 17.4 - -6.73 (Day 48)
ST0004 %T C Da 45 %T Ti Da 45 Max. bod wt loss %
(Primary GE) 5 mg/kg axel q7dx3 (0h), 25 98.0 - -8.93 (Day 45)
tumor— mg/kg carboplatin q7dx3 (0h)
with SOC)
mg/kg paclitaxel q7dx3 (-0.25h), 25 95.4 - -10.1 (Day 45)
mg/kg carboplatin q7dx3 (-0.25h), P0
50 mg/kg bid (0, 4 h) qu3
WO 58067
Tumor Study Groups s
Model, DNA
Damaging
Agent
mg/kg paclitaxel q7dx3, 25 mg/kg (- 34.9 - -10.0 (Day 3)
0.25h), carboplatin q7dx3 (-0.25h), 2
Gy IR qu3 (0 h)
2.5 - -9.20 (Day 10)
mg/kg paclitaxel q7dx3 (-0.25h), 25
mg/kg carboplatin q7dx3 (-0.25h), 2 Gy
IR qu3 (0.25 h), P0 50 mg/kg bid (0, 4
h) qu3 11.1 - -8.21 (Day 3)
mg/kg paclitaxel q7dx3 (-0.25h), 25
mg/kg carboplatin q7dx3 (-0.25h), 2 Gy
IR qu3 (0.25 h), P0 25 mg/kg bid (0, 4
h) qu3
Example I]. The combination ofCompound (I) or Compound (2) with Standard ofCare
drugs or radiation in cancer cell lines
The cell—based experiments and assays were performed with either molecule but
not always with both. Compounds (1) and (2) were generally very r in those assays
and experiments. Analysis of the combination experiments was performed using two
methods: the Bliss Additivity model and the Mixtures Blend method to determine the degree
of synergy, additivity, or antagonism. In the Bliss , a matrix of Bliss scores was
generated for each cell line and treatment, and a sum of the Bliss values over the range of
combination concentrations tested was calculated. The average Bliss score (sum of Bliss
divided by the number of total data ) was then used to categorize the cell line and
treatment as follows: greater than 10 indicates strong synergy, greater than 5 indicates
synergy, between 5 and —5 indicates additivity, less than -5 indicates nism, and less
than -10 indicates strong antagonism. Larger average Bliss values indicate r confidence
in reporting y, and smaller scores indicate greater confidence in reporting nism.
In the Mixtures Blend method combinants were added in a range of optimal ratios using
design of experiment (DOE) software (DX-8 from STAT-EASE); the cells were irradiated
with 2 Gy as required. Synergy was determined using statistical analysis of the data
(ANOVA) to indicate linear (additivity) or statistically significant (p<0. l) non-linear
onism or synergy) mixes of the combinants.
Certain cancer cell lines and their tumor types are listed in Table 16.
WO 58067
Table 16: Cancer cell line list
CELL LINE TUMOR TYPE
DOHH-2 Lymphoma- B cell
DU-4475 Breast
EOL-1 Leukemia
Farage Lymphoma- non-hodgkins B cell
GRANTA-519 Lymphoma- mantle cell
HBL-1 Lymphoma-B cell
HCC2935 Lung-NSCLC
HCC95 Lung-NSCLC
HH Lymphoma-T cell
HT-1 15 Colorectal
JHH-2 Liver
KARPAS-299 Lymphoma- non-hodgkins B cell
KARPAS-422 Lymphoma- non-hodgkins B cell
KARPAS-620 Multiple Myeloma
KASUMl-1 ia, AML
KE-97 Gastric
KELLY Neuroblastoma
KG-1 Leukemia, AML
KG-1a Leukemia, AML
KMS-20 Multiple a
-BM Multiple Myeloma
KMS-34 Multiple Myeloma
LC-1 F Lung-NSCLC
03H Lung-NSCLC
LUA Lung--SCLC
LU-139 Lung--SCLC
MDST8 Colorectal
ML-1 Thyroid
MOLM-13 Leukemia- CML
MV11 Leukemia
NCl-H1048 Lung--SCLC
NCl-H1650 Lung-NSCLC
NCl-H1694 Lung--SCLC
NCl-H1944 Lung-NSCLC
NCl-H1993 Lung-NSCLC
NCl-H2126 Lung-NSCLC
NCl-H2141 Lung--SCLC
NCl-H2171 SCLC
NCl-H2228 Lung-NSCLC
NCl-H446 Lung--SCLC
NCl-H820 Lung-NSCLC
NCl-H841 Lung--SCLC
NCl-H929 le Myeloma
2014/061102
CELL LINE TUMOR TYPE
NOMO-1 Leukemia, AML
OCl-Ly3 Lymphoma- B cell
OCl-Ly7 Lymphoma- B cell
OPM-2 Lymphoma- B cell
OVK18 Lymphoma- B cell
PC-3 Prostate
PC-9 Lung-NSCLC
RL Lymphoma- B cell
RPMl-8226 ma- B cell
epst ma- B cell
TE-1 Esophageal
TE-14 Esophageal
THP-1 Leukemia, AML
U-2932 Lymphoma- B cell
-4 Skin
WSU-NHL Lymphoma- B cell
ZR1 Breast
A. Double Combinations
Compound (2) was tested against a panel of 60 cancer cell lines (see Table 16)
alone and in combination with a panel of xic and non-cytotoxic SOC agents. The 60
cancer cell lines represent lines derived from breast cancer, prostate cancer, lung cancer,
acute myeloid leukemia (AML), myeloma and other cancers. Cells were removed from
liquid nitrogen storage, thawed and expanded in appropriate growth media. Once expanded,
cells were seeded in 384—weli tissue culture treated plates at 500 cells per weii. After 24
hours, cells were d for either 0 hours or treated for E44 hours with Compound (2) in
combination with genotoxin: bieomycin (radio mimetic), doxorubicin (topoisomerase II
inhibitor), etoposide (topoisomerase ii inhibitor), carbopiatin (DNA erosslinker), BMN—673
(PAR? tor), and tareeya (EGFR inhibitor)). At the end of either 0 hours or l44 hours,
eeil status was anatyzed using ATPLite (Perkin Either) to assess the biologioai se of
ceils to drug combinations.
] Compound (2) demonstrated strong synergy with several agents tested: etoposide
(topoisomerase inhibitor), doxorubicin (DNA intercalator), and bleomycin(radiomimetic)
(Figure 23). Some synergy was seen in combination with BMN—673 (PARP tor) and
carboplatin DNA-repair inhibitor). Additivity was seen with erlotinib (EGFR inhibitor)
(Figure 23). When analyzed by cancer cell line type, Compound (2) and BMN—673
demonstrated greatest activity against AML. Compound (2) and etoposide, while highly
active against most lines, was ularly active against all cell lung cancer lines as
was Compound (2) and bicin (see below). Bliss synergy data of Compound (2) in
various tumor types (acute myeloid leukemia (AML), diffuse large B-cell lymphoma
(DLBCL), non-small cell lung cancer (NSCLC), plasma cell myeloma (PCM), small cell lung
cancer (SCLC)) are shown in Figures 24—30: combination of Compound (2) with BMN—673
in Figure 24; combination of Compound (2) with etoposide in Figure 25; combination of
Compound (2) with bleomycin in Figure 26; combination of Compound (2) with erlotinib in
Figure 27; combination of Compound (2) with doxorubicin in Figure 28; combination of
Compound (2) with bleomycin in Figure 29; combination of Compound (2) with carboplatin
in Figure 30.
ations of Compound (2) and doxorubicin or epirubicin (DNA intercalator)
were tested against breast cancer cell lines (Tables 17 and 18), with a comparison between
wild-type and mutant lines being a focus of the study. Independent of plating density,
sensitivity to doxorubicin alone, or BRCA status, the combination of doxorubicin and
Compound (2) was strongly synergistic in all five cell lines and at both Compound (2)
concentrations tested (Bliss analysis). The > 3-fold shift in IC50 of the combination of
doxorubicin and Compound (2) ed to doxorubicin alone also indicates a high degree
of synergy. A similar experiment using Doxorubicin or epirubicin in combination with
Compound (2) in the DU4475 breast cancer line demonstrated strong synergy (Bliss is)
(Table 18).
The combination of the Compound (2) and bicin or epirubicin was strongly
synergistic in all triple-negative breast cancer cell lines evaluated, independent of BRCA
status or plating y.
Table 17: Summary of Combinations with Compound (2) and Doxorubicin in Triple
Negative Breast Cancer Cell Lines
Plating Average Doxorubicin IC50 m IC50
Cell Line Density BRCA status Bliss score (HM) Shift (fold)
HCC-1395 5000 Mutant 11.1 0.5 4.6
HCC-1599 Unknown Mutant 14.3 0.2 4.3
HCC-1937 5000 Mutant 16.6 0.2 3.7
HCC-1937 20000 Mutant 15.6 0.6 3.9
MDA-MB-43 6 5000 Mutant 14.5 0.7 9.1
MDA-MB-436 20000 Mutant 14.4 0.3 4.7
-468 5000 Wild-type 23 .1 0.02 19
MDA-MB-468 20000 Wild-type 24 .7 0.04 13
2014/061102
Table 18: Summary of ations with Compound (2) and Doxorubicin or Epirubicin
in DU4475 Cells
Drug Average Bliss score
Doxorubicin 31.9
Epirubicin 33.3
B. Double and Triple Combinations with and without ion (2 Gy)
The following SOC agents were tested in double combinations with Compound
(1): etoposide (a topoisomerase tor that induces DSBs), cisplatin (DNA cross—linker),
carboplatin (DNA cross-linker), fiuorouracil (5-FU, antimetabolite that inhibits thymidylate
synthase), paclitaxel ic inhibitor that binds to tubulin), cetuximab (EGFR onal
dy), and radiation. Other than the combination of radiation and Compound (1), the
strongest interaction for the double combination studies was etoposide and Compound (1) in
A549 cells (Table 19) and Compound (1) and etoposide in ESO26 (Table 20). These findings
were confirmed using the Bliss Additivity model (Table 21). Other combinations
demonstrated additivity with rare examples of antagonism. While there is not total agreement
in the various lines tested, (as detailed in the other sections) the majority agree and the
conclusions d at are common to each. The same experiment performed using OEl9
cells showed a more complex interaction pattern in the absence of radiation. A significantly
enhanced effect was seen when radiation was added to the ations, reinforcing the
strong relationship between DNA damage (DSB and SSB) and DNA-PK inhibition. The
cancer cell lines in Table 19 indicate: ESOZ6 — gastroesophageal on cancer, OEl9 —
gastroesophageal junction cancer, DMS—53 — SCLC, A549 — lung cancer, c010205 — colon
cancer, H460 — lung cancer, H2009 — lung cancer, FaDu - pharynx cancer, Miapaca2 —
pancreatic cancer, HFLl — human fetal lung fibroblast.
The combination of the Compound (2) and doxorubicin or icin was strongly
synergistic in all triple-negative breast cancer cell lines evaluated, independent of BRCA
status or plating density.
In the triple SOC combination experiments, synergy was demonstrated with the
combination of etoposide, cisplatin, and Compound (1) in the DMS-53 and A549 cell lines.
The major driver for this y was the combination of etoposide with Compound (1).
Paclitaxel, cisplatin, and Compound (1) was additive in the A549 cell line, while cisplatin, 5-
FU and Compound (1) were synergistic in the C010205 cell line. A highly significant
reduction in cell viability was observed upon the on of radiation to these combinations,
principally driven by the contribution of nd (1). Compound (2) demonstrated the
same ation outcomes on cell viability with SOC combinants (using a smaller set of
cancer cell lines) when compared to Compound (1).
Table 19: Effect of Compound (1) in Combination with Genotoxic Agents on the Viability
of Cancer Cell Lines
Combination with
Synergy or Antagonism_
Compound (1)
Cell Line “a g E 3% E g No Radiation Plus Radiation (2 Gy)
U a 5 a: 5
-"V Additivity ND
Strong Synergy ND
V Antagonism ND
A549 --" Synergy Plus
--" Additivity Additivity, Plus
V V Strong Synergy Strong Synergy, Plus
-" Additivity Synergy, Plus
H460 Synergy Plus
H2009 ---- Additivity Plus
C010205 --- Synergy Synergy, Plus
DMS-53 --- Strong Synergy N/A
-' Mix Synergy, Plus
OEl9 V I nism Synergy*, Plus
--" Additivity Synergy*, Plus
V Additivity Additivity, Plus
FaDu
I-II Synergy Plus
---- syneyy ND
HFLl ---- Additivity Additivity, Plus
---- Admuyny ND
vity No effect
ND : Not ined, N/A : Not Applicable: etoposide is a radiomimetic. Plus : enhanced effect of radiation. * Viability
ion driven predominantly by nd ( 1) plus radiation.
Table 20: Effect of Compound (2) in Combination with Genotoxic Agents on the Viability
of the ES026 (GEJ) Cancer Cell Line (Mixtures analysis)
1. Combinations with Comp 2 2. N0 Radiation 3. Plus Radiation
tin, 5-FU Synergy; Comp. 2 with 5-FU Significant reduction in cell
survival driven by Comp. 2 and
radiation
Carboplatin, Paclitaxel Additive overall Significant reduction in cell
survival driven by Comp. 2 and
radiation
Etoposide Significant synergy Not applicable
Based on ICSO of 20 [1M for Comp. 2, 50 [1M for carboplatin, 1.5 [1M for cisplatin, 3 nM for paclitaxel, 0.6 [1M for etoposide
and 20 [1M for 5-FU. Not applicable: etoposide is a radiomimetic.
Table 21: Effect of Compound (2) in Combination with Etoposide on the Viability of Cancer
Cell Lines (Bliss analysis)
Cell Line Average Bliss Score
A549 27.3 (n=1)
ESO26 43.2 6.5 (n=3)
HFL1 8.7 :: 5.6 (n=3)
C. Effect of the Combination of Compound (1) or (2) and SOC in Primary Tumor
Chemosensitivity Assays (TCA)
Primary human tumors tested in Vitro may provide a better indicator of efficacy of
DNA PK inhibition than immortalized cancer cell lines due to their increased heterogeneity
and closer proximity to the patient tumor from which they were derived. A panel of primary
human tumors (NSCLC, pancreatic, esophageal, gastric, etc.) was treated with Compound (1)
to determine the iveness of DNA-PK inhibition in ation with radiation,
bleomycin (a radiomimetic agent that induces DSBs), doxorubicin (DNA intercalator),
cisplatin, carboplatin, etoposide, paclitaxel, or 5—FU.
Compound (1) (10x and 30x IC50) was administered in combination with a dose
range of cin or radiation. Dissociated cells from mouse—passaged tumors were
cultured for 6 days after combination exposure and then assessed for viability using the Cell
Titer—G10 assay. The Bliss vity statistical model was used to ine the degree of
synergy, additivity, or antagonism of each combination treatment.
The ation of Compound (1) and bleomycin or radiation was additive or
synergistic in all tumors tested (29/29) (see Figure 31). In addition, strong synergy was seen
in nearly a third of both bleomycin (9/29) and radiation (3/8) treated tumors in combination
with Compound (1). Similarly, Compound (2) was tested in ation with a dose range
of bleomycin in a smaller subset of tumors (gastric, pancreatic). The combination of
nd (2) and bleomycin was additive or synergistic in all tumors tested (20/20) and
strongly synergistic in a subset of those (3/20) (see Figure 31). These data t that a
DNA-PK inhibitor in combination with radiation therapy may be more y effective than
the standard of care alone.
A panel of primary tumors was also treated with Compound (1) in combination
with a variety of herapeutic agents (gemcitabine, paclitaxel, tin, carboplatin, 5-
2014/061102
FU, etoposide) commonly used in the treatment of the tumor types tested. Additivity was
observed in most tumors treated with Compound (1) and either gemcitabine, (2/4) paclitaxel
(l/5), 5—FU (5/5), or doxorubicin (l/l). However, antagonism was seen in some tumors with
abine (2/4) and paclitaxel (l/5). Synergy or additivity was observed in nearly all
tumors with both carboplatin (5/5) and cisplatin (9/10), but one tumor showed antagonism
with cisplatin. The combination of Compound (1) and etoposide showed strong synergy in all
tumors tested (4/4). These TCA results were consistent with the combination data generated
using cancer cell lines. Overall, these data suggest that a selective DNA—PK inhibitor may
provide added benefit to cancer patients receiving standard of care treatment in a y of
clinical ations.
e 14. Effect ofCompound (1) 0n Clonogenic Survival ofIrradiated Cancer Cell Lines
The clonogenic cell survival assay es the y of a cell to proliferate
indefinitely, y retaining its self-renewing ability to form a colony (i.e., clone). This
assay has been a mainstay in radiation oncology for decades and was used to determine the
effect of Compound (1) on the clonogenicity of a panel of cell lines across multiple tumor
types following radiation. Compound (1) in combination with radiation was shown to be
very efficacious in decreasing the clonogenicity of all cancer cell lines tested with dose
enhancement factors (DEF, the difference in colony number at surviving fraction 0.1) g
from 2.5 to >5. Miapaca2 cells exhibited the lowest DEF (2.5), while in FaDu cells, the
combination of Compound (1) and radiation completely eliminated colony formation with as
little as 0.5 Gy and showed a DEF of >8. A DEF greater than 1.5 is generally considered to
be clinically meaningful; therefore, by these standards, Compound (1) would be characterized
as a strong radio-enhancing agent. These data are consistent with the previous cell viability
data in suggesting that a broad der population can be expected in cancer patients
treated with Compound (1) in combination with radiation.
Although the foregoing invention has been described in some detail by way of
illustration and e for purposes of clarity of understanding, it will be readily apparent to
those of ordinary skill in the art in light of the ngs of this ion that certain changes
and modifications may be made thereto without departing from the spirit or scope of the
appended claims.
All references provided herein are incorporated herein in its entirety by reference.
As used , all abbreviations, s and conventions are consistent with those used in
the contemporary scientific literature. See, e.g., Janet S. Dodd, ed., The ACS Style Guide: A
for Authors and Editors, 2nd Ed., Washington, DC: American Chemical Society,
1997.
Claims (25)
1. A co-crystal comprising a compound of the formula (I) and a co-crystal former, wherein the co-crystal former is adipic acid, wherein each of R1 and R2 is independently hydrogen or deuterium.
2. The stal of claim 1, wherein a molar ratio of the adipic acid to the compound of formula I is about 1 to 2.
3. The co-crystal of claim 2, wherein the nd of formula I is (S)-N-methyl(1-((2'- methyl-[4,5'-bipyrimidin]yl)amino)propanyl)quinolinecarboxamide.
4. The co-crystal of claim 2, wherein the compound of formula I is (S)-N-methyl(1-((2'- methyl-4',6'-dideutero-[4,5'-bipyrimidin]yl)amino)propanyl)quinolinecarboxamide.
5. The co-crystal of claim 3 or 4 having X-ray powder diffraction peaks at about 6.46, 7.91, 11.92, 12.26, 12.99, 14.19, 18.68, and 19.07 °2-Theta.
6. The stal of claim 3 or 4, having a DSC peak in its DSC thermogram at about 195 oC and about 245 oC when heated at 10 oC/minute to 300 oC.
7. A pharmaceutical composition comprising the co-crystal of any one of claims 1-6.
8. The pharmaceutical composition of claim 7 wherein the compound of formula I is (S)-N- methyl(1-((2'-methyl-[4,5'-bipyrimidin]yl)amino)propanyl)quinolinecarboxamide.
9. The pharmaceutical ition of claim 7 wherein the compound of formula I is (S)-N- methyl(1-((2'-methyl-4',6'-dideutero-[4,5'-bipyrimidin]yl)amino)propanyl)quinoline carboxamide.
10. The pharmaceutical composition of claim 7, wherein a molar ratio of the compound of formula I to adipic acid is about 2 to 1.
11. The pharmaceutical composition of claim 7, further comprising a diluent, t, ent, carrier, or solubilizing agent.
12. A method of making a co-crystal comprising: grinding, heating, co-subliming, co-melting, or contacting either (S)-N-methyl(1-((2'- methyl-[4,5'-bipyrimidin]yl)amino)propanyl)quinolinecarboxamide or (S)-N-methyl (1-((2'-methyl-4',6'-dideutero-[4,5'-bipyrimidin]yl)amino)propanyl)quinoline carboxamide with a stal former under crystallization conditions so as to form the cocrystal in solid phase, wherein the co-crystal former is adipic acid.
13. A method of making a co-crystal comprising providing a pre-existing co-crystal as a seed to prepare the co-crystal, wherein the pre-existing co-crystal comprises: (i) either methyl- 8-(1-((2'-methyl-[4,5'-bipyrimidin]yl)amino)propanyl)quinolinecarboxamide or (S)-N- methyl(1-((2'-methyl-4',6'-dideutero-[4,5'-bipyrimidin]yl)amino)propanyl)quinoline carboxamide; and (ii) adipic acid; or the stal to be formed comprises: (i) either (S)-N- methyl(1-((2'-methyl-[4,5'-bipyrimidin]yl)amino)propanyl)quinolinecarboxamide or (S)-N-methyl(1-((2'-methyl-4',6'-dideutero-[4,5'-bipyrimidin]yl)amino)propan yl)quinolinecarboxamide; and (ii) adipic acid.
14. Use of an effective amount of the co-crystal of any one of claims 1-6, or the pharmaceutical composition of any one of claims 7-11, in the cture of a medicament for potentiating a therapeutic regimen for the treatment of cancer in a patient.
15. Use of an effective amount of the co-crystal of any one of claims 1-6, or the pharmaceutical composition of any one of claims 7-11, in the manufacture of a ment for the treatment of cancer in a patient.
16. The use of claim 14, wherein the therapeutic regimen includes radiation therapy.
17. The use of claim 14, wherein the therapeutic regimen es herapy.
18. The use of claim 14, wherein the therapeutic regimen includes both ion therapy and chemotherapy.
19. The use of claim 14, wherein the medicament is to be administered with etoposide, doxorubicin, daunorubicin, epirubicin or bleomycin.
20. The use of claim 14, wherein the cancer is breast cancer, colorectal cancer, gastricesophageal cancer, fibrosarcoma, glioblastoma, hepatocellular cancer, head and neck cancer, melanoma, lung cancer, pancreatic cancer or prostate cancer.
21. The use of claim 15, wherein the cancer is breast cancer, colorectal cancer, gastricesophageal cancer, fibrosarcoma, glioblastoma, hepatocellular cancer, head and neck cancer, ma, lung cancer, pancreatic cancer or prostate cancer.
22. The use of claim 14, wherein the cancer is solid tumors/malignancies, myxoid and round cell carcinoma, locally advanced tumors, metastatic cancer, human soft tissue sarcomas, Ewing's sarcoma, cancer ases, lymphatic ases, squamous cell carcinoma, head and neck us cell carcinoma, esophageal squamous cell carcinoma, oral carcinoma, blood cell malignancies, le myeloma, leukemia, acute lymphocytic leukemia, acute nonlymphocytic leukemia, chronic lymphocytic leukemia, chronic myelocytic leukemia, hairy cell leukemia, effusion lymphomas, thymic lymphoma lung cancer, small cell carcinoma, cutaneous T cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, cancer of the adrenal cortex, ACTH-producing tumors, non-small cell cancers, breast cancer, small cell carcinoma, ductal carcinoma, gastrointestinal cancer, stomach , colon cancer, colorectal cancer, polyps associated with colorectal neoplasia, pancreatic cancer, liver , urological cancer, bladder cancer, primary superficial bladder tumors, invasive transitional cell carcinoma of the bladder, muscle-invasive bladder cancer, prostate cancer, malignancies of the female genital tract, ovarian oma, primary peritoneal epithelial neoplasms, cervical carcinoma, e endometrial cancer, l cancer, cancer of the vulva, uterine , solid tumors in the ovarian follicle, malignancies of the male l tract, testicular cancer, penile cancer, kidney cancer, renal cell carcinoma, brain cancer, intrinsic brain tumors, neuroblastoma, astrocytic brain tumors, glioma, metastatic tumor cell invasion in the central nervous system, bone cancer, osteoma, osteosarcoma, skin cancer, malignant melanoma, tumor progression of human skin nocytes, squamous cell cancer, thyroid cancer, retinoblastoma, neuroblastoma, peritoneal effusion, malignant pleural effusion, mesothelioma, Wilms's tumors, gall bladder cancer, trophoblastic neoplasms, hemangiopericytoma or Kaposi's sarcoma.
23. The use of claim 15, wherein the cancer is solid tumors/malignancies, myxoid and round cell oma, locally advanced tumors, metastatic cancer, human soft tissue as, Ewing's a, cancer metastases, lymphatic metastases, squamous cell carcinoma, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, oral carcinoma, blood cell malignancies, multiple myeloma, leukemia, acute lymphocytic leukemia, acute nonlymphocytic leukemia, chronic lymphocytic leukemia, chronic myelocytic leukemia, hairy cell leukemia, effusion lymphomas, thymic ma lung cancer, small cell carcinoma, cutaneous T cell ma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, cancer of the l cortex, ACTH-producing tumors, non-small cell cancers, breast cancer, small cell carcinoma, ductal carcinoma, gastrointestinal , h cancer, colon cancer, colorectal , polyps associated with colorectal neoplasia, pancreatic cancer, liver cancer, urological cancer, bladder cancer, primary superficial bladder tumors, invasive transitional cell oma of the bladder, -invasive bladder cancer, te cancer, malignancies of the female genital tract, ovarian carcinoma, primary peritoneal epithelial neoplasms, cervical carcinoma, uterine endometrial , vaginal cancer, cancer of the vulva, uterine cancer, solid tumors in the ovarian follicle, malignancies of the male genital tract, testicular cancer, penile cancer, kidney cancer, renal cell carcinoma, brain cancer, intrinsic brain tumors, lastoma, astrocytic brain tumors, glioma, metastatic tumor cell invasion in the central nervous system, bone cancer, osteoma, osteosarcoma, skin cancer, malignant melanoma, tumor progression of human skin keratinocytes, squamous cell cancer, thyroid cancer, retinoblastoma, neuroblastoma, peritoneal effusion, malignant pleural effusion, elioma, Wilms's , gall bladder cancer, trophoblastic neoplasms, iopericytoma or Kaposi's sarcoma.
24. The co-crystal of claim 1, substantially as herein described with reference to any one of the Examples and/or s thereof.
25. The method of claim 12 or 13, substantially as herein described with reference to any one of the es and/or
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361892002P | 2013-10-17 | 2013-10-17 | |
US61/892,002 | 2013-10-17 | ||
PCT/US2014/061102 WO2015058067A1 (en) | 2013-10-17 | 2014-10-17 | Co-crystals of (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as dna-pk inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ719163A NZ719163A (en) | 2021-01-29 |
NZ719163B2 true NZ719163B2 (en) | 2021-04-30 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10716789B2 (en) | Co-crystals and pharmaceutical compositions comprising the same | |
AU2014337154A1 (en) | Co-crystals of (s)-N-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as DNA-PK inhibitors | |
US10815239B2 (en) | Compounds useful as inhibitors of ATR kinase | |
US8841337B2 (en) | Compounds useful as inhibitors of ATR kinase | |
JP6936007B2 (en) | How to Treat Cancer Using A Combination of CHK1 Inhibitor and ATR Inhibitor | |
EP2751088B1 (en) | Compounds useful as inhibitors of atr kinase | |
US8846917B2 (en) | Compounds useful as inhibitors of ATR kinase | |
JP2014522818A (en) | Compounds useful as ATR kinase inhibitors | |
JP2014520161A (en) | Compounds useful as ATR kinase inhibitors | |
JP2014517079A (en) | Compounds useful as ATR kinase inhibitors | |
NZ719163B2 (en) | Co-crystals of (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as dna-pk inhibitors |